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Summary 
 
Targeting tumor vasculature is the common theme for the three separate studies presented in this 
thesis. The studies comprise the roles of components of three signaling pathways (networks) in 
several steps of blood vessel formation, and related tumor growth and dissemination. With our 
first study, we wanted to elucidate the role of selected Wnt signaling members in in vitro and in 
vivo angiogenesis. The aim of the second study was to reveal the advantages of simultaneous 
targeting of all of the constituents of the VEGFR family over the sole inhibition of VEGF and 
VEGFR2. Finally, in our third study we wanted to delineate the role of ErbB2 signaling mediator 
Memo in tumorigenesis, vasculogenesis and metastatic abilities of 4T1 mouse mammary 
carcinoma cells. 
Wnt signaling is highly conserved signaling pathway involved in several developmental 
processes and regulation of adult tissue homeostasis. Accumulating data from mouse knock out 
and in vitro angiogenesis studies indicate its role in blood vessel formation. To decipher the role 
of Wnt signaling components in angiogenesis, we used human umbilical vein endothelial cells 
(HUVEC), and well vascularized Lewis lung carcinomas grown in mice, as our in vitro and in 
vivo models, respectively. In our in vitro studies, we checked for the abilities of recombinant 
Wnt3a, a member of the family considered to activate only canonical Wnt pathway, and Wnt5a, 
so called non canonical Wnt, to induce HUVEC proliferation, migration and survival. We found 
that Wnt3a is a novel proangiogenic factor with the ability to induce HUVEC proliferation and 
migration, but without an effect on their survival. The effects were mediated through the common 
Wnt downstream effector protein Dishevelled. Proliferation induced by Wnt3a is VEGFR 
signaling independent. Wnt5a did not show an effect on any of those processes, but it activated 
signaling, demonstrated by Dishevelled phosphorylation. To test the role of Fz6, a member of 
Wnt receptor family repeatedly shown to be expressed on vasculature from different tissues, in in 
vivo angiogenesis, we injected Fz6 knock out mice and their wild type littermates with Lewis 
lung carcinoma cells. The ablation of Fz6 did not have an effect on the kinetics of tumor growth, 
quantity nor appearance of tumor vasculature.  
While the knowledge about the role of Wnt signaling in angiogenesis is only emerging, the 
importance of vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) in 
vessel formation is well documented. In our work, we wanted to test the effects of simultaneous 
inhibition of VEGFR1, VEGFR2 and VEGFR3 in comparison to inhibition of VEGFR2 or VEGF 
solely, on tumor growth and spread. We found that targeting all three VEGFRs is more effective 
in inhibition of functionality of the lymphatics surrounding the primary tumor and subsequent 
metastatic spread, than targeting VEGFR2 or VEGF alone. Moreover, we show that B16/BL6 
melanoma cancer cells display an in vitro autocrine VEGF/VEGFR signaling loop whose 
inhibition chemosensitizes them to platinum based chemotherapeutics.    
ErbB2 receptor tyrosine kinase belongs to the family of epidermal growth factor receptors. It is 
overexpressed in 20% of human breast cancers, and its expression correlates with highly 
metastatic disease and poor clinical outcome for patients. In a screen for ErbB2 effectors, Memo, 
a novel signaling protein that is mediating migration induced through ErbB2 and several other 
receptor tyrosine kinases, was previoulsy identified in our lab. To test the role of Memo in cancer 
growth, we made use of 4T1, a highly metastatic mouse mammary carcinoma cell line. 
Downregulation of Memo via stable transfection of shRNA in these cells decreased in vivo 
primary tumor growth when compared to control cells. The inspection of tumor vasculature 
revealed that tumors derived from Memo knock down (KD) clones were less vascularized, which 
could possibly explain their growth delay. To delineate the mechanisms behind decreased 
vascularization, we measured the concentration of secreted VEGF in the medium of control and 
Memo KD clones. Our results show that Memo KD clones secrete less VEGF into the medium 
than control clones, indicating that this might relate to the impairment in vascularization of 
tumors derived from these cells. To check the role of Memo downregulation in metastasis 
formation, we injected control and Memo KD clones into the tail vein of BALB/c mice. We 
found that Memo downregulation decreases the metastatic behavior of these cells. In conclusion, 
with this study, we describe the effects of Memo downregulation on several aspects of 
tumorigenesis in mouse mammary carcinoma model. Further studies are needed to decipher the 
signaling pathway that Memo is a part of, and that is responsible for the described effects on 
primary tumor, its vascularization and metastasis formation.  
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I. INTRODUCTION 
 
Targeting tumor vasculature 
The era of anticancer chemotherapy began in the first part of the last century with the use of 
nitrogen mustards and antifolate drugs in the treatments of lymphoid tumors [1]. Ever since, 
the strategy to directly target cancer cells was the major chemotherapeutic approach in 
anticancer treatment. 
However, in 1971, Judah Folkman proposed that inhibition of angiogenesis (targeting tumor 
endothelial cells) could be an effective way to treat human cancer [2]. The growth of tumor 
tissue is highly dependent on blood supply. Moreover, endothelial cells are not displaying 
high mutation rates like cancer cells do and they are more reachable to drugs than cancer 
cells. For these and other arguments, tumor endothelium seemed to be a reasonable target in 
anticancer treatments. This idea gave rise to a new research field that aimed to identify 
molecules and pathways responsible for blood vessel formation. Among them, the family of 
vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) were recognized 
as central players in physiological and pathological angiogenesis. An extensive work in the 
field led to the creation and the recent (2004) FDA (Food and Drug Administration, USA) 
approval of Avastin (Bevacizumab, Genentech), a humanized monoclonal antibody against 
VEGF for the first line treatment of patients with colorectal carcinoma in combination with 5-
fluorouracil (5-FU) based chemotherapy [3]. Avastin was the first drug on the market 
designed specifically to target angiogenesis. From then on, the use of Avastin was approved 
for several other types of human cancer, and two new agents targeting VEGF and VEGFR 
signaling network are used in clinics in anticancer treatments.  
Lymphatic system, although not that significant for the primary tumor growth, was shown to 
be a major promoter of tumor cell spread from the site of origin. Metastatic spread of tumor 
cells is the underlying cause of most cancer related deaths, and this is the reason why a lot of 
effort is being currently made to understand the molecular mechanisms governing formation 
of tumor associated lymphangiogenesis and cancer cell dissemination. 
While the contribution of VEGF and VEGFR family members in the process of vascular 
formation is indisputable, the research field is focusing on the identification of other pathways 
and factors that play a role in several steps of vessel formation.  
In further chapters, I will present the Wnt signaling and its role in angiogenesis, give a 
glimpse into the role of VEGF and VEGFR signaling in vessel formation, and finish with the 
brief overview of ErbB2 signaling and its mediator Memo in breast cancer cell biology. These 
are meant to be the introductory chapters to the research part presenting the role of 
components of Wnt signaling in angiogenesis, the efficacy of novel VEGFR targeting kinase 
inhibitor, and the role of Memo in tumor growth, vascularization and dissemination.  
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1. Wnt signaling in angiogenesis 
1.1. Wnt signaling 
1.1.1. Timeline 
The initial studies on Wnt signaling originate from separate work in the fields of 
developmental genetics using fruitfly Drosophila melanogaster as a model to trace 
developmental phenotypes to their genetic cause, and an attempt from cancer research to 
understand the mechanism by which mouse mammary tumor virus (MMTV) induces 
tumorigenesis.  
In 1973 Drosophila ‘wingless’ (Wg) phenotype (mutant lacking wings) was detected in 
progeny of flies irradiated by X-rays [4]. Later on, in a separate genetic screen for mutations 
that are affecting segmentation pattern during Drosophila embryonic development, Nüsslein-
Volhard and Wieschaus showed that the Wg mutations are causing in addition the loss of 
naked cuticle portion of abdominal segments in Drosophila embryo, where a fraction of each 
segment was deleted and replaced by the mirror image duplicate of the remaining part [5] [6]. 
Subsequently, a work from the same lab and others identified mutations in armadillo (arm, β-
catenin in vertebrates), dishevelled (dsh) and porcupine (porc), causing similar segment 
polarity defects as seen in Wingless mutants; mutations in zeste white 3/shaggy (zw3, encodes 
glycogen synthase kinase 3β) caused opposite phenotypes (reviewed in [7]). Additional 
studies from the laboratories of Perrimon, Nusse and Wieschaus showed that these segment 
polarity genes are all components of the same transduction pathway at present known as the 
canonical Wnt pathway [8]. Moreover, analysis of epistatic relations among arm, dsh, porc 
and zw3 from the same studies using the appearance of abdominal segments as readout (‘all 
naked’ vs. ‘all denticle’) revealed the sequence of events in the pathway. 
In parallel to work from the field of developmental genetics that dissected relations in the Wnt 
pathway through loss of function mutations in large-scale genetic screens, an opposite 
approach (gain of function mutations) led to discovery of the Wnt gene in mammals. In the 
1970s and 1980s tumor viruses were studied intensively in the field of cancer research 
because of their ability to infect and transform non malignant mammalian cells. In 1982 in 
their attempt to explain the tumorigenic properties of MMTV, Roel Nusse and Harold 
Varmus found that very frequently mammary tumors caused by this virus contained the 
insertional site of the virus in the same region of the host genome. The insertion was 
activating the expression of an unknown gene that they named Int1 (integration 1) [9]. Five 
years later the work from Nusse and Lawrence laboratories showed that Int1 is mammalian 
homologue of Drosophila Wg gene [10] [11]. Hence, the term Wnt was coined as an amalgam 
of Wg and Int [12].  
Together with studies using Drosophila and mice as research models, another significant 
contribution to our understanding of Wnt signaling comes from the field of Xenopus leavis 
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embryogenesis. In 1989 Randall Moon’s laboratory showed that injection of vertebrate Wnt1 
mRNA into early Xenopus embryos results in duplication of the body axis and twin-headed 
embryos [13]. Subsequently, axis duplication in frog embryos was used as an assay to 
characterize components of the Wnt pathway (similar to above mentioned segment polarity 
assays in Drosophila) and to reveal novel biochemical interactions between these 
components. As an example, the central biochemical event of a canonical Wnt signaling 
pathway – β-catenin interaction with transcription factors LEF-1 and TCF – was confirmed in 
studies using injection of LEF-1 and XTcf-3 (maternally expressed Xenopus homolog of the 
mammalian transcription factors Tcf-1 and Lef-1) mRNAs into Xenopus embryos [14], [15], 
[16]. 
Taken together, listed experiments from Drosophila and Xenopus embryogenesis, and 
mammalian viral oncogenesis, show high conservation of components and signaling steps of 
Wnt canonical pathway among species, and confirm the concept reported elsewhere that the 
same set of signaling pathways are regulating development and induce cancer when mutated 
[17], [18].  
 
1.1.2. Ligands 
1.1.2.1. Comparative genomics and evolution 
Wnts are a highly conserved, metazoan-restricted family of secreted signaling proteins 
comprising 19 members in humans, 12 in Zebrafish, 7 in Drosophila (for a detailed overview 
of Wnt signaling components across different organisms see [19]). 
In vertebrates, Wnt genes are categorized in twelve distinct subfamilies defined by criteria of 
forming paralogous groups (originating by duplication) that contain orthologous Wnt genes 
(originating by speciation) [20]. 
The majority of human Wnt genes share about 35% of amino-acid sequence identity which is 
higher in case of members of the same subfamily (from 58% to 83%). Members of a 
subfamily are, however, not closely linked within the genome suggesting that they were 
generated by larger genome rearragements (genome duplications or gene translocations) [21]. 
In vertebrates, the orthologs in different species are highly similar in sequence. For example, 
human WNT1 and mouse Wnt1 are 98% identical and human WNT5a and Xenopus Wnt5a 
are 84% identical at the amino-acid level [21]. The sequence identity between orthologous 
proteins in humans and flies ranges between 21% to 42%, while the evolutionary relationship 
between human and the five Caenorhabditis elegans Wnt genes is less apparent [21].  
The finding from phylogenetic analyses on Wnt genes that came as a surprise was that Wnt 
family diversification happened early on during evolution, before the Cambrian explosion, 
which was the time of intense divergence within metazoan subkingdom resulting in the 
appearance of most of the major metazoan taxonomic groups [22]. The unexpected insight 
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came from the analysis of Wnt genes presence in the sea anemone Nematostella vectensis 
which contains nearly all of the Wnt genes found in vertebrates. N. vectensis, a species 
belonging to cnidarians, was shown to display eleven of the twelve Wnt subfamilies [23] 
arguing that at least eleven of twelve Wnt gene subfamilies must have already been present as 
early as before the divergence of cnidarians and bilaterians. The staggered expression along 
the oral-aboral axis of Wnt genes during Nematostella embryogenesis (‘the Wnt code’, [23]), 
suggests an ancient and primary role of Wnts in gastrulation and axial differentiation, the 
function that is taken over by hox genes in bilaterians (the hox expression cluster or ‘the hox 
code’, that is present in bilaterian embryogenesis is missing during cnidarian development) 
[24]. Of a note, besides of the rich Wnt gene repertoire found in Nematostella, the studies 
from the same organism and related cnidarian Hydra show that other components of 
canonical and non canonical Wnt pathways (Wnt/planar cell polarity and Wnt/Calcium 
pathways, introduced in further chapters of the thesis) were already present in these ancient 
organisms [24]. 
In conclusion, the findings from cnidarian genomes show that highly branched Wnt gene 
family and the plentitude of Wnt pathways already existed in organisms with simpler body 
plans, much before the emergence of complex bilaterian morphological and anatomical 
constitution in whose patterning Wnt signaling, together with several other core 
developmental pathways, plays the major role.  
In contrast to many Wnt genes present in Nematostella genome, there are fewer Wnts both in 
nematode and a fly (5 Wnt genes in C. elegans and 7 in Drosophila) than in their common 
ancestor Urbilateria, which exemplifies the major gene loss that occurred in the protostome 
lineage of bilaterian evolution [20]. So, although many of the Wnt genes already existed in a 
genome of lower organisms, they were apparently lost in some of their more developed 
descendants showing that there is no simple correlation between complexity of an organism 
on the morphological and genetic level. 
 
1.1.2.2. Regulation of Wnt expression  
1.1.2.2.1. Regulation at the transcriptional level 
The most of the studies on Wnt transcription regulation were performed in mice analyzing the 
interference with Wnt1 effects on central nervous system (CNS) patterning. Expression of 
Wnt1 is one of the earliest signals associated with CNS patterning, and targeted disruption of 
this gene in mice causes severe abnormalities in midbrain and cerebellar development [25], 
[26]. The cis-acting regulatory region of Wnt1 was shown to be a 5.5 kilobase (kb) enhancer 
3’ of the coding region [27]. Within this enhancer, an evolutionary conserved 110 base pair 
(bp) region was found to be sufficient to activate lacZ reporter in the Wnt1 pattern at neural 
plate stages [28]. Since then, many efforts have been invested to detect transcription factor(s) 
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binding to these regulatory sequences and activating the expression of Wnt1. Pax-2, a paired 
domain containing transcription factor, and Cubitus interruptus (Ci), a transcription regulator 
involved in hedgehog (hh) signaling in Drosophila, were suggested as candidates that bind 
Wnt1 regulatory region based on expression studies, but until now, there is no direct evidence 
of interaction between these factors and Wnt1 gene elements [29]. 
While the activators of Wnt1 expression have not yet been identified, there are several 
proteins known to repress Wnt1 expression, like Emx2, a homeodomain transcription factor, 
and Six3, a member of the Six family of homeobox genes [29]. 
 
1.1.2.2.2. Alternative splicing and post-transcriptional regulation  
The majority of human WNT genes contain four coding exons that transcribe mRNA that is 
translated into proteins approximately 350 amino acids long, ranging in molecular weight 
from 39 kDa (Wnt7a) to 46 kDa (Wnt10a) [21], [30].  All Wnts contain 23 to 25 conserved 
cysteine residues important for proper protein folding and multimerization (Figure 1a). 
Several members of the family appear in different splicing variants, an example of which is 
shown in Figure 1b.                                                                           
 
Figure 1a Structural features of the Wnt 
protein. The amino terminus contains a signal 
sequence (S) that mediates interactions with 
Wnt receptors, but carboxyl terminus was 
shown to be required for activation of these 
receptors [31]. All Wnts contain 23 to 25 
conserved cysteine residues (C) with similar 
spacing, suggesting that the folding of Wnt 
proteins depends on the formation of multiple 
intramolecular disulfide bonds. 
 
Figure 1b Structures of selected members of the 
human WNT gene family. Exons are shown as 
boxes and introns as lines. For each gene, 
‘RNA’ represents the portion of the gene that is 
transcribed and ‘CDS’ represents the portion 
that encodes protein. WNT8a/d is an example of 
a gene with 3’ alternative splicing and WNT16 is 
an example of a gene with alternatively used 5’ 
exons.  Adapted from [21]. 
 
 
As mentioned before, members of the Wnt gene family play significant roles during 
development, and therefore tight regulation of their expression in space and time is of a vital 
importance for an organism. As an example, transient expression of Xenopus Wnt8 (Xwnt8) in 
ventral and lateral mesoderm during gastrulation is required for muscle development, but its 
concomitant downregulation following gastrulation is necessary to prevent overcommitment 
of these cells to a myogenic fate at the expense of scleroteme formation [29]. The negative 
regulation of the expression of Xwnt8 is achieved at the level of RNA stability and translation, 
and is mediated by the 3’-untranslated region (3’-UTR) of Xwnt8 [32]. 
 
1a
 
 
1b
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1.1.2.2.3. Post-translational modifications 
Unlike the many growth factors that were identified and purified as soluble fractions that 
promote cell growth in cell culture, Wnts were discovered in genetic screens, as described in 
previous chapters (1.1.1.). The reason behind this is the fact that Wnts are not freely soluble 
and therefore are difficult to purify [33]. The primary protein structure of Wnts contains a 
signal sequence for secretion, several highly charged amino-acid residues and many potential 
glycosylation sites. According to the primary amino-acid sequence, the Wnt proteins were 
expected to be soluble. In contrast, due to the post-translational modifications, Wnts turned 
out to be highly hydrophobic. Within the endoplasmic reticulum (ER), immature Wnts 
undergo N-glycosylation whose significance for signaling, targeting or secretion of the 
protein has not been deciphered yet. More importantly, murine Wnt3A and Drosophila Wg 
were shown to be post-transcriptionally palmitoylated at a highly conserved cysteine residue 
[33], [34]. While it was shown that this lipid modification is necessary for Wnt function, the 
role that it plays is still not completely clear. It was suggested that Wnt palmitoylation may 
protect the modified cysteine from forming a disulfide bond, preventing the abberant folding 
of the protein [30]. A palmitate group can also act as intracellular signal that allows the proper 
routing of the protein through, for example, compartments of the Wnt-producing cells where 
Wnts acquire their signaling potential; or to lipid rafts, the hydrophobic signaling domains 
within the cell membrane [30], [35]. Furthermore, it was shown that palmitoylation of Wnt 
proteins is needed for their N-glycosylation probably by serving to anchor the proteins to the 
ER membrane in close proximity to the oligosaccharyl transferase (OST) complex that is 
glycosylating Wnts. Finally, hydrophobicity due to palmitoylation could be important after 
secretion for targeting Wnt to membranes of receiving cells, and for their association with the 
receptor [30], [35]. 
Of the proteins that might be involved in Wnt palmitoylation (glycosylation as well), the ER 
membrane-bound O-acyltransferase (MBOAT) Porcupine is the most likely candidate [30], 
[35].  
 
1.1.2.3. Secretion and gradient formation 
After being translated, Wnt proteins move through the ER and trans-Golgi network (TGN) 
within the producing cell to acquire the post-translational modifications described above 
(chapter 1.1.2.2.3.). There are indications that, following the exit from TGN, Wnt proteins 
might be secreted through regulated secretion route, contrary to unregulated, ‘default’ 
secretory pathway. For example, a fraction of Drosophila Wg has been found in the 
endosomal compartment as well as in recycling vesicles [36]. It is not clear, however, whether 
this endocytic part of Wg has been retrieved from the surface, or it enters endosomes directly 
during the secretion process. Another indication that Wnts might be secreted through 
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alternative secretory route comes from the fact that Wg has been found to associate with lipid 
rafts, which are, besides serving as signaling platforms within the cell membrane [37], 
domains that can partition proteins into specialized sorting and secreting routes [38]. 
Recently, the multipass transmembrane protein Wntless (Wls) located at the Golgi and cell 
surface membranes, but shown to be present on endosomes as well, has been implicated in 
Wnt secretion. Lack of Wls results in inhibition of the Wnt transport to the surface of a 
producing cell, and its concomitant intracellular accumulation [39], [40]. Most probably Wls 
acts as a cargo receptor assisting Wnt to reach the site from which it gets released. The other 
Wnt regulator that was discovered to be important for its secretion is retromer, a conserved 
multiprotein complex composed of members of the Vps family [41], [42]. The current 
hypothesis based on the recent work from several groups is that retromer serves to retrieve 
Wls from endosomal compartments to the trans-Golgi network after its internalization from 
the plasma membrane [43], [44], [45], [46], [47], reviewed in [48]. In this way retromer 
prevents Wls degradation in lysosomes and makes it ready for further rounds of Wnt 
transport.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Models of Wls-dependent Wnt secretion. Wnt is lipid-modified in the endoplasmic reticulum by Porc (step 1) 
and travels to the Golgi where it binds to Wls (step 2), facilitating its delivery to the apical plasma membrane (step 3). In 
model 1, Wnt and Wls dissociate on the plasma membrane. Wnt associates with Reggie-1/Flotillin-2 containing 
microdomains, and is internalized (step 4). In endosomal compartments, Wnt is loaded on lipoprotein particles by an 
unknown mechansim (step 5), and is released from the basolateral surface for long-range signalling (step 6). In model 2, 
Wnt and Wls are internalized together (step 4), and dissociate in endosomal compartments (step 5). There, Wnt is loaded 
on lipoprotein particles and released from the basolateral surface (step 6). In both models, Evi is recycled to the Golgi in 
a retromer-dependent manner (step 7). Note that, in both models, membranebound Wnt signals from the apical membrane 
to induce short-range targets, whereas the long-range concentration gradient forms on the basal surface. Evi, Evenness 
interrupted; Porc, Porcupine; Wls,Wntless. Adapted from [48]. 
 
A different mechanism has been proposed for Wnt extracellular gradient formation that 
enables these proteins to bind receptors and signal several cell diameters away from the 
secreting cell. It has been speculated that loading of Wnts to lipoprotein particles which might 
serve as vehicles for the movement, as well as their association with protein Reggie-
1/Flotillin-2 are important for their distant signaling [30], [49], [48]. The regulation and 
processes involved in Wnt trafficking are summarized in Figure 2.  
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1.1.3. Receptors  
The first fz gene was found in genetic screens for regulators of tissue polarity in Drosophila 
[50], [51]. However, due to the functional redundancy among members of the Fz family in 
this model, the connection with Wnt signaling was realized only later on, after several other 
downstream components of the pathway and their relations were already described [52].  
Human and mouse genome contain ten, Drosophila four and C. elegans three fz genes. 
Human fz genes code for sequences ranging from 537 to 706 amino acid residues. Analysis of 
fz primary sequence shows high homology to smoothened (smo), another conserved 
Drosophila gene whose product is involved in transducing Hedgehog signaling [53]. In 
addition, Fz- and Smo-like receptors have been identified in the social amoeba Dictyostelium 
discoideum, despite the absence of Wnt and Hedgehog genes in its genome, implying an 
interesting aspect on the evolution of Wnt signaling [54]. 
Fz are 7 transmembrane spanning (7-TMS) receptors exhibiting extracellular N-terminus with 
cystein rich domain (CRD) important for ligand binding or accumulation (Figure 3.). The N-
terminus is also a site of N-glycosylations whose biological relevance is unknown. 
Intracellular domain of human Fz-1, -2, -4, -5, -7, -8 and -10, but not those of Fz-3, -6, and -9, 
contain the C-terminal motif ‘Ser/Thr/-Xxx-Val’ which constitutes a binding motif for 
proteins with a PDZ domain [55]. 
 
Figure 3. Schematic depiction of Frizzled 
structure. The three domains of a receptor are the 
extracellular, the 7 transmembrane spanning 
segments, and the cytoplasmic domain. The seven 
transmembrane segments (labeled in Roman 
numerals I–VII) of the receptor constitute the 
lipid bilayer domain.  
A conserved disulfide bridge (S–S) occurs 
between two extracellular loops. The intracellular 
loops (labeled 1, 2, and 3) and the C-terminal tail 
of a GPCR constitute the cytoplasmic domains 
that are intimately involved in signal propagation 
to heterotrimeric G-proteins. Adapted from [55]. 
 
 
Fz receptors belong to the superfamily of G protein-coupled receptors (GPCRs, reviewed in 
[56]) with which they share many structural similarities, including 7-TMS region and the 
organization of extra- and intracellular segments. The general functional feature of GPCRs is 
the activation of trimeric G proteins that consist of the GDP/GTP bound alpha subunit (Gα) 
and the tightly associated beta and gamma subunits (Gβγ). Upon activation of a receptor its 
intracellular domain serves as guanine nucleotide exchange factor (GEF) that is catalyzing the 
exchange of G protein bound GDP for GTP, which results in dissociation of a heterotrimeric 
protein into the activated GαGTP and Gβγ subunits. Activated subunits from both Gα and Gβγ 
families are able to transduce signaling to downstream components.  
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Besides sharing the structural features of GPCR family, accumulating data indicate the 
involvement of G proteins in some instances of signaling downstream of activated Fz 
receptors. The first evidence for the requirement of G protein subunits Gα0 and Gαq for 
signaling via Fz1 was provided by the lab of Craig Malbon and Randall Moon. The authors 
used pertussis toxin (ptx) and antisense oligodeoxynucleotides to uncouple specific G protein 
subunits from the receptor activation in mouse F9 teratocarcinoma stem cells. Upon blockade 
of Gα0 and Gαq subunits, the effect of Wnt8 acting through Fz1 on the formation of primitive 
endoderm by mouse F9 teratocarcinoma cells was suppressed [57]. In another study Katanaev 
et al expressed ptx or cholera toxin under the eye specific promoter to target G protein 
subunits in Drosophila eye. Blockade of Gα0 by ptx suppressed the appearance of the eye 
phenotype induced by ectopic expression of Fz [58]. Several other strategies like the use of 
chimeric receptor consisting of portions of the beta adrenergic receptor and C terminus of rat 
Fz1 [59], or the overexpression of human Fz1 and Fz2 in yeast and the interference with G 
protein regulated mating pathway [60], all indicate that in some cases G proteins are involved 
in signaling by Fz receptors [61].  
It is considered that GαGTP subunit could potentially act through axin, a scaffold protein 
involved in Wnt canonical signaling (described in further chapters); or, in the case of other 
Wnt pathways, the interaction with phospholipase C γ (PLCγ) or the tubulin cytoskeleton are 
possible [54]. The interaction of Gβγ subunit with Dishevelled protein (Dvl, introduced in 
further chapters) was shown by Randall Moon lab [62], suggesting that Gβγ subunit, which 
stays at the plasma membrane after trimer dissociation, could recruit Dvl from the cytoplasm 
and mediate its activation.  
However, the evidence for direct role of Fz receptors as GEF is still lacking. At the moment, 
there is a consensus in literature that it is probable that both G protein dependant and 
independent signaling can occur downstream of Fz receptors [54]. 
 
1.1.4. Non conventional ligands and receptors in Wnt signaling  
Besides Wnt and Fz proteins, several other unrelated molecules are involved in signaling as 
initiators or transducers of the Wnt signal. The structures of known ligands, inhibitors, 
receptors and co receptors participating in Wnt signaling are shown in Figure 4. 
Norrin is a secreted protein with a cystein-knot motif, unrelated to Wnt, but with the ability to 
activate the β-catenin pathway through Fz4 and LRP5. Norrin is encoded by the Norrie 
disease gene and is essential for vascular development in the eye and ear. The Norrie disease 
is an X-linked human congenital retinal disease caused by mutations in norrin gene and 
manifested as blindness because of the incomplete vascularization of the peripheral retina 
[63]. More detailed description of Norrin action during eye and ear vascularization is 
provided in chapter 1.2.3.  
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R-spondin is protein with a thrombospondin type I repeat domain. It was shown to be 
required for Wnt dependent myogenesis in Xenopus [64], and its role in angiogenesis has 
been demonstrated recently [65], (chapter 1.2.3.). 
Several natural occurring inhibitors of Wnt signaling are known, and their downregulation, as 
described in chapter 1.1.6., has been detected in some cancers. The five sFRP family 
members are antagosists that directly bind to Wnts preventing them from interaction with Fzs, 
or inhibit the signaling by forming nonfunctional complexes with Fzs. It is thought that during 
development sFRPs control morphogenesis gradients of Wnt activity.  
The Dkk family comprises four members all of which inhibit Wnt signaling either by binding 
to low-density lipoprotein receptor-related protein 5/6 (LRP5/6, see below) thus preventing 
Fz-LRP complex formation, or by promoting endocytosis and removal of LRP5/6 from the 
cell surface membrane. Dkk was shown to be essential for Xenopus embryos head formation 
[64]. 
 
 
Figure 4. Structures of ligands and receptors 
participating in Wnt signaling. C-Knot, 
cysteine-knot motif; TSR, thrombospondin 
type I domain; CRD, cysteine rich domain; 
NTR, netrin domain; TM transmembrane 
domain; E1, EGF-like domain; KR, kringle 
domain; Pro, proline-rich domain; WIF, 
Wnt-inhibitory factor domain; WSC, cell 
wall integrity and stress response component 
domain; CUB, C1q-Uegf-BMP-1 domain. 
Adapted from [64]. 
 
 
 
 
 
 
 
 
 
In addition to Fz proteins described in previous section, receptors from LRP family as well as 
transmembrane receptors Ror, Ryk and Kremen, are participating in Wnt signal reception. 
LRP5, LRP6 and their Drosophila homologue Arrow are a type I single-pass transmembrane 
proteins belonging to a subfamily of the low density lipoprotein (LDL) receptor family, 
whose members play important roles in metabolism and development (reviewed in [66]). 
LRP5/6 and Arrow appear to be specifically required as coreceptors for Wnt/β-catenin 
signaling as discussed in chapter 1.1.5.2.2. 
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1.1.5. Heterogeneity of signaling pathways initiated by Wnts   
The complexity of Wnt intracellular signaling pathways parallels the complexity observed in 
the heterogeneity of Wnt ligands and receptors. Signaling cascades initiated by Wnts include 
the Wnt β-catenin pathway, usually referred to as ‘Wnt canonical pathway’, Wnt planar cell 
polarity (PCP) and Wnt-calcium pathways. The existence of several other pathways 
stimulated by Wnts has been reported recently [67].  
 
1.1.5.1. Dishevelled phosphorylation as a common step in Wnt signaling 
The first known downstream effect of Wnt binding to its receptor that seems to be shared 
among all Wnt signaling branches is Dvl phosphorylation and subsequent activation. Dvl is a 
cytoplasmic modular protein consisting of 500 to 600 amino acids. There are three Dvl 
homologs in human and mice but only one Dvl has been identified in Drosophila [68]. The 
mechanism by which Dvl gets recruited to receptor upon initiation of signaling, as well as the 
nature of ‘activated’ Dvl and the role of phosphorylation in it, are unknown. It was reported 
that Fz can directly bind to PDZ domain of Dvl, but with weak affinity [69]. Casein kinase-
1ε (CK1ε) [70] and -2 (CK2) [71], as well as PAR1 [72] have been implicated in Dvl 
phosphorylation. Protein kinase C δ (PKCδ) was shown to be important for its localization 
and activity in a branch of noncanonical Wnt pathway [73]. 
As mentioned, Dvl phosphorylation was shown to mediate β-catenin and PCP pathways [74], 
as well as Wnt-calcium pathway [75]. However, the mode of Dvl action is different 
depending upon which pathway is being initiated because different domains of the protein are 
involved [68]. 
 
1.1.5.2. Wnt β-catenin pathway  
1.1.5.2.1. β-catenin ‘destruction complex’ 
In the absence of activated Wnt β-catenin signaling, the transcription co-factor β-catenin is 
binding to its ‘destruction complex’ that consists of axin, adenomatous polyposis coli (APC), 
glycogen synthase kinase-3β (GSK-3β) and casein kinase-1α (CK1α). Axin is a cytoplasmic 
scaffold protein which provides a platform for binding of β-catenin, APC and kinases. It has 
been demonstrated in a recent work that assembly of a destruction complex is a highly 
cooperative event that involves the recruitment of components via indirect interactions with 
other bound partners, which results in robustness of a process of complex formation [76]. In a 
complex, CK1α is a ‘priming’ kinase whose phosphorylation of β-catenin on Serine 45 
(Ser45) residue precedes and is required for subsequent GSK-3 phosphorylation of Ser33, 
Ser37, and Threonine 41 (Thr41) residues, positioned at the amino terminal region of the 
protien [77]. Phosphorylated β-catenin gets ubiquitinylated by E3 ubiquitin ligase β-TrCP (β-
transducin repeat containing protein; or its mouse homolog FWD1), and targeted for 
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proteasomal degradation [77], [78]. It has been recently shown that the role of APC in a 
complex is to protect phosphorylated sites of β-catenin from the action of phosphatases, 
before ubiquitination takes place. In the absence of functional APC, Ser/Thr protein 
phosphatase 2A (PP2A) cleaves unprotected phosphate groups and inhibits β-catenin 
degradation [79]. 
 
1.1.5.2.2. Dissasembly of ‘destruction complex’ upon pathway activation 
In addition to binding of a Wnt to Fz, for a Wnt β-catenin signaling to take place, the presence 
of a coreceptor LRP5/6 is required. Binding of Wnt to Fz and LRP5/6 causes the formation of 
their ternary complex [80].  
Two groups have demonstrated that upon ternary complex formation, CK1γ and GSK-3β 
phosphorylate LRP6 at Thr and Ser residues respectively [81], [82], [83]. For phosphorylation 
by CK1γ at Thr residue to take place, aggregation of LRP6 in so called signalosomes at the 
plasma membrane is required. Formation of LRP6 signalosomes was shown to be Dvl 
dependent [84]. The phosphorylation of LRP6 at Ser residue by GSK-3β is axin dependent 
event and requires the recruitment of a complex formed by Dvl-Axin-Gsk3β [85]. It was 
recently shown that formation of phosphatidylinositol 4,5-bisphosphates [PtdIns (4,5)P2] by 
action of frizzled and disheveled on phosphatidylinositol-4-kinase type IIα and 
phosphatidylinositol-4-phosphate 5-kinase type I (PIP5KI), is needed, but not sufficient for 
phosphorylation of LRP at both residues [86]. Phosphorylation of cytoplasmic tail of LRP6 
and recruitment of Axin to activated co receptor causes disassembly of β-catenin ‘destruction 
complex’.  
The experiments mentioned above indicate the crucial role of Axin in regulation of the Wnt β-
catenin signaling, predicted by some earlier reviews [87]. Unlike signaling via receptor 
tyrosine kinases (RTKs, presented in other sections of the thesis), where signal gets amplified 
by action of receptor as a catalyst on downstream components, the removal of a negative 
regulator Axin in Wnt signaling seemes to imply stoichiometric rather than a catalytic 
mechanism of signal transduction [83]. To test whether amplification step takes place during 
Wnt β-catenin signaling as well, Baig-Lewis et al used a chimeric Frizzled2-Arrow protein 
containing the intracellular portion of Arrow (homolog of mammalian LRP) in Drosophila 
that lack endogenous Wg and Arrow. The authors showed that the rescue of Wnt signaling by 
fusion protein in these flies was only partial indicating that Arrow not only plays an essential 
role as a Wg coreceptor, but also may function downstream of signal initiation to amplify the 
initial Wg signal [88]. Indeed, the extracellularly truncated dimerizing version of Arrow 
strongly amplified Wnt signaling in a corresponding developmental context, but without an 
ability to initiate it [88]. 
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This argues that amplification of Wnt signal takes place in vivo, and that this process is 
separated (conveyed by different domains of Arrow) from signal initiation (Figure 5) [88], 
[89]. The amplification function of Arrow/LRP appears to be particularly important for distal 
signaling, and may reflect a general mechanism by which cells detect low levels of diffusible 
molecules such as may occur in the distal part of a morphogen gradient [88]. 
 
 
 
 
 
Figure 5. A two-step model for Wg signal 
transduction. The Wg receptor complex consisting of 
Arrow and Frizzleds initiates the cytoplasmic cascade 
in response to Wg binding. Dishevelled transmits this 
response to the Axin complex and may destabilize the 
complex sufficiently to transduce a minor signal to 
the nucleus, via free Armadillo. For maximal 
signaling, Axin relocates to the cell membrane, where 
it interacts with clustered Arrow/LRP and becomes 
inactivated. Armadillo may then be released from 
Axin and newly synthesized Armadillo is no longer 
destroyed, resulting in amplified transcriptional 
activation in the nucleus. Adapted from [88]. 
 
Upon disassembly of ‘destruction complex’, β-catenin is freed, accumulates in cytoplasm and 
enters the nucleus in a process that requires Rac1 activation. Rac1 is a protein from Rho 
family of GTPases and its role in β-catenin translocation was shown to be dependent on 
phosphorylation of β-catenin at S191 and S605, which is mediated by JNK2 kinase [90]. 
 
1.1.5.2.3. β-catenin action on transcription 
In the nucleus, β-catenin associates with T-cell factor/lymphoid enhancer factor (Tcf/Lef) 
transcription regulators. There are four tcf/lef genes in a vertebrate genome whose target sites 
on DNA are highly conserved. In the absence of β-catenin, Tcf acts as a repressor of gene 
transcription by forming a complex with Groucho/Grg/TLE proteins. Upon activation of the 
signaling, translocated β-catenin physically displaces Groucho from Tcf/Lef and induces 
transcription from various target genes, including c-myc, cyclinD1, fra1, c-jun etc.  
In addition to inducing Tcf/Lef and acting as a transcriptional activator on its own, β-catenin 
was shown to bind coactivators that affect the local chromatin, like the histone acetylase CBP 
and Brg-1 that are a component of the SWI/SNF chromatin remodeling complex.  
Other β-catenin nuclear partner, Legless/Bcl9 and Pygopus were found in Drosophila genetic 
screens. The formation of a trimer between Legless/Bcl9, Pygopus and β-catenin has been 
implicated in nuclear import/retention of β-catenin and transcription [91], [92], [93], [94].  
An interesting view on regulation of transcription by Wnt β-catenin comes from the Martinez 
Arias laboratory. In their reviews, the authors argue in favor of existence of hierarchy 
between core developmental pathways Hedgehog (Hh), Bone morphogenetic proteins 
(BMPs), Wnt, Steroid hormone receptor, Notch and RTKs, in transcription during cell fate 
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specification. To filter the noise that is inherent to every biological system (and so it is to 
transcriptional networks that guide cell transitions) the authors hypothesize the existence of 
initiation and stabilization phases of gene transcription during cell transitions. Because of the 
ability of Wnt proteins to spread over large cell populations, the interactions of β-catenin with 
the chromatin remodeling complexes, and the fact that in some cases it was shown that Wnt 
β-catenin signaling is involved in maintenance rather than initiation of transcription, the Wnt 
β-catenin would be, they hypothesize, a candidate for developmental transcription noise 
filtering pathway (together with Notch) [95], [96].  
 
1.1.5.3. Wnt Planar cell polarity pathway 
Organization of cells in apical-basolateral and planar planes are of a crucial importance for a 
tissue to act as a unit. The involvement of Wnt pathway in planar cell polarity (PCP) was 
realized early on with discovery of Drosophila fz and dvl mutants. Flies deficient for these 
genes display disoriented cuticular hair and bristles (Figure 6a-b), as well as disordered 
ommatidia and photoreceptors in the eye [50], [97], [98], [99]. A similar phenotype of 
disoriented fur/hair was described in fz6 deficient mice [100], [101], Figure 6c-d. 
 
 
 
Figure 6. PCP and the organization of tissues. 
Proximal-distal orientation of hairs on appendages in 
Drosophila melanogaster and mouse. a Wing cells of 
D. melanogaster generate an actin hair that points 
distally in wild-type cells. b Mutations in planar cell 
polarity (PCP) genes disrupt this orientation and 
instead, wing hairs create swirls and waves (a fz 
mutant is shown). c,d The pattern of mammalian 
fur/hairs, similar to D. melanogaster wing hairs, is 
regulated by frizzled (Fz)/PCP signalling. In fz 
mutant animals, hairs do not point uniformly distally 
but appear in swirls and waves (a wild-type and a Fz6 
mutant mouse paw are shown in c and d, 
respectively). Adapted from [102] 
 
In case of Drosophila hair and bristles, planar cell polarity stems from antagonizing 
distribution of components of Fz/Fmi core PCP proteins within individual hair producing 
cells. The components of the Fz/Fmi system include Fz and Flamingo (Fmi, also known as 
Starry night/Stan), Dishevelled (Dsh; Dvl in mammals), Prickle (Pk), Strabismus/Van Gogh 
(Stbm/Vang) and Diego (Dgo; Diversin and Inversin in vertebrates). In Drosophila pupal 
wing cells the mentioned proteins are asymmetrically distributed, with Fz-Dsh-Dgo 
complexes enriched at the distal end of each cell, and Stbm-Pk complexes localizing 
proximally (Figure 7., reviewed in [103]). Fmi, an atypical cadherin thought to provide a 
homophilic adhesion function, is evenly distributed at both ends of the cell. An actin based 
hair will always form at a distal side of each cell, where Fz and Dsh are localized. A similar 
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pattern of PCP components distribution has been recently described in mammalian hair germs 
[104], [105]. 
It is thought that coordinated polarization within the plane of cells arises from intercellular 
communication between Fz, Fmi, and Vang [106]. 
Besides regulating hair follicle orientation in the skin, the planar cell polarity pathway was 
shown to govern vertebrate convergent extensions, neural tube closure, eyelid closure, hair 
bundle orientation in inner ear sensory cells etc. 
 
Figure 7. Schematic presentation of the generation of 
asymmetric core PCP protein localization in Drosophila wing 
cells. In pupal wing cells, the core PCP proteins of the 
Fz/Fmi cassette become asymmetrically localized to 
proximal and distal cell membranes. Proximal is left and 
distal is right in all panels. A single cell at different stages 
maturing from left to right is shown in the respective panels 
a–c. (a) Schematic of the localization of the core PCP 
proteins prior to any asymmetry detection at the onset of their 
interactions. (b) During polarization the Fz-Dsh-Dgo 
complexes become enriched at the distal end of each cell, 
whereas the Stbm-Pk complexes concentrate proximally. (c) 
Final stage of polarization with all complexes resolved in 
either distal or proximal cell ends. An actin-based hair is 
formed close to the distal vertex of each cell (where Fz-Dsh 
are localized). Adapted from [103]. 
 
The Wnt pathway initiated during planar cell polarity is schematically outlined in Figure 8b. 
Until now, PCP ligand for Fz has not been found, but in mammals Wnt5a and Wnt11 have 
been shown to have a permissive role [101], [103]. Upon Fz activation the signal is 
transduced via Dvl to downstream members of Rho family of GTPases, Rho and Rac whose 
action through RhoA/Rho kinase (ROCK) and Jun-N-terminal kinase (JNK), respectively, 
induce reorganization of cytoskeleton. 
 
1.1.5.4. Wnt calcium pathway 
Wnt5a and Fz2 are the example of a ligand receptor pair that initiates the Wnt Calcium (Wnt 
Ca2+) pathway. Upon ligand binding, phospholipase C (PLC) gets activated via Gβγ (see 
chapter 1.1.3.) and Dvl. PLC is catalyzing the conversion of phosphatidylinositol-4,5-
biphosphate (PIP2) into inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 gets 
freed from the membrane and binds to IP3 receptor which releases calcium ions from 
intracellular stores. Released calcium acts on calcium-sensitive proteins, like protein kinase C 
(PKC), calcium-calmodulin dependent kinase II (CamKII), and/or calcineurin (CaCN) [107].  
Wnt Ca2+ signaling was shown to be important in processes of cell adhesion and tissue 
separation during gastrulation.   
The schematic depiction of Wnt Ca2+ and other Wnt pathways described in previous chapters 
are shown in Figure 8. Different Wnt signaling routes are mediated through distinct Dvl 
domains. 
Fz 
Dsh 
Dgo 
Stbm
Pk
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Figure 8. Dishevelled mediates at least three signaling cascades. (A) The canonical Wnt pathway. Wnt signals are 
received by Fz receptor and LRP coreceptor. The signal is transduced through Dvl and various other proteins, leading 
to the stabilization of β-catenin, which then together with LEF/TCF controls the transcription of target genes. (B) The 
non-canonical or planar cell polarity (PCP) cascade. A signal is received by Fz receptor and transduced via Dvl to 
Rac and Rho, which then activate downstream targets to modulate the actin cytoskeleton. (C) The Wnt Ca2+ 
pathway. Wnt signaling through the Fz receptors and Dvl and G-proteins leads to the release of intracellular calcium 
and signaling via PLC, CamKII and PKC. GBP, GSK3 Binding Protein; JNK, Jun kinase; ROCK, Rho-associated 
coiled-coil forming kinase. See text for other abbreviations. Adapted from [68]. 
 
 
1.1.6. Wnt signaling in cancer 
Although mammalian Wnt1 was discovered through genetic screens for insertional site of 
MMTV at the beginning of eighties (see chapter 1.1.1.), the connection between Wnt 
signaling and human cancer was established more than a decade after. The laboratories of 
Polakis, Vogelstein and Kinzler showed in 1993 that known tumor suppressor APC binds to 
β-catenin [108], [109]. Mutations in APC were previously found to cause human hereditary 
intestinal cancer syndrome known as Familiar Adenomatous Polyposis (FAP). FAP patients 
inherit mutations in APC on one allele, and, if the mutation on the second allele is acquired, 
they develop benign colon adenomas (polyps). Additional mutations in K-Ras, p53 and 
Smad4 genes through clonal evolution are required for polyp to progress to malignant colon 
carcinoma [110]. Besides FAP, acquisition of APC mutations in both alleles was frequently 
identified in sporadic colorectal cancers (CRC) [110]. 
Three years after revealing interaction between APC and β-catenin, it was realized that 
mutations that inactivate APC lead to constitutive stabilization of β-catenin [111]. 
Inappropriate stabilization of β-catenin, documented in 90% of colorectal cancers [112], 
[113], increases its action as a transcription cofactor and causes upregulation of Tcf/Lef 
transcriptional repertoire in intestines [114], [115]. The subsequent work from Hans Clevers 
group helped to decipher the role that Wnt β-catenin pathway plays in maintenance and 
pathology of highly proliferative intestinal epithelium. In an intestinal crypt, the Wnt gradient 
provides proliferating signals for progenitor cells [116] and controls the expression of the 
EphB/EphrinB countergradient that establishes the crypt-villus boundary [117]. Disruption of 
 17
Wnt β-catenin signaling depletes the epithelial stem cell compartment [118], [119], [120], 
while its upregulation, as mentioned, starts a genetic program that evokes abnormal 
proliferation of crypt epithelial cells and adenomatous state. In their attempt to reveal the 
genes that cause transformation of normal epithelium, Clevers lab found that ablation of 
cMyc rescues APC deficiency in the intestine [121], [122]. Currently, several groups are 
trying to find other molecules that are involved in either Wnt β-catenin transcription, or 
regulation of the pathway. Recently, Randall Moon lab, in their RNA interference screen in 
human DLD1 colon adenocarcinoma cells, found that AGGF1, a chromatin-associated protein 
is required for β-catenin transcription [123]. In a separate work, two groups discovered that 
CDK8, a cyclin dependent kinase, is needed for β-catenin binding to cMyc promoter, and that 
transcription factor E2F1, that is negatively regulated by CDK8 and retinoblastoma tumor 
suppressor protein (pRb), counteracts the activity of β-catenin [124], [125], [126].  
Besides its evident role in colon cancer formation, deregulated Wnt β-catenin signaling has 
been detected as a primary cause of the human hair follicle tumors [113], [110]. 
Wilms tumor, a cancer of the kidney whose appearance is closely connected to development, 
was shown to display mutations in β-catenin in 10% of cases [127]. In a recent study, Rivera 
et al found that inactivating mutations in another gene, WTX are present in about one third of 
Wilms tumors [128]. WTX, as shown by Major et al, is a novel component of β-catenin 
destruction complex that negatively regulates β-catenin and in this way acts as a tumor 
suppressor [129], [130].  
Mutations in β-catenin have not been reported in breast cancer. However, there is evidence, 
that the expression of negative regulators of pathway, like sFRP1, is suppressed in breast 
carcinomas [131]. Reintroduction of these regulators in human cancer cell lines, as shown by 
recent work from our lab, reduces their ability to grow as xenografts [132]. 
As described above, deregulated Wnt β-catenin pathway is frequently detected in several 
types of human carcinomas. For this reason, a lot of effort is being made to design 
therapeutics that would block the aberrant pathway activation. Some already existing 
substances, like non steroidal antinflammatory drugs (NSAIDs) were shown to reverse polyp 
growth in patients with FAP most probably by acting on the capability of cells to degrade β-
catenin [112].  
As the central event in β-catenin action on transcription is its association with TCF/LEF 
factor, the formation of this complex is of an interest as a pharmaceutical target. High 
throughput screens of natural compounds revealed three molecules that had the ability to 
inhibit TCF/β-catenin complex formation that in addition showed efficiency in secondary 
assays of Xenopus axis duplication and inhibition of growth of colon cancer cell lines with 
constitutively active Wnt β-catenin signaling [133]. However, the essential role of Wnt β-
catenin signaling in homeostasis of adult tissues and stem cell compartments [113], [110] as 
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well as the binding of β-catenin to TCF, E-cadherin and APC through overlapping domains, 
raise concerns about the negative effects of TCF/β-catenin interaction blockade on healthy 
tissues [112].  
While the causative role of deregulated Wnt β-catenin signaling in different types of human 
cancer is well documented, the role of non canonical Wnt pathways in tumorigenesis is less 
evident. Several publications indicate the expression of Wnt5a as a marker of highly 
aggressive melanomas. In melanoma, Wnt5a was shown to enhance cell migration and 
invasion acting through Fz5 and PKC [134], [135]. 
   
1.2. Angiogenesis 
Angiogenesis is a process of new blood vessel formation from preexisting vasculature [136], 
[137]. During development initial vascular plexus is formed by vasculogenesis, a process that 
involves direct aggregation of angioblasts, precursors of endothelial cells that share an origin 
with haematopoietic progenitors. Vasculogenesis is followed by angiogenesis that causes 
subsequent expansion and refinement of vascular network, as shown in Figure 9. 
 
Figure 9. Development of the vascular systems: 
during vasculogenesis, endothelial progenitors give 
rise to a primitive vascular labyrinth of arteries and 
veins. During subsequent angiogenesis, the network 
expands, pericytes (PCs) and smooth muscle cells 
(SMCs) cover nascent endothelial channels, and a 
stereotypically organized vascular network emerges. 
Lymph vessels develop via transdifferentiation from 
veins. Adapted from [138]. 
 
In addition to wound healing that is characterized by extensive angiogenesis, the only adult 
tissues in which angiogenesis takes place are cycling ovary and placenta during pregnancy. 
Deregulated excessive angiogenesis is the cause or a hallmark of several pathological states, 
for example cancer, diabetic eye disease, rheumatoid arthritis. In contrast, insufficient 
angiogenesis is seen in conditions such as the coronary heart disease, stroke and delayed 
wound healing, to name a few [136]. 
 
1.2.1. The beginnings of angiogenesis research field 
The foundations to the field of angiogenesis were given by surgeon Judah Folkman at the 
beginning of 1970s. Although the connection between tumor growth and vascularization was 
realized by early tumor researches more than a century ago, it was only sporadically 
investigated in several publications since then on (reviewed in [139], [140]). However, in 
1971 Judah Folkman postulated that antiangiogenesis could be an effective strategy in cancer 
treatment [2]. Subsequently, the Folkman group identified several angiogenesis factors and 
inhibitors, and improved our understanding of the role of angiogenesis in tumor formation 
[136], [140]. Many of the angiogenesis assays used nowadays were established by the same 
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lab. Moreover, like stated by Napoleone Ferrara, the researcher whose group participated in 
identification of vascular endothelial growth factor (VEGF), ‘the hypothesis that targeting 
angiogenesis could be a strategy to treat cancer and various other diseases has been 
significant in inspiring many investigators to join this field’ [139]. Another aspect of Judah 
Folkman’s work and angiogenesis research that was visionary at the time was that it promoted 
the concept of targeted therapy for the treatment of cancer. 
The subsequent studies in the angiogenesis field resulted in discovery of signaling pathways 
involved in blood vessel formation and maturation, and more important for cancer research, in 
creation of an effective anticancer drug that is targeting angiogenesis.  
 
1.2.2. Signaling pathways governing blood vessel formation 
Blood vessels consist of an endothelial cell monolayer that is lining the lumen of the vessel, 
followed by a layer of supportive smooth muscle cells (or pericytes in case of capillaries) 
embedded in the vascular basement membrane (VBM) that consists of type IV collagen, 
laminin and proteoglycans.  
 
Figure 10. Blood vessel architecture. The 
vascular basement membrane interacts 
directly with the pericytes, which are on 
the outside, and the endothelial cells, 
which line the inside of the vessel. 
Adapted from [141]. 
 
 
In majority of healthy adult tissues the balance between angiogenic factors and inhibitors is 
keeping endothelial cells in quiescent, non proliferative state (Figure 11.). Endothelial cells 
are among the most quiescent cells of the body with a turnover time usually counted in 
months. However, during angiogenesis they proliferate rapidly within days. It was suggested 
that in conditions such as cancer formation or wound healing, the balance of angiogenic 
activators and inhibitors shifts in favor of activators, and the so-called angiogenic switch, 
followed by the expansion of vascular bed, takes place. 
 
Figure 11. The angiogenic balance. Angiogenesis is orchestrated by 
a variety of activators and inhibitors. Activators of endothelial-cell 
proliferation and migration are mainly receptor tyrosine kinase 
ligands, such as vascular endothelial growth factor (VEGF), 
fibroblast growth factors (FGFs), platelet-derived growth factor 
(PDGF) and epidermal growth factor (EGF), but can also be of very 
different origin, such as lysophosphatic acid (LPA). The first 
described angiogenic inhibitor was thrombospondin-1, which 
modulates endothelial-cell proliferation and motility. Many 
inhibitory molecules, such as ‘statins’, are derived from larger 
proteins that have no effect on angiogenesis. Adapted from [142]. 
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1.2.2.1. Tumor angiogenesis 
Many of the steps of physiological angiogenesis are recapitulated by tumor blood vessel 
formation, although, because of the access to excessive amounts of growth factors, tumor 
associated vasculature is more leaky, tortuous, disorgarnized and less functional.  
During cancer formation, hypoxia is the most prominent trigger of angiogenic switch. In the 
situation of low oxygen in tissues that are not adequately perfused with vasculature, the 
hypoxia inducible factor (HIF) is initiating transcription from the set of angiogenic activators. 
In the presence of oxygen, a specific proline residue of HIF in the oxygen dependent 
degradation domain of the protein, gets hydroxylated which facilitates the recognition of HIF 
by von Hippel Lindau tumor suppressor (VHL) which is the substrate recognition component 
of the ubiquitin protein ligase complex that catalyzes the transfer of ubiquitin to lysine residue 
of a substrate. Hydroxylated and polyubiquitinylated HIF is targeted for degradation. In the 
absence of oxygen, hydroxylation and VHL mediated polyubiquitinylation of HIF are 
suppressed, so HIF accumulates, enters the nucleus and activates ‘angiogenic’ gene 
expression, among which VEGF seems to be the most relevant for the induction of angiogenic 
response (reviewed in [143]). High levels of VEGF expression alone were shown to be 
sufficient to evoke angiogenic response in quiescent vasculature [144]. The action of 
angiogenic growth factors (VEGF; basic fibroblast growth factor, bFGF; platelet derived 
growth factor, PDGF), chemokines and matrix metaloproteinases (MMPs) causes degradation 
of the VBM and endothelial cell sprouting. Degradation of the mature VBM promotes 
endothelial cell proliferation and migration, as well as the liberation of sequestered vascular 
growth factors and the detachment of pericytes.  
The recent work from several groups added to our understanding of the sprouting 
angiogenesis. Three different cell types can be distinguished in angiogenic sprouts. The tip 
cells are located at the very end of the growing sprout. These cells are of a migrating and non 
proliferative phenotype and characterized by the expression of the Notch ligand Delta like 
ligand 4 (Dll4). The Dll4 acts in paracrine manner on Notch receptors expressed by adjacent 
highly proliferative stalk cells to downregulate the expression of the vascular endothelial 
growth factor receptor 2 (VEGFR2, see chapter 3.1.3.) in these cells. The downregulation of 
VEGFR2 causes the neighboring stalk cells to become less responsive to VEGF proliferative 
signals and finally acquire the quiescent tube cell phenotype. In this way, Notch signaling 
limits the action of VEGF on vasculature and protects the nascent blood vessels from 
excessive proliferation [145], [146], [147], [148], [149], [150]. Recently, it was shown that 
inhibition of Notch signaling in tip cells causes the upregulation of the vascular endothelial 
growth factor receptor 3 (VEGFR, chapter 3.1.4.) in these cells [151] and results in sprouting 
angiogenesis [152], [153]. Consequently, the inhibition of Notch signaling in tumor 
vasculature causes the increase in the number of vascular sprouts because of the elevated 
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levels of VEGFR2 and VEGFR3. Paradoxically, this results in slower tumor growth because 
the overall vascular system, although consisting of more sprouts, is less mature and less 
functional.  
Experiments mentioned above highlight the importance of stabilization and maturation of 
nascent blood vessels for their proper function. This process requires the recruitment of 
supporting mural cells (smooth muscle cells or pericytes) and generation of extracellular 
matrix. Several pathways are known to be involved in this processes, among them platelet 
derived growth factor (PDGF), sphingosine-1-phosphate (SIP1), angiopoietin1-Tie2, and 
transforming growth factor β (TGFβ). 
In addition to sprouting angiogenesis described above, several other processes contribute to 
tumor blood vessels formation (Figure 12). Intususspective angiogenesis is a process of 
remodeling of existing vessels (vessels become thinner or increase in volume) that gives rise 
to new blood vessel usually placed in the lumen of preexisting vessel. This process does not 
require proliferation of endothelial cells and is very rapid (within hours or even minutes). It 
was shown recently that after irradiation or anti angiogenic therapy tumors switch from 
sprouting angiogenesis to intususspection probably because this is the fastest way to 
reconstitute more stabe vascular network [154]. 
 
 
 
 
 
Figure 12. Different mechanisms 
of tumor vascularisation. 
Diagram represents the six 
different types of vascularisation 
observed in solid tumors, 
including sprouting angiogenesis, 
intussusceptive angiogenesis, 
recruitment of endothelial 
progenitor cells, vessel co-
option, vasculogenic mimicry 
and lymphangiogenesis. The 
main key players involved in 
these processes, if known, are 
indicated. Adapted from [155]. 
 
Vessel cooption is the ‘hijack’ of host vasculature by avascular tumors seen in rat C6 glioma, 
murine Lewis lung carcinoma, murine ovarian cancer, human melanoma, and human Kaposi 
sarcoma.  
More than a decade ago it was described that tumor blood vessels can be formed by 
incorporation of circulating bone marrow derived endothelial progenitor cells (EPC) that are 
characterized by expression of surface markers CD34, CD31, VEGFR2, Tie2 and CD14. 
Mobilization of EPC is promoted by several growth factors, chemokines and cytokines.  
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Another way of tumor vessel formation is by so-called vasculogenic mimicry or formation of 
circulatory system by cancer cells themselves. This process is characterized by cancer cell 
dedifferentiation and formation of tube like structures [155].  
 
1.2.3. The role of Wnt pathway in angiogenesis 
The evidence for involvement of Wnt signaling in angiogenesis is provided by studies of mice 
that are deficient for components of the pathway, and by in vitro studies using endothelial 
cells to recapitulate several steps of angiogenesis.  
Mice deficient for Wnt2, Wnt4, Wnt7b, Frizzled4 and Frizzled5 display different localized 
angiogenic phenotypes.  
Wnt2 knockout mice suffer from defects in placental vascularization due to reduced 
capillaries of fetal origin. The placental defects result in reduced weight of newborn pups and 
their perinatal lethality [156].  
The role of Wnt4 during development is to regulate sex specific vasculature and steroid 
production in mammalian gonads. Wnt4 represses mesonephric endothelial and steroidogenic 
cell migration in the XX gonad, preventing the formation of a male-specific coelomic blood 
vessel and the production of steroids. Wnt4 deficient mice develop characteristics of male 
gonads in XX background [157].  
Wnt7b null mice die perinatally because of respiratory failure originating presumably from a 
defect in major pulmonary vessel [158]. They also fail to regress transient retinal vasculature, 
the process that is dependent on macrophage derived Wnt7b signals [159].  
Fz-5 was shown to be essential for angiogenesis in yolk sac and placenta [160]. 
Fz4 is the most studied member of Wnt signaling network in context of angiogenesis, since its 
deregulation or mutations in its unconventional ligand Norrin are causing human retinal 
diseases Familial Exudative Vitreoretinopathy (FEVR) and Norrie disease, respectively. 
These are retinal vascular diseases characterized by incomplete retinal neovascularization that 
causes varying degrees of visual impairment. Several evidences (the similarity of vascular 
phenotype, specificity of binding, activation of downstream canonical pathway etc) indicate 
that these molecules function like ligand receptor pair that is involved in retinal 
vascularization [161], [162], [63], [163]. Fz4 and Norrin mutant mice also display defects in 
female reproductive angiogenesis [159].  
Like elaborated in previous chapters, many of the ‘general’ angiogenic factors (VEGFs, 
angiopoietins), that influence vasculature in several different tissues, have been described. 
However, little is known about tissue specific regulators of blood vessel formation. The 
vasculature of brain forms highy specialized structure named blood brain barrier (BBB) that is 
preventing the invasion of toxins and pathogens from blood to neural tissue. It was presumed 
that blood vessels in brain form by similar process as throughout body and that they 
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subsequently acquire this highly specialized feature because of the instructive role of 
surrounding neural tissue. However, several very recent papers found that brain vasculature is 
differing from that in other tissues by the presence of activated Wnt β-catenin signaling. The 
McMahon group showed that dual depletion of Wnt7a and Wnt7b and interruption of 
downstream Wnt canonical pathway during development causes defects in vasculature of 
central nervous system [164]. In agreement with this study, the important role of canonical 
Wnt signaling in induction of proteins that form blood brain barrier was reported by the 
Dejana group [165]. Barres and coworkers showed that conditional inactivation of β-catenin 
in endothelial cells specifically disrupts central nervous system vasculature, and renders the 
rest of the vasculature intact [166]. Taken together, these studies indicate that in stead of 
displaying systemic effect on vascular biology (like in case of VEGF), canonical Wnt 
signaling is essential for proper vascular formation locally in central nervous system. 
However, the studies from Wnt2, Wnt4, Wnt7b, Frizzled4 and Frizzled5 mice show that 
influence of Wnt signaling network is not limited to angiogenesis coupled with neural tissue. 
Given the redundancy among family members and multiplicity of signaling pathways initiated 
by Wnts (see previous chapters) it is not simple to reconcile the angiogenic phenotypes of 
individual members of the signaling network into a completed picture. However, the essential 
role of Wnt signaling in angiogenesis in many different contexts is emerging. 
The expression of Wnts and Fzs has been documented in various endothelial and smooth 
muscle cell types [167], [168]. Moreover, Wnts are paracrine factors that could be expressed 
by variety of cells and activate signaling on neighbouring endothelium. Masckauchan et al 
detected expression of Fz4, Fz5, Fz6 genes on Human Umbilical Vein Endothelial Cells 
(HUVEC) [169]. The expression of Fz1, 3, 5, and 7 was reported by other labs [163].  
The D’Amore group revealed the versatile role of Wnts in in vitro endothelial cell biology. 
Wnt1 and Wnt5a showed opposing effects on proliferation and tube formation of bovine 
aortic endothelial cells (Wnt1 activated both processes; Wnt5a slowed them down, and also 
did not induce the transcription from βcatenin target genes). Wnt2 showed no effect [170]. 
Endogenous activity of canonical Wnt pathway has been documented in cultured endotheial 
cells [168]. It was shown by Kitajewski group that ectopically expressed β-catenin, Wnt1 and 
Wnt5a induce proliferation of human umbilical vein endothelial cells. In this context, Wnt1 
activates canonical pathway, while the Wnt5a acts through non canonical Wnt signaling 
pathway [169], [171]. The permissive role of planar cell polarity pathway in endothelial cell 
biology has been documented [172]. 
Recently, involvement of atypical Wnt signaling ligand Rspondin3 (Rspo3) in commitment of 
progenitor cells towards endothelial cell lineage was confirmed [65]. Rspo3 was shown to be 
efficient in cell culture experiments, inducing proliferation and angiogenesis of cultured 
endothelial cells.   
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In our study, we show that Fz4 and Fz6 are expressed by human umbilical vein endothelial 
cells (HUVEC) and can convey the Wnt signal to downstream components. We report Wnt3a 
as a novel proangiogenic factor with the ability to induce HUVEC proliferation and 
migration, but without an effect on their survival. Proliferation induced by Wnt3a is VEGFR 
signaling independent. Wnt3a was able to induce canonical Wnt pathway in our model. In 
contrast to promotive effects of Wnt3a on in vitro angiogenesis, Wnt5a did not induce 
proliferation or migration. To test the role of expressed Fz6 in in vivo angiogenesis, we 
injected Fz6 deficient mice and their wild type littermates with Lewis lung carcinoma cells. 
The ablation of Fz6 did not have an effect on quantity or appearance of tumor vasculature.  
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2. VEGF receptors in cancer 
2.1. Vascular endothelial growth factors, discovery and biology 
The members of the vascular endothelial growth factor (VEGF) family are secreted dimeric 
glycoproteins characterized by six conserved cysteine residues that form the so-called 
cysteine knot motif.  
The first member of the family, VEGF or VEGFA, was discovered in 1983 and named tumor 
vascular permeability factor (VPF) because of its ability to induce vascular leakage in the skin 
[173]. Later on, in a separate study, Napoleone Ferrara and colleagues described a novel 
vascular endothelial cell specific growth factor (VEGF) isolated from media conditioned by 
bovine pituitary follicular cells [174]. In 1989 work from the Ferrara and Connolly groups 
demonstrated that VEGF and VPF were the same molecule [175], [176], [177]. 
VEGF is a heparin-binding, homodimeric glycoprotein weighing 45 kDa. The human VEGF 
gene consists of eight exons separated by seven introns. Four different isoforms are generated 
by alternative splicing, containing 121, 165, 189 and 206 amino acids respectively after signal 
sequence cleavage. The isoforms are termed VEGF121, VEGF165, VEGF189 and VEGF206, of 
which VEGF165 is the major isoform. The splicing isoforms differ in their ability to bind 
heparin and consequently range in their availability; from freely diffusible VEGF121, to almost 
completely sequestered VEGF189 and VEGF206. VEGF165 is of intermediate properties, 
because it is secreted, but with a significant fraction remaining bound to the cell surface and 
extracellular matrix [178]. 
Although angiogenesis is a complex process involving several signaling pathways, it is 
thought that the availability of VEGF is the limiting step in the creation of novel blood 
vessels. VEGF is a strong mitogen for endothelial cells, inducing their migration, survival and 
permeability. Inactivation of a single VEGF allele results in embryonic lethality [179], [180], 
while disruption of the autocrine VEGF signaling loop in endothelial cells causes their 
progressive degeneration [181].  
VEGF is expressed by most cancer cell types and some tumor stromal and cancer infiltrating 
cells [178]. It was shown in 1993 that inhibition of VEGF suppresses angiogenesis and tumor 
growth in mice [182]. These results were the first confirmation of an early Judah Folkman 
hypothesis (see previous chapters) about simultaneous targeting of tumor angiogenesis and 
growth.   
The other VEGF family members include placental growth factor (PlGF), VEGFB, VEGFC 
and VEGFD. VEGF homologues encoded by Orf viruses are collectively named VEGFE and 
VEGF like proteins found in snake venoms are usually termed VEGFF. The specificity of 
binding between VEGFs and their receptors is depicted in Figure 13. 
PlGF is mainly expressed in placenta, heart and lungs. PlGF knockout mice do not display 
any apparent phenotype, but were shown to recover poorly from experimental myocardial 
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infarction and hind limb ischemia [183]. While PlGF seems to be dispensable for 
developmental angiogenesis and adult vascular homeostasis, accumulating data suggest that it 
might play important role in cancer, in particular because of its ability to recruit macrophages 
and bone marrow progenitor cells. Because of this quality and other proangiogenic effects, 
targeting PlGF is considered to be a strategy which might improve existing antiangiogenic 
therapies [184].  
VEGFB is one of the least characterized members of the family. Like PlGF, it is not required 
in angiogenesis during development, as in adult tissues. The role of VEGFB in tumor 
angiogenesis and the effects of its blockade on tumor growth remain to be determined. 
While VEGF, PlGF and VEGFB are considered to be factors involved in regulation of 
vascular growth and homeostasis, VEGFC and VEGFD have been characterized as 
lymphangiogenic factors. Unlike other family members that generate different isoforms by 
alternative splicing, VEGFC and VEGFD undergo proteolytic processing. This type of 
modification strongly increases their affinity for their receptors, vascular endothelial growth 
factor receptor 2 and 3 (VEGFR2 and VEGFR3). Hence, the degree of posttranslational 
processing of these factors may in part determine the rate of (lymph)angiogenesis. The 
enzymes known to process VEGFC and VEGFD are the serine protease plasmin and members 
of proprotein convertase family [185]. 
VEGFC was independently found and cloned in 1996 by the groups of Kari Alitalo and 
William Wood [186], [187]. During development, VEGFC, in parallel to its receptor 
VEGFR3, is expressed predominantly in regions where lymphatic vessels develop [188]. In 
adult mice, VEGFC is expressed highly in lymph nodes and to a lesser extent in the heart, 
lung and kidney [189]. Overexpression of VEGFC in mouse skin keratinocytes and in chick 
differentiated chorioallantoic membrane induces lymphangiogenesis without effecting 
angiogenesis [190], [191], [192]. The lymphangiogenic activity of VEGFC was shown to be 
mediated through VEGFR3, as modified protein able only to bind this receptor is sufficient to 
induce lymphangiogenic response [193]. In 2004, the studies on VEGFC knockout mice 
showed that this factor is required for the development of lymphatic vasculature, but is 
dispensable for the formation of blood vessels. In VEGFC deficient mice endothelial cells do 
commit to lymphatic lineage, but fail to sprout and form the lymphatic system. Because of 
this defect these mice die prenatally. The requirement of VEGFC was shown to be dose 
dependent as heterozygous mice survived, however they still suffered from cutaneous 
lymphatic hypoplasia and lymphedema. The lymphangiogenesis observed in VEGFC 
deficient mice was rescued by introduction of recombinant VEGFC and VEGFD, but not 
VEGF [194]. Besides of its developmental role in the formation of lymphatics, it was shown 
that VEGFC mRNA gets upregulated in endothelial cells in response to proinflammatory 
cytokines [189]. 
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VEGFD was discovered in 1998 [195]. Unlike human VEGFD which binds VEGFR2 and 
VEGFR3, mouse homolog binds exclusively to VEGFR3. During development, mouse 
VEGFD is expressed in limb buds, heart, lung and skin. In adult human tissues, VEGFD 
mRNA is prominently expressed in the heart, lung, skeletal muscle, colon and small intestine 
[195]. As in the case for VEGFC, overexpression studies have shown that VEGFD strongly 
induces lymphangiogenesis [193], [196], [197]. In spite of this, ablation of VEGFD did not 
prevent development of normal lymphatic system in mice as was observed in the VEGFC 
knockout [198]. 
The action of VEGFC and VEGFD on lymphatics is mediated through VEGFR3, while the 
signaling through VEGFR2 was shown to evoke effects on the blood vascular endothelium in 
some experimental models. These experiments also showed that VEGFD is a stronger 
angiogenic factor than VEGFC [192]. 
Several years ago, work from groups of Michael Detmar, Michael Pepper and Marc Achen 
showed that ectopic expression of VEGFC or VEGFD in breast [199], pancreatic [200], and 
other mouse tumor models [201], increases lymphangiogenesis and promotes tumor 
metastasis. Subsequently, other studies confirmed the role of the VEGFC, VEGFD and 
VEGFR3 axis in tumor lymphangiogenesis and metastatic spread, suggesting that targeting 
these pathways may suppress cancer progression (reviewed in [185]).  
 
2.2. Vascular endothelial growth factor receptors 
The VEGF receptors are comprised of two families, VEGFRs and neuropilins. VEGFRs 
which are closely related to Fms, Kit and PDGF receptors, are type III receptor tyrosine 
kinases consisting of seven extracellular immunoglobulin-like domains (six in the case of 
VEGFR3), a single transmembrane spanning region and an intracellular consensus tyrosine 
kinase sequence that is interrupted by a kinase insert domain (Figure 13). Upon ligand 
binding receptor dimerization is induced. 
Neuropilins are coreceptors for VEGFs. They consist of a large extracellular domain of about 
860 amino acids, followed by single transmembrane spanning domain and intracellular 
domain that is conserved among family members (reviewed in [202], [203]).  
 
2.2.1. VEGFR1 
VEGFR1 (or Fms like tyrosine kinase, Flt1), the first known member of the family, was 
discovered in 1992 [204]. It is expressed on the surface of vascular endothelial cells, but also 
on bone marrow cells such as macrophages and monocytes. VEGFR1 binds VEGF, PlGF and 
VEGFB. Through alternative splicing, VEGFR1 encodes a soluble variant, the precise 
biological role of which is not known. 
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Interestingly, this receptor binds VEGF with a much higher affinity than does VEGFR2, 
however the binding induces only weak tyrosine kinase activity. For this reason it was 
suggested that VEGFR1 acts as a decoy receptor that regulates angiogenesis by sequestering 
VEGF [205]. Studies of VEGFR1 knockout mice confirmed this hypothesis, showing that the 
loss of this receptor causes embryonic lethality due to vascular overgrowth and 
disorganization [206], [207]. Moreover, mice expressing membrane anchored variant of the 
receptor lacking the tyrosine kinase domain are not only viable, but also do not exhibit any 
vascular defects [208]. 
The ability of VEGFR1 to signal however, seems to be important for the effects observed in 
bone marrow derived cells, namely monocyte migration and differentiation, and the 
recruitment of endothelial cell progenitors from bone marrow [209], [210]. VEGFR1 
signaling is also crucial for the release of hepatotrophic growth factors by liver sinusoidal 
endothelial cells, the mechanism shown to be essential for protection of the liver from toxic 
damage [211]. Another important characteristic of this receptor is that by intracellular 
crosstalk it can strengthen the signaling induced by VEGFR2. It is thought that in this way 
VEGFR1 plays an essential role during pathological angiogenesis and in wound healing 
[205], [212], [213]. 
The expression of VEGFR1 is elevated in lung, prostate, breast and colon cancer, pulmonary 
adenocarcinoma, hepatocellular carcinoma, glioblastoma, multiple myeloma and 
nephroblastoma. In the case of breast cancer and non small cell lung cancer, expression of 
VEGFR1 is predictive of poor prognosis, metastasis and recurrence. It was shown over the 
past several years that inhibition of VEGFR1 suppresses tumor growth and metastasis in 
various tumor models [184]. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Schematic representation of VEGF family ligands and their receptors. VEGFs show 
distinct patterns of receptor specificity. VEGF binds to VEGFR1 and -2 and to receptor 
heterodimers, while VEGFC and -D bind VEGFR2 and -3. Receptor-specific interactions have 
been described for some VEGF variants: PlGF and VEGF-B exclusively bind VEGFR1 and 
VEGFE interacts only with VEGFR2. VEGFF variants interact with either VEGFR1 or -2. 
Adapted from [214]. 
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2.2.2. VEGFR2 
VEGFR2 (kinase insert domain receptor, KDR or fetal liver kinase, Flk1) was found to be a 
receptor for VEGFs in 1992 [215]. It binds VEGF, VEGFC, VEGFD, VEGFE and VEGFF. 
VEGFR2 is expressed on the surface of endothelial cells (vascular and lymphatic), neuronal 
cells, osteoblasts, pancreatic duct cells, retinal progenitor cells, megakaryocytes and 
hematopoietic stem cells [189]. Its expression is down regulated in the adult blood vascular 
endothelial cells, and is again upregulated in the endothelium of angiogenic blood vessels 
[189]. 
VEGFR2 was shown to be the main transducer of VEGF’s proliferative, migratory, survival 
and permeability effects on endothelial cells. Mice deficient for this receptor die during 
embryogenesis due to failed vascular development and hematopoiesis [216].  
Signaling pathways and proteins activated by phosphorylated VEGFR kinase include 
phospholipase Cγ, PI3 kinase, Ras GTPase activating protein and the Src family kinases 
[217], [218]. Activation of Raf-Mek-Erk upon phosphorylation of Tyr1175 and recruitment of 
PLC γ1 pathway is thought to be essential for induction of proliferation. Signaling through 
focal adhesion kinase (FAK) was shown to play a role in the migration induced through 
VEGFR2, while its survival effects are transduced by the action of the PI3kinase/Akt pathway 
(Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. VEGFR2 phosphorylation sites and signal transduction. Intracellular domains of dimerized and 
activated VEGFR2 is shown with tyrosine-phosphorylation sites that are indicated by numbers. Circled R 
indicates that use of the phosphorylation site is regulated dependent on the angiogenic state of the endothelial 
cell. Dark blue squares in the receptor molecules indicate positions of tyrosine residues. Binding of signaling 
molecules (dark blue ovals) to certain phosphorylation sites (boxed numbers), initiates signalling cascades 
(light blue ovals), which leads to the establishment of specific biological responses (pale blue boxes). The 
mode of initiation of certain signalling chains is unclear (dashed arrows). Final biological outcomes that are 
coupled to the respective receptors are indicated in pink boxes. DAG, diacylglycerol; eNOS, endothelial nitric 
oxide synthase; FAK, focal adhesion kinase; HSP27, heat-shock protein-27; MAPK, mitogen-activated 
protein kinase; MEK, MAPK and ERK kinase; PI3K, phosphatidylinositol 3′kinase; PKC, protein kinase C; 
PLCγ, phospholipase Cγ; Shb, SH2 and β-cells; TSAd, T-cell-specific adaptor. Adapted from [217]. 
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Vascular permeability is thought to be induced through Src family kinases, nitric oxide action 
or the effect on components of adherens and gap junctions (VE cadherin, β-catenin, Occludin) 
[217].  
 
2.2.3. VEGFR3 
VEGFR3, also known as fms like tyrosine kinase 4, Flt4, which binds VEGFC and VEGFD, 
is expressed on all endothelia during development, but is restricted in adulthood to lymphatic 
endothelial cells and certain fenestrated blood vasculature [189]. However, it is upregulated in 
proliferating endothelial cells and in pathologic conditions such as tumors (see chapter 
1.2.2.1), [219]. Missense mutations in VEGFR3 in humans have been linked to hereditary 
lymphedema [189].   
VEGFR3 signaling is involved in angiogenesis, lymphangiogenesis and hematopoiesis. The 
ablation of VEGFR3 causes embryonic lethality due to defective remodeling of the primary 
vascular plexus and abnormal hematopoiesis [220]. Overexpression of soluble VEGFR3 in 
mouse skin inhibits fetal lymphangiogenesis, while the other vasculature remains normal 
[221]. Recently it was shown that simultaneous deletion of the VEGFR3 ligands VEGFC and 
VEGFD in mice does not phenocopy the vascular phenotype of VEGFR3 deficient mice, but 
resembles the phenotype observed in the single VEGFC knock out mice [222]. This suggests 
that either another as yet unknown ligand is binding to this receptor to induce angiogenic 
signals, or that VEGFR3 is exerting its angiogenic role through heterodimerization with 
another receptor.  
Activation of VEGFR3 induces proliferation, migration and survival of lymphatic endothelial 
cells [223]. Activated receptor was shown to recruit Shc and Grb2 via phosphorylated 
Tyr1337. Also, VEGFR3 can form functional heterodimers with VEGFR2 inducing different 
phosphorylation pattern of the cytoplasmic tail of receptor than when the homodimers are 
formed [224].  
In conclusion, VEGFR3 is considered to be attractive target in anticancer treatments because 
of its upregulation in some tumors, and of its important and separate roles in angiogenesis 
versus lymphangiogenesis [153]. 
 
2.2.3. Neuropilins 
Neuropilins (NRPs) were discovered in 1987 as antigens for antibodies that bind neuropiles 
and plexiform layers in the Xenopus tadpole nervous system. A decade later, it was shown 
that these molecules are receptors for class III secreted semaphorins, which transmit repulsive 
signals during axon guidance [203]. In 1998 the group of Michael Klagsbrun found that NRPs 
are expressed by endothelial cells and are able to bind VEGFs [225]. Neuropilins are VEGFs 
coreceptors that enhance their signaling. NRP1 binds VEGF, VEGFB and PlGF, while NRP2 
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binds VEGF, VEGFC and PlGF. In terms of the receptors, VEGFR2 and VEGFR1 interact 
with NRP1 and NRP2, respectively.  
In addition to neuronal abnormalities, overexpression of NRP1 causes vascular defects [226]. 
NRP1 knockout mice die embryonically due to cardiovascular abnormalities [227]. In 
contrast to the essential role of NRP1 during development, NRP2 knockout mice are viable 
into adulthood, but show lower degrees of retinal neovascularization after ischemia [203].  
In parallel to the discovery of the role of NRPs in angiogenesis, the role of these receptors in 
tumor biology became apparent. NRP1 and/or NRP2 expression is correlated with increased 
tumor angiogenesis and aggressiveness in many different tumor types. Accumulating 
evidence suggests that neuropilins play a role in the survival of tumor cells [203], [228].  
Recently, it was shown that antibody mediated blockade of NRP1 in combination with anti 
VEGF treatments results in an additive effect on tumor growth inhibition. Vessels from 
tumors treated with both anti NRP1 and anti VEGF antibodies were less efficient in their 
ability to associate with pericytes in comparison to tumors treated only with anti VEGF 
targeted therapies [229]. 
 
2.3. Targeting VEGF/VEGFR signaling in cancer  
2.3.1. Targeting angiogenesis 
Avastin (Bevacizumab, Genentech, [3]) is a humanized VEGF monoclonal antibody that was 
approved by the Food and Drug Administration (FDA) for anticancer treatment in 
combination with chemotherapy in 2004. Avastin was the first drug on the market created to 
specifically target angiogenesis. At present, it is used as a first line treatment in combination 
with chemotherapy for late stage metastatic colorectal cancer, NSCLC and previously 
untreated metastatic breast cancer. Due to the primary role of VEGF in angiogenesis (chapter 
3.1.), the strategy to block this growth factor in order to reduce tumor vasculature was 
reasonable. However, emerging data suggest that supression of several other pathways and 
processes should be taken into consideration in order to accomplish greater effects on tumor 
growth reduction. The mode of action of Avastin and mechanisms of tumor adaptation to 
therapy are depicted and discussed in Box 1. 
Avastin is not the only cancer therapeutic targeting members of the VEGF family or their 
receptors. Sorafenib (Nexavar, Bayer/Onyx) and sunitinib (Sutent, Pfizer) are VEGFR 
tyrosine kinase inhibitors approved for treatment of renal carcinoma (both), gastrointestinal 
stromal tumors (sunitinib) and hepatocellular carcinomas (sorafenib) as single agents [230]. It 
is important to emphasize that tyrosine kinase inhibitors, because of their mode of action at 
the ATP binding pocket, are rather more selective than specific in blockade of their targets. 
Consequently, it is possible that some of the observed clinical effects are due to non specific 
inhibition of other tyrosine kinases [231]. 
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Box 1. Figure is schematically showing 
mechanisms of tumor adaptation or escape from 
angiogenesis inhibition by an anti VEGF agent.  
The adaptation includes the increase in other 
growth factors (FGFs for example), recruitment 
of bone marrow derived cells (like myeloid cells), 
pericyte recruitment and invasiveness [232]. 
Accumulating data suggest that contribution of 
other VEGFs (including PlGF) and VEGFRs to 
tumor angiogenesis should be considered when 
thinking about targets additional to anti VEGF 
therapy.  
A) Decreased level of active VEGF after Avastin 
treatment reduces tumor growth and increases OS 
and PFS in several late stage human cancers 
when used as a first line treatment in combination 
with chemotherapy [230]. However, the mode of 
action of Avastin on vasculature and tumor cells 
is not apparent at present. It was suggested that in 
addition to pruning existing vessels and 
preventing the formation of new ones, the major 
role of anti VEGF action is to normalize tumor 
vasculature and consequently increase delivery 
and efficacy of classical chemotherapeutics 
[233].  
B) Anti VEGF treatment induces hypoxia in tumor tissue that, in return, increases the upregulation of other strong 
proangiogenic factors, like FGF2. Increased expression of other angiogenic growth factors could be the mode of tumor 
escape, but it is possible that this quality is acquired by tumors prior to treatment, like in case of late stage breast cancer 
[232]. Therefore, the inhibiton of several proangiogenic pathways could decrease tumor angiogenesis and growth more 
efficiently. In addition to VEGFs and FGFs, an attractive candidate for supression would be HIF, factor that induces 
transcriptional response in hypoxia (see chapter 1.2.2.1.).  
C) Hypoxia induces recruitment of various bone marrow derived cells that either serve as building blocks for nascent vessels 
(endothelial and pericyte progenitors) or local reservoir of growth factors (myeloid cells, tumor associated macrophages, 
monocytes), [234]. 
D) In response to vascular regression caused by antiangiogenic therapy endothelial cells increase pericyte or smooth muscle 
cell recruitment. Coverage of blood vessels by pericytes decreases their sensitivity to anti VEGF treatment. Consequently, 
combinatorial inhibition of VEGF and PDGF shows improved efficacy on inhibition of angiogenesis and tumor growth 
[235]. However, the idea of dual inhibition should be considered with precautions because some experiments indicate that 
loosening blood vessels by smooth muscle cell dissociation increases metastatic dissemination of tumors [232].  
E) Another adaptation of tumor cells to angiogenesis inhibition is increase of their ability to metastasize. Interestingly, it was 
shown that VEGF itself decreases the ability of glioblastoma cells to disseminate both in vitro and in vivo [236]. 
F) Preclinical studies suggest that blockade of PlGF, VEGFR1, VEGFR3 and NRPs is also efficient in tumor growth 
inhibition [237], [184], [153], [229]. In some cases, when combined with anti VEGF therapy, the inhibitors of these growth 
factors and receptors show additive effect on tumor growth [229]. The efficiency of these inhibitors and the regimen of their 
use are waiting to be confirmed in clinical trials.  
While the angiogenic effects of VEGFC and VEGFD are understudied, their role in tumor lymphangiogenesis is well known 
[238]. Induction of these VEGFs increases lymphangiogenesis and  metastasis in several preclinical tumor models, 
suggesting that their blockade could be beneficial for cancer patients [239], see the following chapter. 
Preclinical studies also indicate that inhibition of Notch pathway could stimulate tumor growth suppression through 
inhibition of functional angiogenesis [240], see chapter 1.2.2.1. 
It is not excluded that in response to anti VEGF therapy the fore mentioned factors and their receptors get upregulated.  
G) The effects of Avastin on tumor growth suppression show that targeting angiogenesis, in addition to being an attractive 
idea, is efficient strategy in cancer treatment. Nevertheless, further studies are needed to elucidate signaling networks that 
regulate the process. Simultaneous inhibition of several factors and processes will probably increase the effect on tumor 
blockade.  
OS, overall survival, PFS, progression free survival 
 
 
 
2.3.2. Targeting lymphangiogenesis and tumor cells 
In addition to its essential role in angiogenesis, involvement of VEGF/VEGFR signaling 
network in dissemination through lymphatic system and its role in tumor cell biology are 
equally important for cancer treatment. 
Metastasis is the main cause of deaths from cancer and many efforts are being invested to 
dissect signaling pathways involved in this process. Lymphatic system is important route for 
tumor cell dissemination, and the presence of tumor cells in lymph nodes is used as 
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prognostic factor in nearly every type of carcinomas. Previously, it was thought that cancer 
cells use preexisting vessels to disseminate through lymphatic system. However, eight years 
ago the inductive role of VEGFC/VEGFD/VEGFR3 axis in tumor lymphangiogenesis has 
been documented (chapter 3.1.). Since then, several reports tried to evaluate the effect of 
VEGF/VEGFR inhibition in tumor spread through lymphatics.  
The groups of Alitalo, Sleeman and Joos delivered soluble VEGFR3 to either human lung 
cancer xenografts, mammary tumor cells growing in rats, or murine melanoma model. 
Soluble receptor binds expressed ligands and therefore prevents them from signaling with 
endogenous signaling partners. Introduction of soluble VEGFR3, they showed, causes 
reduction in intratumoral lymphangiogenesis and metastasis in regional lymph nodes and 
lungs [241], [242], [243]. In another study, the same inhibitory effect on lymphangiogenesis 
and metastasis was achieved by blocking the expression of VEGFC using RNA interfering 
approach [244]. The recent work from the group of Mihaela Skobe found that inhibition of 
VEGFR3 with antibody is more efficient in suppression of metastasis than inhibition of 
VEGFR2. Furthermore, the authors show that combination of antibodies against both 
receptors has a capability of suppressing metastasis even if the treatment is applied after 
metastasis formation, the concept that they are further investigating [245]. In addition to these 
studies, the anti(lymph)angiogenic and antimetastatic properties of VEGFD antibody were 
described by Stacker and collaborators in a VEGFD dependent mouse tumor model [201].  
However, in contrast to reports mentioned above, Wong and colleagues achieved the 
reduction in tumor lymphangiogenesis by blocking VEGFC by siRNA or usage of soluble 
VEGFR3 in prostate cancer cells, but this did not correlate with incidence of metastasis to 
lymph nodes. It is important to note that they report the strong reduction in intratumoral 
lymphatics (more than 95%), but the surrounding marginal lymphatics at the tumor-stromal 
interface was not affected. This suggests that these marginal vessels are more important for 
tumor cell dissemination than intratumoral lymphatics [246].  
Clinical data suggest that VEGFC expression in tumor cells correlates with lymph node 
metastasis in lung, colorectal and prostate cancer and may be a prognostic factor in ovarian 
and cervical cancer. VEGFD expression is associated with lymphangiogenesis in colorectal 
cancer and poor prognosis in epithelial ovarian carcinoma. 
Accumulating data indicate the role of VEGF/VEGFR signaling in tumor cell biology. 
VEGFRs and neuropilins have been detected on tumor cells of various types [230]  [228], 
[203]. Functional VEGF/VEGFR autocrine signaling loops have been described in breast 
cancer, melanoma, and leukemias [247], [248], [249]. Furthermore, it was shown that 
VEGFRs promote invasion of lung adenocarcinoma cells, and migration of colorectal and 
pancreatic carcinoma cells [250], [251], [252], [253]. Consequently, the effects of 
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VEGF/VEGFR inhibitors in certain conditions can partially be attributed to the direct effect 
on tumor cells.   
In our study [254], we wanted to test the effects of pan VEGFR tyrosine kinase inhibitor 
(PTK787/ZK222584, Vatalanib, Novartis Pharma/Schering [255]), in comparison to those of 
an anti VEGFR2 blocking antibody (DC101, ImClone Systems, [256]) and anti VEGF 
antibody (Pab85618 or Avastin, anti mouse and anti human VEGFA antibody, respectively). 
We compared their ability to inhibit tumor growth, vascularization and metastatic 
dissemination in a mouse melanoma model. In addition, we tested their effects on in vitro 
tumor cell biology. 
PTK787/ZK (PTK/ZK in further text) is tyrosine kinase inhibitor selectively blocking 
VEGFR1, VEGFR2, VEGFR3, PDGFR-β and c-Kit [257]. It was shown to reduce tumor 
growth, angiogenesis and metastasis formation in preclinical models [258], [259], [154] and it 
displayed activity in clinical trials [260], [261], [262]. We used this inhibitor in orthotopic 
B16/BL6 melanoma model, an aggressive metastatic subline derived from B16 cells [263]. 
We showed that inhibition of VEGFR1, VEGFR2 and VEGFR3 by PTK/ZK displays 
comparable effect to VEGF and VEGFR2 inhibitors on primary tumor growth. PTK/ZK and 
DC101 had similar inhibitory effects on lymphangiogenesis in metastatic sites, but only 
PTK/ZK reduced the formation of metastasis. Inspection of peritumoral lymphatic vessel 
functionality performed by checking their ability to uptake injected dye showed that 
functional lymphatics was reduced in PTK/ZK treated tumors. Using human lymphatic 
endothelial cells (LECs) as an in vivo model, we showed that besides of VEGFA, VEGFC 
also increases proliferation and survival of these cells, an effect that can be blocked by 
PTK/ZK, but not Avastin. 
In regard to tumor cell biology, we report the existence of autocrine VEGF/VEGFR signaling 
loop in B16/BL6 melanoma cells whose inhibition by PTK/ZK, but not DC101, reduced the 
migration of these cells in Boyden chamber. In addition, we show that interruption of PI3K 
and ERK1/2 survival pathways in B16/BL6 melanoma cells by addition of PTK/ZK or 
DC101 sensitizes these cells to platinum based chemotherapeutics.  
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3. ErbB2 interactome in breast cancer 
3.1. ErbB2, an amplifier of EGFR signaling network 
ErbB2 (HER2, Neu) is a member of the epidermal growth factor receptor family that 
comprises four transmembrane spanning receptor tyrosine kinases. Other family members are 
the founding epidermal growth factor receptor (EGFR or ErbB1), ErbB3 and ErbB4. 
Structurally, ErbB family members consist of an extracellular EGF related peptide binding 
region, a transmembrane helix, and an intracellular region comprised of a well conserved 
tyrosine kinase domain and a less conserved regulatory C terminal tail.  
Historically, the ErbB oncogene was found through its presence in the genome of avian 
erythroblastosis virus (v-ErbB), a transforming retrovirus that rapidly induces leukemia in red 
blood cell precursors (an erythroleukemia). Later on, in 1984, it was shown that the coding 
sequence for epidermal growth factor receptor closely relates to that of the erbB oncogene. 
This realization was the first connection made between a growth factor receptor and an 
oncogene. Subsequently, the remaining members of the family, ErbB2, ErbB3, and ErbB4, 
were discovered. ErbB2, the main focus of several further chapters, was discovered on the 
basis of its amplification in a human mammary carcinoma cell line [264], [265]. 
Several epidermal growth factor (EGF) related peptides have been shown to activate the 
members of this RTK family including EGF, transforming growth factor (TGF) α, 
amphiregulin, betacellulin, heparin-binding EGF, epiregulin and neuregulins. Interestingly, no 
ligands have been found that bind to the ErbB2 receptor, and the ErbB3 receptor does not 
display kinase activity, thus it can only signal when coupled to another member of the family. 
Ligand binding induces receptor homo or heterodimerization and subsequent activation of 
their intrinsic RTK activity. ErbB heterodimers induce downstream signaling more strongly 
than homodimers [266]. 
Though the ErbB2 receptor does not bind ligands, it has been shown by Nancy Hynes’ group 
to be the preferential dimerization partner for the other members of the family [267]. For 
several reasons, ErbB2 is considered to be the amplifier of the ErbB signaling network. First, 
protein microarray data show that this receptor binds to a much larger subset of 
phosphotyrosine binding proteins, than the other activated receptors. Second, heterodimers 
containing ErbB2 are characterized by higher affinity and broader specificity for ligands 
because of the slow rates of growth factor dissociation. Finally, ErbB2 containing 
heterodimers undergo slow endocytosis and more frequently recycle back to the cell surface 
[268]. For these reasons, deregulation of ErbB2 signaling has detrimental effects on cell fate, 
which will be described in further chapters.  
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3.2. ErbB2 signaling in breast cancer  
In 1987 the groups of William McGuire, Axel Ullrich and Dennis Slamon showed that 
overexpression of the erbB2 oncogene in human breast cancers correlates with relapse and 
decreased survival of patients [269]. Subsequently Nancy Hynes group confirmed these 
findings and reported a correlation between ErbB2 protein expression and both the nodal 
status and nuclear grading of breast carcinomas [270]. These findings laid down the 
foundations for ErbB2 targeted therapy for a subset of breast cancers (for a review on the role 
of ErbB receptors and their signaling in breast and lung cancers, see [271]). Molecular 
analyses of gene expression patterns of breast carcinomas and normal breast tissue revealed 
that ErbB2 overexpressing cancers represent one of six major molecular subtypes of normal 
and transformed breast tissue [272]. The exact mechanism by which ErbB2 overexpression 
exerts its oncogenic effects is still poorly understood. However, the poor clinical outcome of 
patients with tumors bearing the ErbB2 amplicon is connected to its ability to confer 
resistance to various chemotherapeutic agents and to increase the proliferation, migration, 
survival and angiogenic capabilities of the cancer cells. For these reasons, the signaling 
elicited through this receptor is of a central interest in breast cancer research and breast cancer 
targeted therapy.  
 
3.3. The role of ErB2 binding partners in breast cancer 
The extracellular EGF related peptide binding region of the ErbBs consists of four domains. 
The binding of a ligand to domains I and III induces a conformational change that exposes 
domain II, which is involved in receptor homo and heterodimerization. The key residues 
necessary for ligand binding are not conserved in ErbB2’s extracellular domain and the 
structure of the ligand binding domain prevents the binding of EGF related peptides to this 
site. However, ErbB2 constitutively adopts a conformation in which the dimerization domain 
II is exposed, making it amenable to binding ligand bound receptors [273]. Still, other 
structural mechanisms exist to prevent spontaneous dimerization of ErbB2 [266]. 
Upon ligand binding and receptor dimerization, the phosphorylation of 
the intracellular domains and recruitment of signaling mediators take 
place. Five tyrosine phosphorylation sites within the ErbB2 intracellular 
domain have been described (Figure 15). These sites are refered to as 
YA, YB, YC, YD and YE, respectively [274], [275]. It was shown by 
the Muller group that each of the ErbB2 YA-YD sites individually can 
mediate in vitro transformation of normal breast cells via the 
recruitment of different cytoplasmic mediator proteins to mutated 
constitutively activated ErbB2 [276]. 
Figure 15. ErbB2 intracellular phosphorylation sites. 
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Further analyses were performed by this group to determine the contribution of individual 
phosphorylation sites to the tumorigenic and metastatic capabilities of the ErbB2 receptor in 
breast cancer [276]. The authors used mutant, constitutively active rat ErbB2 receptor (Neu) 
bearing only one autophosphorylation site at a time, expressed under the mammary specific 
promoter MMTV in transgenic mice. They showed that the biological profiles of tumors 
originating from signaling through the ErbB2 sites YC, YD, and YE are strikingly similar in 
pathologic features and gene expression patterns. In contrast, signaling elicited through the 
YB site induced tumors of different morphology (focal papillary tumors, in contrast to YC, 
YD and YE which induced multifocal, solid and nodular tumors). Consequently, the number 
of lung metastasis from these tumors was significantly higher than observed for any other 
individual ErbB2 phosphorylation site. These findings indicate that different roles exist for 
each phosphorylation site and the proteins that they recruit, in ErbB2 mediated tumorigenesis 
and metastasis formation. 
The main cytoplasmic signaling mediators of activated ErbB2 and their contribution to the 
breast tumorigenesis and metastasis are discussed below. 
 
3.3.1. ShcA 
The mammalian ShcA gene encodes for a protein with three splice isoforms, namely p46, p52 
and p66. All of the isoforms are similar in structure, containing two phosphotyrosine binding 
motifs (PTB) and a single Src homology 2 (SH2) domain, enabling them to bind docking sites 
on activated receptor tyrosine kinases. Human ShcA also contains a central collagen 
homology 1 (CH1) region which contains three tyrosine phosphorylation sites at residues 
239/240 and 317 (313 in mice), respectively. When phosphorylated, these sites are capable of 
inducing Ras/MAPK dependent and independent signaling [277]. In the context of ErbB2 
signaling, ShcA is found to associate with phosphorylated YD and YE sites [278]. 
Clinical data suggest that increased ShcAY317 phosphorylation, in combination with reduced 
p66ShcA levels correlates with nodal status, disease stage and relapse in breast cancer 
patients [277]. The contribution of ShcA to ErbB2 mediated angiogenesis, tumorigenesis and 
metastatic dissemination has been untangled recently by several groups at McGill University, 
Canada. First, it was shown by the laboratory of Morag Park that ShcA is essential for 
induction of VEGF expression through the Met/HGF and ErbB2 receptors, and for the 
initiation of tumor angiogenesis [279]. The contribution of the individual ShcA 
phosphorylation sites to cancer and metastasis formation downstream of ErbB2 has been 
analysed by the laboratories of William Muller and Tony Pawson. Using an immortalized 
mammary epithelial cell line transformed with either activated ErbB2 (Neu), or the variants 
mutant for each of the phosphorylation sites, they show that all three ShcA tyrosine 
phosphorylation sites are important for ErbB2 induced mammary tumor outgrowth, 
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intravasation and angiogenesis. Moreover, they provide evidence to suggest that ShcA 
expression within the mammary epithelium is essential for ErbB2 induced mammary tumor 
development [280]. It is worth mentioning, however, that ShcA is necessary for several steps 
of tumor formation and dissemination not only downstream of ErbB2, but also of Polyoma 
middle T antigen. 
Besides the described roles for ShcA downstream of ErbB2 in VEGF induction, tumor 
formation and metastasis, its role in mammary carcinoma cell motility and invasion has been 
confirmed in vitro. It was shown by Peter Siegel’s group that ShcA is necessary for 
transforming growth factor (TGF) β induced cell motility and invasion via ErbB2 [281]. 
Taken together, the experiments described herein reveal an essential role for ShcA in ErbB2 
induced VEGF production, tumor angiogenesis, mammary tumor outgrowth, intravasation 
and TGF-β induced motility. 
 
3.3.2. Grb2 
Grb2 (growth factor receptor bound protein 2) is an adaptor protein which binds to several 
receptor tyrosine kinases, among them ErbB2 via the YB (direct) and YD (through Shc) sites. 
Two different isoforms of Grb2, obtained through alternative splicing, exist and the protein 
contains one SH2 and two SH3 domains.  
The significance of Grb2 binding to the YB site of activated ErbB2 has been deciphered by 
the Muller laboratory. The ErbB2 YB site overexpressing mice exhibited a significantly 
higher number of metastasis in lungs, compared to any of the other ErbB2 tyrosine site 
models. These results indicate that the recruitment of different signaling mediators induces 
differential biological responses downstream of activated ErbB2 [274], [276]. 
 
3.3.3. Memo 
Memo (mediator of ErbB2 driven cell motility) is a protein that was first identified in our lab 
based on its ability to bind the phospho YD site of the ErbB2 receptor [278]. It is encoded by 
a single gene, and is found in all branches of life, from bacteria to humans. The crystal 
structure of Memo revealed that it is homologous to class III nonheme iron dependent 
dioxygenases. However, no metal binding or enzymatic activity has been detected for Memo 
[282]. Memo does not contain the typical adaptor protein domains such as PTB or SH2. 
Initially, it was suggested that ShcA mediates its binding to the YD site of ErbB2, as Memo 
was detected along with ErbB2 in ShcA immunoprecipitates. Moreover, immunodepletion of 
Shc from reticulocytes decreased the binding of Memo to the ErbB2 phospho YD site [278]. 
However, it was shown that the immobilized YD peptide is able to bind specifically to 
purified Memo, suggesting that at least in a this in vitro system Memo and ErbB2 interact 
directly [282]. Interaction of Memo with cofilin and PLCγ1 was shown to be essential during 
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ErbB2 induced cell migration [283]. Memo deficient, ErbB2 expressing breast cancer cells 
form actin fibers and grow lamellipodia in response to ErbB2 activation, but do not organize 
the microtubule cytoskeleton [284]. Although discovered as an ErbB2 binding partner, we 
were able to show that Memo has a broader role downstream of receptor tyrosine kinases, as 
its downregulation also impaired the migratory ability of T47D cells in response to FGF-2 
(activator of  several FGFRs) and EGF (ErbB1 ligand).  
The current studies in our lab are aimed at deciphering the contribution of Memo to 
tumorigenesis, vasculogenesis, metastasis formation and in vitro motility downstream of 
several receptor tyrosine kinases (RTKs). We are using cell lines and mouse tumor models 
driven by different RTKs to dissect the role of Memo in their oncogenic sinaling.  
In the work presented here, I describe the effects of Memo downregulation on tumor growth, 
angiogenesis, VEGF release, extravasation and colonization of distant organs of 4T1 
mammary carcinoma cells.  
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II. AIMS OF THE WORK 
 
In our lab we are investigating signaling pathways that are driving breast tumorigenesis and 
metastasis formation. The main focus of our research is deregulated ErbB2 signaling. 
However, we are interested in contributions of Wnt pathway to tumorigenesis and tumor 
angiogenesis, and the role of vascular endothelial growth factor receptors (VEGFRs) in tumor 
growth and metastatic spread. 
The main goals of the first project presented in this thesis were to determine the role of the 
components of Wnt signaling in endothelial cell biology in vitro and in vivo. Several lines of 
evidence from cell culture and mouse knock out studies suggest the involvment of this 
signaling pathway in angiogenesis (see introductory chapters). We wanted to describe and 
understand the effects of Wnt3a and Wnt5a ligands on human umbilical vein endothelial cell 
(HUVEC) proliferation, migration and survival. The other goal was to decipher the 
contribution of Fz6, Wnt receptor shown to be expressed on surface of endothelial cells 
derived from variety of tissues, to tumor growth and angiogenesis. 
The aim of the second project was to delineate the effects of targeting three VEGFRs on 
tumor growth, vascularization and metastatic spread. We wanted to compare the efficacy of 
the agent that targets all known receptors to that of the VEGF and VEGFR2 targeting 
molecules. Regarding the tumor cell biology, our intention was to delineate effects of 
targeting VEGF and VEGFR family members on proliferation, migration, and 
chemosenzitation of cancer cells. 
ErbB2 receptor tyrosine kinase is a member of epidermal growth factor receptor family and it 
is overexpressed in 20% of human breast cancers (chapter 3). For this reason our laboratory is 
interested in finding the proteins that are interacting with this receptor to convey its signaling. 
Recently, we identified Memo, a novel protein that is mediating ErbB2 driven cell motility 
[278]. In the study presented here, we wanted to decipher the role of Memo in tumor 
formation, vascularization and metastatic spread of 4T1 mouse mammary carcinoma model.  
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Abstract 
Angiogenesis, the process of new blood vessel formation from preexisting vasculature, is 
characteristic of several pathophysiological processes including cancer. Consequently, 
untangling signaling pathways that guide angiogenesis is of a central interest for development 
of antiangiogenesis based therapies. Here we report the inductive role of Wnt3a in 
proliferation and migration of cultured human umbilical vein endothelial cells (HUVEC), but 
without an effect on their survival. In a search for probable downstream mediators of Wnt3a 
effects on HUVEC biology, we found that upon treatment with Wnt3a, phosphorylation of 
Dvl and β-catenin stabilization take place. Moreover, we identified upregulation of c-Myc, 
Tie-2 and Connexin 43 transcripts in same conditions, indicating that these genes might be 
involved in proangiogenic responses of HUVEC treated with Wnt3a. Wnt5a did not show any 
effect in same assays, though it did induce Dvl phosphorylation. Our microarray data 
performed on cultured HUVEC revealed that Wnt receptors Fz4 and Fz6 are expressed at 
significantly higher levels than other Fzs. The analyses of the role of Fz6 receptor in tumor 
angiogenesis in vivo revealed that ablation of this receptor in mice does not affect the ability 
of LLC cells to grow, and does not influence their vascularization. Taken together, our data 
indicate that Wnt3a has the ability to induce the canonical Wnt pathway in cultured HUVEC, 
and can stimulate their proliferation and migration. 
 
Introduction 
Wnts are a family of secreted glycoproteins that bind to transmembrane Frizzled (Fz) 
receptors and initiate signaling cascades with indispensable roles during development, cell 
proliferation, migration, and survival [285]. Several pathways downstream of Wnt binding to 
Frizzled are known, Wnt β-catenin (or Wnt ‘canonical’ pathway) being the most studied. In 
the absence of activated Wnt β-catenin signaling, the transcription co-factor β-catenin is 
targeted for degradation by a destruction complex that consists of axin, adenomatous 
polyposis coli (APC) and glycogen synthase kinase-3β (GSK-3β). Activation of the canonical 
Wnt pathway results in recruitment of the cytoplasmic mediator Dishevelled and disassembly 
of destruction complex causing the stabilization of the β-catenin. Stabilized β-catenin 
accumulates in the cytoplasm, enters the nucleus, and acts as a co-activator of T-cell 
factor/lymphoid enhancer factor-1 (TCF/LEF) transcription factors and initiates transcription 
from their target genes. Among several ‘non-canonical’ Wnt pathways, Wnt planar cell 
polarity (PCP) and Wnt calcium pathways are the best understood, for a review see [286]. 
Both pathways activate Dishevelled, but diverge further down to either GTPases Rho/Rac, or 
calcium activated protein kinase C (PKC) and calcium/calmodulin dependent-protein kinase 
II (CamKII), respectively. Although usually described as individual pathways, reported 
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crosstalk and shared components between downstream Wnt signaling branches suggest the 
possibility that Wnts act through complex intracellular signaling network [287].  
Angiogenesis is a process of new blood vessel formation from pre-existing vasculature [138]. 
In order to form blood vessels, endothelial cells need to proliferate, migrate and survive. The 
importance of Wnt signaling in these processes is emphasized by the fact that mice deficient 
for Fz4 [288], Fz5 [160], or Wnt2 [156] are impaired in blood vessel formation. Mutations 
within human Fz4 gene cause defective vascularization of the eye and the ear [161], [63].  
In this study, we show that Fz4 and Fz6 are expressed by Human Umbilical Vein Endothelial 
Cells (HUVEC) and can convey the Wnt signal to downstream components. We report that 
Wnt3a induces HUVEC proliferation and migration, but without an effect on their survival. 
Proliferation induced by Wnt3a is VEGFR signaling independent.  
 
Results 
Human Umbilical Vein Endothelial Cells express Fz-4 and Fz-6 
It has already been shown that Frizzled receptors and other components of the Wnt pathway 
are expressed by HUVEC [168]. To analyze the expression of Frizzled receptors in the 
HUVEC used in our experiments we performed a microarray analysis. The results indicate 
that Fz4 and Fz6 are expressed at a much higher level than the other Frizzled receptors 
(Figure 1a). Fz4 receptor is known to stimulate PKC activation, [289] and β-catenin 
stabilization [290], [291], [63]. Fz6 induces PKC activation too, [289] and is involved in 
tissue/planar cell polarity [101]. It was shown that Fz6 can negatively regulate the canonical 
Wnt β-catenin pathway [292]. The expression of both receptors was confirmed by PCR 
(Figure 1b). 
 
Wnt3a and Wnt5a induce Dvl3 phosphorylation in HUVEC  
Signaling cascades stimulated by Wnts are diverse including the Wnt β-catenin, Wnt planar 
cell polarity (PCP) and Wnt-calcium pathway. The first known downstream effect of Wnt 
binding to its receptor Frizzled is Dishevelled phosphorylation and activation. Dvl 
phosphorylation was shown to mediate β-catenin and PCP pathways [74] as well as Wnt-
calcium pathway [75], and is established as a general biochemical assay for Wnt protein 
function [293].  
In order to test the functionality of expressed Fz4 and Fz6 receptors, we treated HUVEC with 
commercially available Wnt3a and Wnt5a ligands. Historically, Wnt3a was considered as a 
member of a subclass of Wnt family that activate only the canonical pathway [294]. However, 
accumulating evidence suggests that the outcome of downstream signaling is dictated by the 
ligand and receptor context in each system studied. For example, Wnt5a, a typical ‘non-
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canonical Wnt’ [294], was shown to stabilize β-catenin if co-expressed with Fz4 and LRP5 
[291]. In the same manner, it was reported that Wnt3a can act through a non-canonical 
pathway during osteoblastogenesis [295]. In our experiments we used Wnt3a and Wnt5a to 
try to activate different Wnt signaling routes through the expressed Fz4 and Fz6. Both Wnts 
were used at concentration of 200 ng/ml, and Dvl phosphorylation, as demonstrated by the 
shift in Dvl band in Western blot, was checked 1, 2 and 8 hours after treatment. As shown in 
the Figure 2a, both Wnts induced a shift in Dvl3 band indicating pathway activation. Wnt3a 
appeared to induce Dvl phosphorylation more potently than Wnt5a. When used together with 
Wnt ligands, recombinant Fz4 abrogated the effect on Dvl3 phosphorylation (Figure 2b), 
which shows that it can compete with the endogenous receptors to bind to Wnts.  
 
Wnt3a induces HUVEC proliferation in a VEGFR signaling independent manner 
To analyze the effect of pathway activation on HUVEC proliferation, we used Wnt3a and 
Wnt5a in a BrdU ELISA incorporation assay. VEGF-A, a factor known to induce HUVEC 
proliferation [296] was used as a positive control. As shown in Figure 3a, Wnt3a stimulated 
HUVEC proliferation, but the effect was abolished when Wnt3a was added in a combination 
with recombinant Fz4. In spite of the ability to induce Dvl3 phosphorylation (Figure 2), 
Wnt5a did not increase HUVEC proliferation in our assay even at a concentration of 800 
ng/ml (Figure 3b). Since activated Wnt signaling can induce VEGF transcription [297], we 
tested if the effect of Wnt3a on HUVEC proliferation is due to VEGF upregulation, by 
employing a VEGFR kinase inhibitor PTK787/ZK [255] together with Wnt3a in a 
proliferation assay. PTK787/ZK did not influence Wnt3a induced proliferation, showing that 
stimulation of proliferation by Wnt3a in HUVEC is VEGFR signaling independent (Figure 
3a). 
To check for the ability of Wnt3a to induce HUVEC proliferation in the presence of CamKII 
inhibitor, we used this growth factor together with increasing concentration of KN93, an 
inhibitor that prevents the binding of calmodulin to CamKII. As seen from the Figure 3c, 
KN93 was able to reduce Wnt3a induced proliferation when used at concentration of 0.5 μM, 
indicating the requirement of CamKII for Wnt3a induced proliferation 
 
Wnt3a induces HUVEC migration, but neither Wnt promotes survival in a condition of 
medium starvation 
The ability of endothelial cells to migrate is required during blood vessel formation. We 
performed migration assays with HUVEC in Boyden chambers using Wnt3a and Wnt5a as 
chemoattractants in the lower chamber. As shown in Figure 4, the number of migratory 
HUVEC in response to Wnt3a was significantly higher compared to control or Wnt5a, 
indicating that Wnt3a stimulates HUVEC migration.    
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Next, we tested whether either of the Wnt ligands can rescue HUVECs from starvation 
induced apoptosis. For this purpose, we took advantage of the YO-PRO reagent, a dye that 
enters only apoptotic cells. VEGF was used as a positive control. Neither of the Wnts 
influenced HUVEC survival (Figure 5), while VEGF significantly increased it. 
 
Wnt3a but not Wnt5a induces β-catenin stabilization 
To check for the downstream signaling pathway initiated by Wnt3a and Wnt5a, we did 
immunoblot analysis with antibody detecting β-catenin 2h, 8h and 24h after stimulation. We 
detected increase in β-catenin band upon treatment with Wnt3a, but not Wnt5a (Figure 6), 
indicating canonical Wnt pathway activation. 
 
Wnt3a and Wnt5a transcriptional targets in HUVEC 
To try to understand the mechanism by which Wnt3a induces biological effects in HUVEC, 
we checked for the up-regulation of known Wnt target genes that are angiogenesis related. c-
Myc is known canonical Wnt transcriptional target gene [298] with documented roles in cell 
proliferation and migration [299]. Another protein involved in cell-cycle progression 
downstream of canonical Wnt signaling is CyclinD1 [300]. MMP-1 and Tie-2, have been 
shown as transcriptional targets of Wnt5a in HUVEC induced by non-canonical Wnt 
signaling [171], but are not listed as canonical Wnt target genes[19]. Finally, Connexin43, a 
cellular gap junction protein, has been reported to be a target of Wnt pathway present in 
vasculature [168]. We isolated RNA from non-treated or Wnt3a and Wnt5a treated HUVEC 
samples and performed semiquantitative PCR on prepared cDNA, using primers for c-Myc, 
Tie-2, Connexin 43, MMP-1 and CyclinD1. As depicted in Figure 7, Wnt3a induces the 
expression of c-Myc, Tie-2 and Connexin 43 strongly, already 5h after treatment, and the 
effect persists 24h after adding the ligands. In contrast, Wnt5a did not induce cMyc up-
regulation at any time point, but we detected an increase in Tie-2 and Connexin 43 transcripts 
24h after treatment. Neither Wnt3a nor Wnt5a influenced transcription of MMP-1 and 
CyclinD1. In conclusion, our data show that the expression of genes known as both canonical 
(c-Myc), and non-canonical Wnt target genes (Tie-2) are upregulated upon Wnt3a treatment. 
 
In vivo LLC growth in Fz6 deficient mice 
Our in vitro data suggest the positive role of Wnt signaling in endothelial cell biology. 
Activation of the pathway by Wnt3a through either Fz4 or Fz6 receptor induced Dvl3 
phosphorylation in HUVEC and enhanced their ability to proliferate and migrate.  
To test the importance of Wnt signaling through Frizzled receptors in endothelial cells in an 
in vivo model, we injected Fz6 deficient mice with Lewis Lung Carcinoma cells (LLC) and 
monitored tumor growth. LLC cells developed well vascularized tumors already within a 
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week after injection and served as a good model to monitor effect of Fz6 ablation on blood 
vessel formation. Tumor growth was measured in comparison to wild-type and Fz6+/- 
littermates. As seen from the Figure 8a, Ablation of Fz6 did not have an effect on primary 
tumor growth. The staining of tumor sections with CD31 antibody and subsequent inspection 
of tumor vasculature revealed no differences between the appearance and quantity of 
vasculature in control and tumors grown in Fz6 deficient mice (Figure 8b). Fz4 deficient mice 
we could not use in the same experiment, because we were not able to generate these mice in 
Bl6 background. 
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2. RESEARCH ARTICLE 2  
Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks 
lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to 
platinum-based chemotherapeutics 
 
Author’s contribution to the article 
1) Delineating the expression of VEGFRs in MDA435, A375 and B16Bl6 cells in vitro and 
on lymph node metastasis derived from B16Bl6 cells by immunochemistry (Figure 3a and 3d 
in the article, experiment conducted together with Patrizia Sini, PS) 
2) Analysis of the expression of VEGFRs in B16Bl6 cells in vitro by flow cytometry cell 
sorting (FACS) method, before and after membrane permeablization (Figure 3b, experiment 
conducted together with PS)  
3) B16/Bl6 in vitro migration assay in the presence or absence of increasing concentrations of 
PTK/ZK (Figure 4b, experiment conducted together with PS) 
4) Defining the molecular pathway that confers the ability of PTK/ZK to chemosensitize 
cancer cells to platinum based chemotherapeutics in vitro.  
In order to find the molecular pathway that is mediating PTK/ZK induced chemosensitization, 
I have checked the status of AKT and phospho AKT, survivin, cleaved caspase 3, and cleaved 
PARP by immunoblotting after treatment with cisplatin alone, or in combination with 
PTK/ZK, using B16/Bl6, MDA 435, DU145 and A375 cells. I could not detect differences in 
protein levels of any of the mentioned downstream mediators of apoptosis after 
combinatiorial treatment with cisplatin and PTK/ZK in comparison to these agents alone. 
However, PS found that the effect of PTK/ZK on chemosensitation of B16/Bl6 cells is 
mediated by MAPK pathway (Figure 5).  
5) Delineating the expression of VEGFRs on A549 cells in vitro by FACS method (Figure 6c) 
6) Analysis of combinatorial effects of cisplatin and PTK/ZK on apoptosis in A549 cells 
(Figure 6c) 
All the Figures were prepared for publication by Patrizia Sini. 
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3. Memo downregulation impairs 4T1 mammary tumor growth and metastasis 
formation 
 
Introduction 
ErbB2 is a member of the epidermal growth factor receptor family, and is overexpressed in 
20% of breast cancers, primarily due to gene amplification. Its overexpression correlates with 
aggressive disease and poor clinical outcome [271]. Analyses of the ErbB2 cytoplasmic 
domain revealed five tyrosine phosphorylation sites (YA-YE), four of which (YA-YD) are 
capable of mediating transformation of normal breast cell lines in vitro downstream of 
mutant, constitutively active ErbB2 [274]. In a screen for ErbB2 binding partners, our lab 
identified a novel protein named Memo that binds to YD site of activated ErbB2 and mediates 
motility induced through this receptor [278]. Besides its coupling to heregulin induced ErbB2 
signaling, Memo was shown to mediate migration initiated by FGF2 and EGF, implying that 
it has a broader role downstream of several receptor tyrosine kinases (RTKs). As it is known 
that deregulation of signaling through RTKs is a trigger for several steps of tumorigenesis and 
metastasis formation, we wanted to delineate the contribution of Memo to each of these steps. 
In the work presented here we show the effects of Memo downregulation on primary tumor 
growth, angiogenesis, VEGF production and the metastatic properties of the highly aggressive 
mouse mammary carcinoma cell line 4T1.  
 
Results 
Memo knock down 4T1 cells form tumors with delayed kinetics 
To analyze the role of Memo in tumor growth we made use of 4T1 and 67NR cell lines, both 
of which originate from a spontaneously arising mouse mammary tumor [301]. The 4T1 cell 
line is highly metastatic, while the 67NR is a nonmetastatic cell line.  
We first stably infected 4T1 cells with a control or memo-targeted shRNA construct. These 
control and Memo knock down (KD) clones (Figure 1a) were then orthotopically injected into 
the mammary fat pads of BALB/c female mice. As shown in Figure 1b and 1c, growth of the 
control clones (LacZ.2 and LacZ.M) was more rapid in comparison to the Memo KD clones 
(7i and 7L). Statistical analysis carried out on individual (Figure 1b) and pooled (Figure 1c) 
data sets from control and Memo KD clones revealed a significant delay in Memo KD clone 
tumor growth kinetics. 
In contrast, downregulation of Memo in 67NR cells by two different shRNAs (shRNA series 
7, clones 7-10.4C, and 7-10.11F; and shRNA series 10, clones 10-10X.1F, and 10-6.10B, 
Figure 1d) did not affect their ability to grow in mice (Figure 1e). Spontaneous tumor 
regression was observed in some of the mice injected with both control and Memo KD 
clones. 
 61
Tumors derived from Memo KD clones are less vascularized 
The ability of tumor cells to release vascular growth factors and form vasculature is correlated 
with their ability to grow. In order to grow beyond 1 mm in diameter tumor tissue needs a 
blood supply. To analyze if the delay in growth of tumors derived from Memo KD clones 
reflects their reduced vascularization, we examined the vasculature of tumors from Memo KD 
and control cells. Quantification of the area of tumor sections stained by the endothelial cell 
specific PECAM antibody at days 4, 7 and 9 after injection, revealed reduced vascularization 
in Memo KD derived tumors. The difference was most prominent at days 4 and 7, and less 
striking at day 9 (Figures 2a, b). These results indicate an initial delay in vascularization of 
Memo KD derived tumors. 
 
Memo KD 4T1 clones release less VEGF in comparison to control clones 
VEGF is a strong proangiogenic factor and considered to be the main inducer of angiogenesis 
in hypoxic tumor tissue (introductory chapter 2). To explain the reduction in vascularization 
observed in Memo KD derived tumors we performed an ELISA assay to test the level of 
VEGF secreted in the medium of control and Memo KD cells. We found that Memo KD 
clones secreted less VEGF into the cell culture medium than control clones (Figure 3), 
indicating that this might be the cause of their impaired ability to induce tumor angiogenesis 
in vivo.      
 
Memo KD clones are impaired in their ability to extravasate and colonize lungs 
Memo was discovered in context of tumor cell migration [278]. For this reason we wanted to 
examine the ability of Memo KD clones to colonize distant tissues when present in 
bloodstream. We injected control and Memo KD clones into the tail vein of BALB/c female 
mice and examined the lungs for the presence of metastasis 12 days after injection. 
Macroscopic examination of the lungs indicated a difference in the presence of metastases in 
lungs of the mice injected with control and Memo KD clones. The lungs from the control 
injected mice were larger and their surface was completely covered with metastases (Figure 
4a, b, c). In contrast, mice injected with Memo KD clones displayed less metastases, and the 
normal lung tissue was clearly visible (Figure 4a). Histological examination of lung tissue 
sections stained with hematoxylin and eosin, followed by quantification of the surface area 
covered with metastases revealed a reduced presence of cancer cells in lungs derived from the 
mice injected with Memo KD cells (Figure 4c). In line with this, the total surface area of lung 
sections from control injected mice was larger than those in Memo KD injected mice, as they 
were more densly filled with metastases. These experiments indicate an important role for 
Memo in tumor cell dissemination, specifically in steps of extravasation from blood vessels 
and/or colonization of the lungs.    
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Effects of Memo downregulation on cell survival in conditions of CoCl2 induced 
oxidative stress 
Hypoxia is a main inducer of VEGF expression in tumor tissue and Memo KD cells, as 
mentioned previously, secrete less VEGF into the medium. To check if Memo has a broader 
role in the response to oxidative stress, we treated 4T1 control and Memo KD clones (two and 
three different clones, respectively) with cobalt chloride (CoCl2), a known hypoxia mimicking 
agent, and measured cell survival. We detected a high variability in the survival rates of 
different 4T1 clones in CoCl2 induced stress conditions. However, the pooled data display the 
trend most prominent at concentration of 300 μM CoCl2 that Memo KD clones are more 
susceptible to oxidative stress than the control clones (Figure 5), which might partially 
account for their impaired ability to survive in conditions of oxidative stress in tumor tissue.    
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IV. DISCUSSION 
 
Cancer is a disease characterized by the deregulation of several molecular pathways that in 
turn orchestrate inappropriate execution of several processes in affected body cells such as 
proliferation, survival, migration, growth factor release. This results in the formation of 
malignant tissue that disrupts body’s homeostasis. Initial strategies to treat cancer with 
chemotherapeutics developed in the first part of the previous century took advantage of the 
fact that in contrast to majority of normal, nontransformed body cells, cancer cells undergo 
rapid division. The first anticancer drugs (antifolate drugs and DNA alkylating agents) thus 
exhibited their activity by either inhibiting DNA synthesis in cancer cells, or damaging its 
structure. However, in the majority of cases, cancer cells develop resistance to these cytotoxic 
agents, thus yielding only limited success, by delaying disease progression without curing it. 
Moreover, these treatments often caused unwanted side effects in rapidly dividing healthy 
tissues. For these reasons, the development of cytotoxic DNA targeting therapeutics reached 
its efficacy plateau during the nineteen eighties, without fulfilling the final goal of cancer 
eradication.  
At this time, the strategy of targeted therapy began to emerge. Knowledge about the signaling 
pathways involved in proliferation, survival, migration and molecular cross talk between 
cancer cells and the surrounding and distal tissues was rapidly increasing. Soon it became 
clear that deregulation of the signaling pathways orchestrating developmental processes and 
adult tissue homeostasis are the main cause of malignant transformation. Those pathways 
include the receptor tyrosine kinases (RTKs), Wnt, Notch, Hedgehog, bone morphogenetic 
proteins (BMPs) and steroid hormone receptors. Among these, the contribution of the large 
family of RTKs to cancer formation is currently the best exploited in anticancer treatments 
[302].  
Both DNA targeting cytotoxic agents and RTK inhibitors are tailored against targets within 
cancer cell itself. However, it is becoming increasingly evident that, although cancer 
originates from deregulation at the cellular level, the progression to a clinically relevant tumor 
mass includes recruitment of surrounding nontransformed tissue and the build up of its own 
vascular supply. For this reason, the cross talk between tumor cells and the surrounding tissue 
is studied in detail. The same holds true for the process of tumor angiogenesis. 
The idea of targeting tumor angiogenesis has been continuously investigated since 1971. In 
1971, Judah Folkman suggested that tumor vasculature might be a valuable target in 
anticancer treatments. In contrast to cancer cells, endothelial cells are not susceptible to high 
mutation rate and they are easily accessible to drugs. Together with the fact that the cancer 
tissue is highly dependent on blood supply, these were strong arguments in favor of targeting 
angiogenesis. The undeniable proof of concept came with the recent clinical trials showing 
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efficacy of Avastin, a drug targeting VEGF, in certain types of cancer in combination with 
chemotherapy [3].  
Taken together, the clinical data show the indisputable efficacy of targeted therapy. However, 
like in the case of classical chemotherapy, the benefits for patients in the majority of cases are 
not absolute, meaning the disease is not cured. An important difference between targeted 
therapies and chemotherapy however, is that we are currently only at the beginning of 
exploration of this new paradigm. The knowledge about signaling networks involved in tumor 
growth, vascularization, stroma and bone marrow cell recruitment, and metastasis formation 
is only partial. Further studies are needed to untangle the complete signaling networks driving 
these processes in order for researchers to be able to validate the final reach of targeted 
therapy, and give rise to novel paradigms in cancer treatment.  
The work presented in this thesis is directed towards better understanding the signaling 
pathways involved in tumor vascularization and related tumor growth and dissemination. We 
show the involvement of Wnt3a in several steps of in vitro angiogenesis, the effects of 
targeting VEGFRs on tumor growth and dissemination in a preclinical model, and finally, the 
effects of downregulation of the ErbB2 mediator Memo on tumor growth, vascularization and 
dissemination in 4T1 mouse mammary carcinoma cells. 
 
Wnts are a family of secreted glycoproteins that bind to the transmembrane Frizzled receptors 
and initiate signaling cascades with indispensable roles during development, cell 
proliferation, migration, and survival [285]. Several pathways downstream of Wnt/Frizzled 
are known, Wnt β-catenin (or the ‘canonical’ Wnt pathway) being the most studied. Among 
the ‘non-canonical’ Wnt pathways, the Wnt planar cell polarity (PCP) and Wnt calcium 
pathways are the best understood. Although usually described as individual pathways, 
reported crosstalk and shared components between downstream Wnt signaling branches 
suggest that Wnts exert their effects through complex intracellular signaling network [287]. 
Excessive activation of Wnt signaling was confirmed to have causative role in colon cancer 
formation, and deregulation of its negative regulators has been detected in some cases of 
breast cancer. For these reasons, targeting Wnt signaling holds great therapeutic promise.  
Angiogenesis is the process of new blood vessel formation from preexisting vasculature. In 
order to grow beyond 1 mm in diameter, tumor tissue needs a blood suply. At present, several 
anticancer drugs whose primary mode of action is to target angiogenesis are being used in the 
clinic. However, these agents have been shown to cause resistance that emergs several months 
after the beginning of the treatment regimen, thus rendering the drug ineffective in future 
treatments rounds [232], [230]. To improve the efficacy of antiangiogenesis therapy, more 
detailed knowledge about tumor blood vessel formation is needed. In this context, it is 
becoming evident that signaling networks other than VEGF/VEGFR play important roles in 
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tumor angiogenesis. Accumulating data from cell culture and mouse knock out studies 
suggest a role for the Wnt pathway in angiogenesis (see previous chapters). While known 
growth factors like the VEGFs and FGFs exhibit their roles on vasculature from many 
different sites, the current data suggest that the influence of components of Wnt signaling is 
limited to certain tissue types. For example, conditional inactivation of β-catenin in 
endothelial cells specifically disrupts central nervous system vasculature, while the rest of the 
vasculature remains intact [166]. In a similar way, humans with mutations in Fz4 gene suffer 
from familial exudative vitreorethinopathy (FEVR), a disease that is characterized by 
incomplete retinal vascularization.  
In the search for novel regulators of angiogenesis, we wanted to test the roles of the Wnt3a 
and Wnt5a ligands and the Fz6 receptor in different steps of in vivo and in vitro angiogenesis. 
Among the numerous Wnt family members, we have chosen to work with Wnt3a and Wnt5a 
because they are representatives of the so called canonical and noncanonical Wnt ligands, 
respectively. However, it should be mentioned that the classification of Wnt family members 
to canonical and non canonical is only conditional, meaning that pathway activation is context 
dependent [303]. 
To determine which Fz receptors are expressed by endothelial cells, microarray analysis was 
performed on HUVEC, a primary endothelial cell line isolated from human umbilical vein. 
We found that Fz4 and Fz6 are expressed at significantly higher levels by HUVEC than the 
other receptors of the same family. Our results are in agreement with those obtained by 
Masckauchan et al, with the difference that we did not detect the Fz5 transcript [169]. 
Differences in the Frizzled expression from tissues of different individuals are well known, 
and are probably due to functional redundancy among the family members [168]. 
Interestingly, when Daneman et al analysed expression of the Frizzled receptors in 
endothelial cells isolated from the murine central nervous system they found that Fz4, Fz6 
and Fz8 are expressed in these cells, indicating the significance of these receptors for in vivo 
endothelial cell biology [166]. 
In order to activate the Fz4 and Fz6 receptors expressed by HUVEC, we treated the cells with 
recombinant Wnt3a and Wnt5a ligands. As readout of pathway activation we monitored the 
electrophoretic band shift of the protein Dishevelled (Dvl), which indicates its 
phosphorylation status. As current data suggest that Dvl is downstream of all known Wnt 
pathways, Dvl phosphorylation is considered to be a general biochemical assay for Wnt 
protein function [293]. Treatment with either ligand resulted in phosphorylation of the Dvl 
protein, indicating functional activation of the Fz4 and/or Fz6 receptors.  
Angiogenesis is a tightly regulated, multistep biological process. In order to form blood 
vessels, endothelial cells need to proliferate, migrate and survive. Using our in vitro system 
we wanted to test the role of Wnt3a and Wnt5a on HUVEC proliferation, migration and 
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survival. Using the BrdU incorporation assay, we were able to show that Wnt3a induces 
HUVEC proliferation and migration, but has no effect on their survival. Contrary to what was 
presumed in the literature [163], proliferation induced by Wnt3a is VEGFR signaling 
independent as it was not affected by a VEGFR inhibitor. This result suggests that Wnt3a is a 
direct, VEGF independent, proangiogenic factor.  
In contrast to Masckauchan et al, we did not detect any proliferative effects of Wnt5a on 
HUVEC, which may be explained by the difference in receptor expression as previously 
mentioned.  
To discern which receptor conveys Wnt3a induced proliferation, we made use of purified 
Fz4-cysteine rich domain (CRD). When administered to HUVEC together with Wnt3a, the 
Fz4-CRD protein inhibited the proliferative effects of Wnt3a, suggesting that this receptor 
might transduce the Wnt3a proliferative signals.  
In a search for downstream pathway activation, we checked the status of β-catenin after 
Wnt3a stimulation, and detected its stabilization, indicating activation of canonical Wnt 
pathway.  
In order to explain the mechanism by which Wnt3a induces its biological effects in HUVEC, 
we treated the cells with the ligand and looked for up regulation of known angiogenesis 
related Wnt target genes by semi-quantitative PCR. c-Myc is a known β-catenin 
transcriptional target gene [298] with documented roles in cell proliferation and migration 
[299]. Another cell cycle regulator downstream of canonical Wnt signaling is CyclinD1 
[300]. Several proangiogenic genes, among them MMP-1 and Tie-2, have been shown to be 
transcriptional targets of Wnt5a and non-canonical Wnt signaling in HUVEC [171], but are 
not listed as canonical Wnt target genes. Finally, Connexin43, a cellular gap junction protein, 
has been reported to be a target of the Wnt pathway in the vasculature [168]. We were able to 
show that Wnt3a induces the expression of c-Myc, Tie-2 and Connexin 43 transcripts, while it 
did not influence the transcription of MMP-1 or CyclinD1. In conclusion, our data show that 
the expression of genes known as both canonical (c-Myc) and non-canonical (Tie-2) Wnt 
target genes is upregulated upon Wnt3a treatment. Some of these genes (c-Myc for example) 
could be potential mediators of Wnt3a effect on HUVEC proliferation and migration. 
Downstream targets activated by the Wnt Calcium (Wnt Ca2+) pathway include calcium-
sensitive protein calcium-calmodulin dependent kinase II (CamKII) [107]. To check if Wnt3a 
is exhibiting its effect on HUVEC proliferation via the Wnt Ca2+ pathway and CamKII, we 
administered Wnt3a together with increasing concentrations of KN93, a selective CamKII 
inhibitor which binds to the calmodulin binding site of the enzyme. KN93 was able to reduce 
Wnt3a induced proliferation when used at concentration of 0.5 μM, indicating the 
requirement of CamKII for Wnt3a induced proliferation. 
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Taken together, β-catenin stabilization and upregulation of known canonical Wnt target gene 
c-Myc indicate activation of canonical Wnt pathway upon Wnt3a treatment. However, as 
mentioned, we also detected upregulation of Tie2 transcript, a gene that was shown to be 
downstream of non canonical Wnt signaling in HUVEC. We have also shown that CamKII 
inhibitor that is blocking a branch of Wnt calcium pathway decreases proliferation induced by 
Wnt3a. These results suggest the possibility that Wnt3a induces both canonical and non 
canonical Wnt signaling in our model. 
It was stated previously that expression of Fz6 has been repeatedly confirmed in several 
independent analyses of endothelial cells. For this reason, we wanted to test the role of this 
receptor in in vivo angiogenesis. We chose to investigate the role of Fz6 ablation using the 
Lewis lung carcinoma tumor model as it is well established that several of the steps of 
normal, physiological angiogenesis are recapitulated by tumors when forming blood vessels. 
Another reason to choose a tumor model is because of its relevance to cancer research studies. 
We compared the growth of tumors in mice deficient for Fz6 and their wild-type littermates. 
We did not detect significant differences in primary tumor growth, nor vascularization of 
tumors derived from Fz6 deficient mice in comparison to their wild-type littermates. 
However, it should be kept in mind that the tumor cells, surrounding activated stroma and 
recruited bone marrow derived cells are potential source of different growth factors that could 
interfere with the effects of Fz6 ablation.  
Taken together, our data implicate Wnt3a as a novel proangiogenic factor that plays a role in 
the induction of HUVEC proliferation and migration, but without an effect on their survival. 
Ablation of Fz6 in mice did not appear to affect either tumor growth or vascularization. 
However more appropriate models are needed to draw conclusions about the requirements of 
the pathways downstream of this receptor for tumor growth and angiogenesis.  
 
While the role of Wnt family members in angiogenesis is only emerging, the role of 
VEGF/VEGFR signaling network is very well documented. However, questions remain about 
the contribution of individual components to tumor growth, vascularization, dissemination 
and susceptibility to standard chemotherapeutics. To determine the effects of simultaneous 
inhibition of three VEGFRs in comparison to inhibition of either VEGFR2 or VEGF alone, 
we used the pan-VEGFR inhibitor PTK787/ZK (PTK/ZK, Vatalanib, Novartis 
Pharma/Schering), an anti VEGFR2 blocking antibody (DC101, ImClone Systems, [256]) and 
anti VEGF antibodies (Pab85618 and Avastin, anti mouse and anti human VEGFA 
antibodies, respectively). We show in an in vitro tumor model that simultaneous inhibition of 
all three VEGFRs by PTK/ZK significantly reduces functionality of the lymphatics 
surrounding tumors as well as the metastatic spread as compared to the individual 
administration of the other agents. In vitro, we show that VEGFA and VEGFC can induce 
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lymphatic endothelial cell (LEC) proliferation and survival. PTK/ZK was able to suppress the 
effects of both of these VEGFs, while Avastin was only successful in inhibiting the effects of 
VEGFA on LEC proliferation and survival. Increasing evidence suggest that anti 
VEGF/VEGFR treatment effects not only endothelial, but also tumor cell biology (chapter 
2.3.2.). We show here that PTK/ZK reduces the in vitro migration of B16/BL6 tumor cells, 
probably by primarily inhibiting VEGFR1. Interruption of PI3K and ERK1/2 survival 
pathways in B16/BL6 melanoma cells by PTK/ZK or DC101 also sensitized these cells to 
platinum based chemotherapeutics. Taken together, our results dissect individual 
contributions of several members of the VEGF/VEGFR signaling network to tumor growth, 
vascularization, lymphatic functionality, metastatic spread and in vitro tumor cell biology. 
 
Two decades ago, the Hynes group was among those who reported the discovery of 
amplification of the ErbB2 oncogene and the overexpression of its protein in a subset of 
breast cancers [269], [270]. Overexpression of the ErbB2 receptor tyrosine kinase is detected 
in 20% of cases of human breast cancer, and correlates with highly aggressive disease and 
poor clinical outcome for patients. Since these initial discoveries, oncogenic ErbB2 signaling 
has remained among the top research focuses in the field of breast cancer research.  
Recently, our group reported the finding of a novel protein that mediats microtubule 
outgrowth and cancer cell migration downstream of activated ErbB2. The protein was named 
Memo, or mediator of ErbB2 driven cell motility. Memo binds to the phospho YD site of the 
ErbB2 receptor (Tyr1226/7) [278]. Interaction of Memo with cofilin and PLCγ1 downstream 
of activated ErbB2 was shown to be essential for maintaining the directionality of cell 
migration induced through this receptor [283]. Although discovered in a screen for ErbB2 
binding partners, we were able to show that Memo has a broader role downstream of RTKs, 
as its downregulation impaired not only the migratory ability of T47D cells in response to 
heregulin (ErbB2 activator), but also in response to FGF2 (activator of  several FGFRs) and 
EGF (ErbB1 ligand) stimulation. Being aware of the importance of signaling through RTKs 
in tumor formation, angiogenesis, growth factor release, bone marrow cell recruitment and 
several steps of tumor dissemination, we wanted to test the role of Memo in the in vivo 
growth and dissemination of the 4T1 cell line which was isolated from a mammary tumor that 
spontaneously arose in a BALB/cfC3H mouse. 
Memo was downregulated in 4T1 cells by the stable transfection of a Memo shRNA 
construct. To determine the effects of Memo downregulation on primary tumor growth, we 
injected control and Memo downregulated 4T1 clones into the mammary fat pads of 
mammary glands of BALB/c female mice. We observed a significant delay in primary tumor 
growth upon Memo downregulation. To explain this effect, we inspected the vasculature of 
tumors derived from control and Memo knock down clones. The staining for the endothelial 
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cell specific surface molecule PECAM (platelet endothelial cell adhesion molecule, also 
known as CD31) revealed that tumors derived from Memo knock down (KD) clones were 
less vascularized in comparison to control tumors of similar size. In order to explain the 
impairment in angiogenesis observed in Memo downregulated tumors, we investigated the 
ability of Memo knock down cells to secrete vascular endothelial growth factor (VEGF), a 
strong angiogenic growth factor. Using an in vitro VEGF ELISA assay we found that Memo 
knock down cells secrete less VEGF into the medium than control cells, which may account 
for the observed in vivo effects on tumor vascularization.  
As previously mentioned, metastasis formation is the main cause of cancer related deaths. The 
process of metastasis formation includes several steps which together are reffered to as the 
‘invasion metastasis cascade’ [304]. These include: localized invasion, which enables in situ 
carcinoma cells to breach the basement membrane; intravasation into either lymphatic or 
blood microvessels; transport through the circulation; settlement in microvessels of various 
organs; extravasation; micrometastasis formation; and finally colonization, or 
macrometastasis formation. The likelihood of a single cancer cell successfully completing all 
these steps is low, however, the magnitude of the cancer cells present in a tumor and their 
high mutation rates explain why metastsis related deaths are one of the main healthcare issues 
of our time. For this reason, signaling pathways that are driving individual steps of ‘invasion 
metastasis cascade’ are of a central interest in cancer research. 
To test the role of Memo in metastasis formation in vivo, we again made use of the 4T1 cell 
model, which has been shown to be highly metastatic. To check the ability of Memo knock 
down 4T1 cells to extravasate and colonize distant organs, we performed tail vein injections 
and quantified the numbers of metastatic foci that were present in the lungs after twelve days. 
We were able to show that downregulation of Memo in 4T1 cells reduces the number of lung 
metastases after tail vein injection, indicating a role for Memo in the invasion-metastasis 
cascade.  
We know from data generated in our lab that 4T1 cells display autocrine FGFR signaling loop 
whose inhibition slows down primary tumor growth and reduces number of lung metastasis 
[305]. As Memo was also shown to be required for migration downstream of FGF, we wanted 
to determine if the effects of Memo KD are mediated through the FGFR pathway. We first 
checked the status of FGFR signaling in Memo KD cells. Our initial data show that the FGF1 
and FGFR1 transcripts are decreased in Memo KD cells, suggesting that the Memo 
downregulation does affect FGFR signaling, potentially explaining the effects observed on 
4T1 tumor cell biology. To confirm the involvement of Memo in FGFR mediated signaling, 
further characterization of the status of the components of this signaling network after Memo 
downregulation is needed. Stable reintroduction of key component (eg FGF1, FGFR1) into 
Memo KD cells would further our understanding of where Memo is acting in this pathway. 
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With our future studies we would also like to decipher the signaling pathway that influences 
VEGF production in 4T1 cells which, as our data suggest, is disrupted upon Memo 
downregulation. In this context, the interaction of Memo with signaling molecule ShcA, 
which is known to be required for VEGF induction downstream of some RTKs (introductory 
chapter 3.3.1.), could be interesting to explore in more detail.  
Taken together, our data show that Memo knock down reduces 4T1 in vivo growth, 
vascularization, dissemination and in vitro VEGF secretion. Further studies are needed to 
decipher the functional link between Memo and the signaling pathways driving these 
processes in 4T1 cells.  
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V. FIGURES 
 
Wnt 3a promotes proliferation and migration of HUVEC 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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Figure 8. 
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Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Sequence 5’-3’ Size/bp
Connexin43 Forw 
Rev 
AACTGCTGGAGGGAAGGTGTGG 
CATGAGCCAGGTACAAGAGTGTGG 
333 
c-Myc Forw 
Rev 
TGCTCCATGAGGAGACACCG 
ATGTGTGGAGACGTGGCACC 
200 
cyclinD1 Forw 
Rev 
GTCCATGCGGAAGATCGTCG 
TCTCCTTCATCTTAGAGGCCACG 
185 
MMP-1 Forw 
Rev 
GCCTGATGTGGCTCAGTTTGTCC 
TGTCTGCTTGACCCTCAGAGACC 
194 
Tie-2 Forw 
Rev 
TTATTTCTGTGAAGGGCGAGTTCG 
AATATCAGGTACTTCATGCCGGG 
223 
Fz4 Forw 
Rev 
GGAAATGGTTGGGTGAAGCCTG 
TTTTTGATGCTGGGGTCGGG 
215 
Fz6 Forw 
Rev 
TCTCTGCTGTCTTCTGGGTTGG 
TCCGCTTTCACCTCTCTCATTG 
346 
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Memo downregulation impairs 4T1 mammary tumor growth and metastasis formation 
 
Figure 1. 
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 85
Figure 4. 
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Figure 5. 
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VI. FIGURE LEGENDS 
Wnt 3a promotes proliferation and migration of HUVEC 
 
Figure 1. HUVEC express Fz4 and Fz6 receptors. 
a) Microarray analysis was performed on HUVEC to determine the Fz receptors expressed by 
these cells. The experiment was performed in Novartis Pharma AG. 
b) The expression of Fz4 and Fz6 in HUVEC was confirmed by semi quantitative PCR. 
 
Figure 2. Wnt3a and Wnt5a induce Dvl3 phosphorylation in HUVEC; recombinant Fz4 
competes for both Wnts.  
a) HUVEC were stimulated with either Wnt3a (200 ng/ml) or Wnt5a (200 ng/ml) for 2h and 
8h. Dvl3 was analyzed by immunoblotting with specific antiserum. The slower migrating 
band represents P-Dvl3. 
b) HUVEC were treated with Wnt3a (200 ng/ml), Wnt5a (200 ng/ml) in the presence or  no 
sFz-4 (5 μg/ml) for 1h. Dvl3 was analyzed by immunoblotting with specific antiserum. The 
slower migrating band represents P-Dvl3. 
 
Figure 3. Wnt3a induces HUVEC proliferation in VEGFR signaling independent manner. 
HUVEC were incubated with indicated concentrations of a) Wnt3a or VEGF-A in the 
presence or absence of sFz-4 (5 μg/ml), PTK/ZK (1μM), b) increasing concentrations of 
Wnt5a, c) Wnt3a and increasing concentrations of CaMKII inhibitor KN93 for 48 hours at 
37ºC. Proliferaton was assessed using an in vitro cell proliferation BrdU ELISA kit.   
 
Figure 4. Wnt3a induces HUVEC migration.  
a) Wnt3a (200 ng/ml) and Wnt5a (200 ng/ml) were used as chemoattractants in migration 
assay that was performed in a Boyden Chamber. The cells resuspended in Endothelial Cell 
Basal Medium (Promo Cell, C-90210) supplemented with 1% FBS were allowed to migrate 
for 6 hours  at 37ºC.  
b) The nuclei of migrated cells were stained with Hoechst33342  and the number of migrated 
cells was counted. Columns, mean; bars, SE. p<0.05 versus control (ANOVA). 
 
Figure 5. Wnt3a and Wnt5a are not survival factors for HUVEC.  
HUVEC resuspended in Endothelial Cell Basal Medium supplemented with 0.5% FBS were 
incubated with a) Wnt3a (200 ng/ml) or b) Wnt5a (200 ng/ml) or VEGF-A (20ng/ml), sFz-4 
(5 μg/ml) or PTK/ZK (1μM, VEGFR inhibitor, Novartis Pharma/Schering AG) for 48 hours 
at 37ºC. Cell death was measured using the YO-PRO assay. 
 
 89
Figure 6. Wnt3a and Wnt5a induce β-catenin stabilization 
a) HUVEC were stimulated with Wnt3a (200 ng/ml) or Wnt5a (200 ng/ml), in the presence or 
no sFz4 (5 μg/ml) for 24h. Total β-catenin and α-tubulin were analyzed by immunoblotting 
with specific antiserum.  
b) Quantifications of Western blots were carried out using the ImageQuant software. 
 
Figure 7. Wnt3a and Wnt5a transcriptional targets in HUVEC.  
HUVECs were treated for 5 and 24 hours in the presence or absence of Wnt3a (200 ng/ml), or 
Wnt5a (200 ng/ml). RNA was isolated, transcribed to cDNA and semiquantitative PCR was 
performed with primers for c-Myc, Tie-2, Connexin 43, MMP-1, Cyclin D1 and GAPDH. 
 
Figure 8. LLC growth in vivo in Fz6 knock out mice.  
a) Fzd6 +/+, Fzd6 +/-, Fzd6 -/- male and female mice from five littermates aged between 1 
and 5 months were injected with 0.5 million Lewis Lung Carcinoma (LLC) cells in 100 μl of 
PBS, subcutaneously into mid-dorsal region. Tumor growth was measured using a vernier 
caliper. Graph is presenting average tumor growth. N (Fzd6 +/+ mice) = 9, N (Fzd6 +/- mice) 
= 10, N (Fzd6 -/- mice) = 8. 
b) Tumors were taken at day 18 after injection. Fixed frozen sections were stained for CD31 
and the surface positive for staining was quantified using ImagePro software. N (Fzd6 +/+ 
mice) = 2, N (Fzd6 -/- mice) = 3. 
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Memo downregulation impairs 4T1 mammary tumor growth and metastasis formation  
 
Figure 1.  
Memo knock down 4T1 mouse mammary carcinoma cells form tumors with delayed kinetics. 
a) The level of Memo expression in control and Memo knock down (KD) 4T1 clones was 
determined by immunoblotting. α-Tubulin expression is shown as a loading control.  
b) Control and Memo KD 4T1 clones were injected into the mammary gland of female 
BALB/c mice (0.5 million cells in 100 μl PBS). Tumor growth was followed for 21 days. 
Data represents the average tumor volume in 6 mice over time.  
c) Statistical analysis (Wilcoxon signed rank test) was done on pooled data from control and 
Memo KD clones to evaluate the effect of Memo downregulation on 4T1 tumor cell growth.   
e) The level of Memo expression in control and Memo knock down (KD) 67NR clones was 
determined by immunoblotting. α-Tubulin expression is shown as a loading control.  
f) Control and Memo KD 67NR clones were injected into the mammary gland of female 
BALB/c mice (0.5 million cells in 100 μl PBS). Tumor growth was followed for 28 days. 
Data represents the average tumor volume in 3 or more mice over time.  
 
Figure 2.  
Tumors derived from Memo KD clones are less vascularized. 
a) Sections from tumors derived from control and Memo KD clones were taken at days 4, 7 
and 9 post injection and immunostained for the endothelial marker PECAM (shown in red). 
The tissue is counterstained with the nuclear dye Hoechst (blue).  
b) To determine vessel density, the area positive for PECAM was calculated and divided by 
the total surface area of the analysed section. The graph presents the percentage of the total 
area covered with vessels.  
 
Figure 3.  
Memo KD 4T1 clones secrete less VEGF in comparison to control clones. 
The medium from control and Memo knock down cells was analysed for the presence of 
secreted VEGF by the method of enzyme linked immunosorbent assay (ELISA). Supernatants 
from three wells of growing cells were combined then assayed in triplicates in a way that 
standard errors on a graph refer to technical replicates. The graph represents the amount of 
VEGF per ml of supernatant normalized to 10000 cells. 
 
Figure 4. 
Memo KD clones are impaired in their ability to extravasate and colonize lungs. 
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a) 4T1 control and Memo KD cells were injected into the tail vein of BALB/c female mice (6 
mice per group). Mice were sacrificed 12 days after injection. Images depict lungs that were 
immediately taken out.  
b) Graph is presenting average weight of dissected lungs and heart from mice injected either 
with control or Memo KD clones. 
c) H&E staining was done on fixed frozen sections, and images of consecutive sections (12 
μM thick) were taken with automatized slidescanner. The graph is presenting total area of 
sections and area covered with metastasis, that were both measured using Imaris software. 
Note that, besides of the area covered with metastasis, total area of section is larger too in 
case of mice injected with control cells. 
 
Figure 5. 
Effects of Memo downregulation on survival of 4T1 clones in conditions of oxidative stress 
induced by CoCl2. 
4T1 cells resuspended in growth medium were plated at density 5000 cells per well and 
allowed to seed overnight. The next day medium was exchanged and the cells were incubated 
with increasing concentrations of CoCl2 (300 μM, 600 μM, and 900 μM), or equal volume of 
PBS (control). Cell death was measured using the YO-PRO assay. Graph is showing the 
percentage of cells undergoing apoptosis. 
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VII. MATERIALS AND METHODS 
Wnt 3a promotes proliferation and migration of HUVEC  
 
Cell culture and reagents 
Human umbilical vein endothelial cells (HUVECs) were obtained from Promo Cell and 
grown on plates coated with 1.5% gelatin, either in Endothelial Cell Growth Medium (Promo 
Cell, C-22010) supplemented with 2.5% Fetal Bovine Serum (FBS, Sigma, St Louis, MO, 
USA) or when indicated, in Endothelial Cell Basal Medium (Promo Cell, C-90210) 
supplemented with 0.5% or 1% FBS. For experiments cells not more than passage 6, were 
used. Lewis lung carcinoma (LLC) cells were maintained in RPMI1640, 10% FCS, 1% L-
glutamine, 100 IU/ml penicillin, 100 μl/ml streptomycin. Recombinant Wnt3a, Wnt5a and 
Fz4 were purchased from R&D Systems, Minneapolis, MN, USA. Purified VEGF and PTK 
787/ZK were provided by Dr. Amanda Littlewood Evans (Novartis Pharma AG, Basel, 
Switzerland). In this study we used antibodies against β-catenin (BD Transduction 
Laboratories, Franklin Lakes, NJ, USA), Dishevelled-3 (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA), α-tubulin (Lab Vision Corporation, Fremont, CA, USA), CD31 (BD 
Biosciences Pharmingen, San Jose, CA, USA), and HRP-conjugated anti-mouse secondary 
antibody (GE healthcare, Little Chalfont, Buckinghamshire, UK). 
 
Detection of Fz4 and Fz6 by PCR 
RNA from HUVECs cultured in 6 well plates was isolated using the RNeasy MiniKit 
(Qiagen) following the instructions from the manufacturer. cDNA was obtained using 
Ready-to-Go You-Prime First-strand beads (Amersham Biosciences). 
Semiquantitative PCR was done using primers for Fz4 and Fz6 (sequences and 
amplified bands’ size are given in Table1). Conditions for PCR were: 94ºC for 5 
minutes, followed by 29 cycles of 94ºC for 1 minute, 55ºC for 1 minute and 72ºC for 
1 minute and 20 seconds.  
 
Western blot analysis 
HUVECs grown in Endothelial Cell Growth Medium with 2.5% FBS were treated with 
Wnt3a (200 ng/ml), Wnt5a (200 ng/ml), recombinant Fz4 (5 μg/ml), or PBS (control). Cells 
were harvested at different time points in NP-40 protein extraction buffer (1% Nonident P-40, 
50mM Tris pH7.5, 120 mMNaCl, 5 mM EDTA [ethylenediaminetetraacetic acid], 1 mM 
EGTA [ethylene glycol tetraacetic acid], 2 mM sodium vanadate, 20 mM β-glycerophosphate, 
10 μg/mL  aprotinin, 10 μg/mL leupeptin, 0.5 mM PMSF [phenylmethylsulphonyl fluoride], 
50 mM NaF, and 1 mM dithiothreitol).  
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Equal amounts of protein samples were denatured for 10 minutes at 95°C in sample buffer 
and separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Western blot 
analysis was done using antibodies against β-catenin, Dishevelled-3 and α-tubulin in 10% 
horse serum in TBS-T buffer (0.2M NaCl, 25 mM tris pH 7.5, 0.5 ml/l Tween-20), followed 
by incubation with α-mouse-HRP secondary antibody. The signal detection was performed 
with ECL (enhanced chemiluminiscence, GE Healthcare) according to manufacturer’s 
instructions. Quantifications of Western blots were carried out using the ImageQuant TL 
version 2005 software package from Amersham Biosciences (now part of GE Healthcare). 
 
BrdU incorporation assay 
HUVECs were plated on a 96 well plate at a density of 5000 cells/well and incubated over 
night in a complete growth medium. The next day, medium was exchanged to Endothelial 
Cell Basal Medium supplemented with 1% FBS. Twenty-four hours later cells were treated 
with Wnt3a (200 ng/ml), Wnt5a (200 ng/ml), VEGF (20 ng/ml) or an equal volume of PBS in 
the presence or absence of recombinant Fz4 (5 μg/ml), PTK/ZK787 (1μM) or equal volumes 
of PBS and DMSO as a control. The treatments were done in Endothelial Cell Basal Medium 
supplemented with 1% FBS. BrdU was added to cells 12 hours prior to the assay that was 
performed 2 days after treatment with ligands. BrdU detection was done using the Cell 
Proliferation Biotrak ELISA System (GE Healthcare) following the instructions of the 
manufacturer.  
 
Migration assay 
The cell migration assay was performed in a 24-well Boyden Chamber. HUVECs were 
resuspended in Endothelial Cell Basal Medium supplemented with 1% FBS and added to the 
upper chamber of the well, and either Wnt3a (200 ng/ml) or Wnt5a (200 ng/ml) were used as 
chemo-attractants in the lower chamber. The cells were allowed to migrate for 6 hours at 
37ºC, and then the cells were removed from the upper surface by scraping with a cotton swab. 
Cells that had migrated across the membrane were fixed in 4% PFA/PBS and the nuclei 
stained with Hoechst 33342. The number of cells was counted. Each condition was done in 
triplicate. 
 
Survival assay  
HUVECs were plated on 96 well plate at density 5000 cells per well, and grown over night in 
complete growth medium. To measure the effects on survival, cells were then grown in 
Endothelial Cell Basal Medium supplemented with 0.5% FBS. The cells were treated with 
Wnt3a (200 ng/ml), Wnt5a (200 ng/ml), VEGF (20 ng/ml) or an equal volume of PBS in the 
presence or absence of recombinant Fz4 (5 μg/ml), PTK 787/ZK (1μM) or equal volumes of 
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PBS and DMSO as control. Cells were incubated with ligand for 48 hours at 37ºC. Survival 
was measured using the YO-PRO assay. YO-PRO is a fluorescent dye that enters the nuclei 
of apoptotic cells, but not those that are viable. To determine the cells undergoing apoptosis 
and total cell number, respectively, we measured the fluorescence after the addition of the dye 
to the cells in culture, and subsequently after the cell lysis. 
  
Wnt pathway target gene detection 
HUVECs were treated with Wnt3a (200 ng/ml), Wnt5a (200 ng/ml) or an equal volume of 
PBS as a control for 5h or 24h. RNA was isolated using the RNeasy MiniKit (Qiagen) 
following the instructions from the manufacturer. cDNA was obtained using the Ready-to-Go 
You-Prime First-strand beads (Amersham Biosciences). Semiquantitative PCR was done 
using primers for c-Myc, Tie-2, Connexin 43, MMP-1 and CyclinD1. Primers (see Table 1 for 
sequences and amplified bands’ size) were designed using Vector NTI. Conditions for PCR 
were: 95ºC for 4 minutes followed by 10 cycles of 95ºC, 60ºC, 72ºC for 30 seconds and 25 
cycles of 95ºC, 55ºC, 72ºC for 30 seconds.  
 
In vivo tumor growth 
Wild-type, heterozygous and Fz6 knock-out mice [100] backcrossed into the Bl6 background 
were injected with 0.5 million LLC cells in 100 μl of PBS. The injection was done 
subcutaneously into the mid-dorsal region and tumor growth was measured using a vernier 
caliper. Tumor volume was calculated using formula for the volume (V) of ellipsoid, 
V=(4/3)πabc, with the assumption that the height of the tumor equals its width (b=c). 
Fixed frozen sections were stained for CD31 and the surface positive for staining was 
quantified using ImagePro software (Media Cybernetics, Bethesda, MD, USA). 
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Memo downregulation impairs 4T1 mammary tumor growth and metastasis formation  
 
Cell culture and reagents 
The mouse mammary tumor cell lines 4T1 and 67NR, obtained from Dr. R. Weinberg, 
Whitehead Institute for Biomedical Research, USA, were grown in DMEM supplemented 
with 10% heat inactivated FCS (Amimed, Allschwil, Switzerland) and Penicillin and 
Streptomycin. 
PECAM antibody was obtained from BD Biosciences Pharmingen, San Jose, CA, USA, and 
α-tubulin from Lab Vision Corporation, Fremont, CA, USA. 
 
Injection of tumor cells into mammary gland 
Half a milion 4T1 and 67NR cells were resuspended in PBS and injected into the fourth, 
inguinal mammary fat pad of 8-12 week old female BALB/c mice. Tumor growth was 
measured with a vernier caliper, and tumor volume calculated using the formula for the 
volume of ellipsoid, V=(4/3)πabc, in case of 4T1, and cylinder, V=πr2h in case of 67NR 
clones. 
 
Vessel quantification 
PECAM immunostaining on tumor sections, taken 4, 7 and 9 days after injection, was 
performed to visualize vasculature (sectioning, staining and images acquisition, were done by 
Dr Regis Masson). Area positive for PECAM was calculated using Image Pro (image 
processing software, Media Cybernetics) and divided with total surface of selected area of 
interest to get the percentage of vessel coverage.  
 
VEGF ELISA 
Control and Memo knock down cells were plated at density of 8000 cells per well in 96 well 
plate in a growing medium. The medium was collected after 24 h and the concentration of 
secreted VEGF assessed using ELISA kit (Quantikine Immunoassay mouse VEGF, R&D 
Systems) following the instructions from manufacturer. Supernatants from three wells of 
growing cells were joined together and divided into three wells on an ELISA plate in a way 
that standard errors refer as technical replicates. 
 
Tail vein injection 
BALB/c female mice were injected into the tail veins with 7.5x105 4T1 mammary carcinoma 
cells (6 mice per group, injection perfomed by Julien Dey). Mice were sacrificed 12 days after 
injection, lungs and heart were taken out and weighed. Subsequently, lungs were imaged and 
prepared for histology. H&E staining was done on fixed frozen sections (12 um thick), and 
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images of consecutive sections were taken with Mirax slidescanner. Area covered with 
metastasis was measured using Imaris software. 
 
Survival assay  
4T1 control and Memo knock down clones (two and three different clones, respectively) were 
plated in 96 well plate at density 5000 cells per well, and grown over night in complete 
growth medium. To measure the effects of Memo downregulation on 4T1 cell survival in 
conditions of hypoxia, the medium was exchanged the next day and the cells were incubated 
with increasing concentrations of CoCl2 (300 μM, 600 μM, and 900 μM), or equal volume of 
PBS (control). Cell death was measured using the YO-PRO assay. YO-PRO is a fluorescent 
dye entering the nuclei of apoptotic cells, but not those that are viable. To determine the cells 
undergoing apoptosis and total cell number, respectively, we measured the fluorescence after 
the employment of the dye to the cells in culture, and subsequently after the cell lysis. Graph 
is showing the percentage of cells undergoing apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 97
VIII. REFERENCES 
 
1. Chabner BA, Roberts TG, Jr.: Timeline: Chemotherapy and the war on cancer. Nature reviews 2005, 
5(1):65-72. 
2. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186. 
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-
VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3(5):391-400. 
4. Sharma RP: Wingless, a new mutant in D. melanogaster. Drosophila Information Service 1973, 
50(134). 
5. Nusslein-Volhard C, Wieschaus E: Mutations affecting segment number and polarity in Drosophila. 
Nature 1980, 287(5785):795-801. 
6. Nusslein-Volhard C WE, Kluding H Mutations affecting the pattern of the larval cuticle in 
Drosophila melanogaster: I. Zygotic loci on the second chromosome. Wilhelm Roux's Archives of 
Developmental Biology 1984, 193:267-282. 
7. Bejsovec A: Flying at the head of the pack: Wnt biology in Drosophila. Oncogene 2006, 
25(57):7442-7449. 
8. Klaus A, Birchmeier W: Wnt signalling and its impact on development and cancer. Nature reviews 
2008, 8(5):387-398. 
9. Nusse R, Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a 
provirus integrated in the same region of the host genome. Cell 1982, 31(1):99-109. 
10. Rijsewijk F, Schuermann M, Wagenaar E, Parren P, Weigel D, Nusse R: The Drosophila homolog of 
the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 1987, 
50(4):649-657. 
11. Cabrera CV, Alonso MC, Johnston P, Phillips RG, Lawrence PA: Phenocopies induced with antisense 
RNA identify the wingless gene. Cell 1987, 50(4):659-663. 
12. Nusse R, Brown A, Papkoff J, Scambler P, Shackleford G, McMahon A, Moon R, Varmus H: A new 
nomenclature for int-1 and related genes: the Wnt gene family. Cell 1991, 64(2):231. 
13. McMahon AP, Moon RT: Ectopic expression of the proto-oncogene int-1 in Xenopus embryos leads 
to duplication of the embryonic axis. Cell 1989, 58(6):1075-1084. 
14. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W: Functional 
interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382(6592):638-642. 
15. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R: Nuclear localization of beta-
catenin by interaction with transcription factor LEF-1. Mech Dev 1996, 59(1):3-10. 
16. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, Roose J, 
Destree O, Clevers H: XTcf-3 transcription factor mediates beta-catenin-induced axis formation in 
Xenopus embryos. Cell 1996, 86(3):391-399. 
17. Jiang J, Hui CC: Hedgehog signaling in development and cancer. Developmental cell 2008, 
15(6):801-812. 
18. Ramjaun AR, Downward J: Ras and phosphoinositide 3-kinase: partners in development and 
tumorigenesis. Cell Cycle 2007, 6(23):2902-2905. 
19. http://www.stanford.edu/~rnusse/wntwindow.html. 
20. Prud'homme B, Lartillot N, Balavoine G, Adoutte A, Vervoort M: Phylogenetic analysis of the Wnt 
gene family. Insights from lophotrochozoan members. Curr Biol 2002, 12(16):1395. 
21. Miller JR: The Wnts. Genome Biol 2002, 3(1):REVIEWS3001. 
22. Conway Morris S: The Cambrian "explosion": slow-fuse or megatonnage? Proceedings of the 
National Academy of Sciences of the United States of America 2000, 97(9):4426-4429. 
23. Kusserow A, Pang K, Sturm C, Hrouda M, Lentfer J, Schmidt HA, Technau U, von Haeseler A, 
Hobmayer B, Martindale MQ et al: Unexpected complexity of the Wnt gene family in a sea anemone. 
Nature 2005, 433(7022):156-160. 
24. Guder C, Philipp I, Lengfeld T, Watanabe H, Hobmayer B, Holstein TW: The Wnt code: cnidarians 
signal the way. Oncogene 2006, 25(57):7450-7460. 
25. McMahon AP, Bradley A: The Wnt-1 (int-1) proto-oncogene is required for development of a large 
region of the mouse brain. Cell 1990, 62(6):1073-1085. 
26. Thomas KR, Capecchi MR: Targeted disruption of the murine int-1 proto-oncogene resulting in 
severe abnormalities in midbrain and cerebellar development. Nature 1990, 346(6287):847-850. 
27. Echelard Y, Vassileva G, McMahon AP: Cis-acting regulatory sequences governing Wnt-1 
expression in the developing mouse CNS. Development (Cambridge, England) 1994, 120(8):2213-
2224. 
28. Rowitch DH, Echelard Y, Danielian PS, Gellner K, Brenner S, McMahon AP: Identification of an 
evolutionarily conserved 110 base-pair cis-acting regulatory sequence that governs Wnt-1 
expression in the murine neural plate. Development (Cambridge, England) 1998, 125(14):2735-2746. 
29. Tian Q, Jin H, Cui Y, Guo C, Lu X: Regulation of Wnt gene expression. Dev Growth Differ 2005, 
47(5):273-281. 
30. Coudreuse D, Korswagen HC: The making of Wnt: new insights into Wnt maturation, sorting and 
secretion. Development (Cambridge, England) 2007, 134(1):3-12. 
31. Hoppler S, Brown JD, Moon RT: Expression of a dominant-negative Wnt blocks induction of MyoD 
in Xenopus embryos. Genes Dev 1996, 10(21):2805-2817. 
 98
32. Tian Q, Nakayama T, Dixon MP, Christian JL: Post-transcriptional regulation of Xwnt-8 expression 
is required for normal myogenesis during vertebrate embryonic development. Development 
(Cambridge, England) 1999, 126(15):3371-3380. 
33. Willert K, Logan CY, Arora A, Fish M, Nusse R: A Drosophila Axin homolog, Daxin, inhibits Wnt 
signaling. Development (Cambridge, England) 1999, 126(18):4165-4173. 
34. Zhai L, Chaturvedi D, Cumberledge S: Drosophila wnt-1 undergoes a hydrophobic modification and 
is targeted to lipid rafts, a process that requires porcupine. The Journal of biological chemistry 2004, 
279(32):33220-33227. 
35. Mikels AJ, Nusse R: Wnts as ligands: processing, secretion and reception. Oncogene 2006, 
25(57):7461-7468. 
36. Pfeiffer S, Ricardo S, Manneville JB, Alexandre C, Vincent JP: Producing cells retain and recycle 
Wingless in Drosophila embryos. Curr Biol 2002, 12(11):957-962. 
37. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1(1):31-39. 
38. Schmidt K, Schrader M, Kern HF, Kleene R: Regulated apical secretion of zymogens in rat pancreas. 
Involvement of the glycosylphosphatidylinositol-anchored glycoprotein GP-2, the lectin ZG16p, 
and cholesterol-glycosphingolipid-enriched microdomains. The Journal of biological chemistry 2001, 
276(17):14315-14323. 
39. Ching W, Nusse R: A dedicated Wnt secretion factor. Cell 2006, 125(3):432-433. 
40. Banziger C, Soldini D, Schutt C, Zipperlen P, Hausmann G, Basler K: Wntless, a conserved membrane 
protein dedicated to the secretion of Wnt proteins from signaling cells. Cell 2006, 125(3):509-522. 
41. Coudreuse DY, Roel G, Betist MC, Destree O, Korswagen HC: Wnt gradient formation requires 
retromer function in Wnt-producing cells. Science (New York, NY 2006, 312(5775):921-924. 
42. Prasad BC, Clark SG: Wnt signaling establishes anteroposterior neuronal polarity and requires 
retromer in C. elegans. Development (Cambridge, England) 2006, 133(9):1757-1766. 
43. Belenkaya TY, Wu Y, Tang X, Zhou B, Cheng L, Sharma YV, Yan D, Selva EM, Lin X: The retromer 
complex influences Wnt secretion by recycling wntless from endosomes to the trans-Golgi 
network. Developmental cell 2008, 14(1):120-131. 
44. Franch-Marro X, Wendler F, Guidato S, Griffith J, Baena-Lopez A, Itasaki N, Maurice MM, Vincent JP: 
Wingless secretion requires endosome-to-Golgi retrieval of Wntless/Evi/Sprinter by the retromer 
complex. Nature cell biology 2008, 10(2):170-177. 
45. Pan CL, Baum PD, Gu M, Jorgensen EM, Clark SG, Garriga G: C. elegans AP-2 and retromer control 
Wnt signaling by regulating mig-14/Wntless. Developmental cell 2008, 14(1):132-139. 
46. Port F, Kuster M, Herr P, Furger E, Banziger C, Hausmann G, Basler K: Wingless secretion promotes 
and requires retromer-dependent cycling of Wntless. Nature cell biology 2008, 10(2):178-185. 
47. Yang PT, Lorenowicz MJ, Silhankova M, Coudreuse DY, Betist MC, Korswagen HC: Wnt signaling 
requires retromer-dependent recycling of MIG-14/Wntless in Wnt-producing cells. Developmental 
cell 2008, 14(1):140-147. 
48. Bartscherer K, Boutros M: Regulation of Wnt protein secretion and its role in gradient formation. 
EMBO Rep 2008, 9(10):977-982. 
49. Hausmann G, Banziger C, Basler K: Helping Wingless take flight: how WNT proteins are secreted. 
Nat Rev Mol Cell Biol 2007, 8(4):331-336. 
50. Gubb D, Garcia-Bellido A: A genetic analysis of the determination of cuticular polarity during 
development in Drosophila melanogaster. J Embryol Exp Morphol 1982, 68:37-57. 
51. Vinson CR, Conover S, Adler PN: A Drosophila tissue polarity locus encodes a protein containing 
seven potential transmembrane domains. Nature 1989, 338(6212):263-264. 
52. Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP, Andrew D, Nathans J, Nusse R: A new 
member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 1996, 
382(6588):225-230. 
53. Alcedo J, Ayzenzon M, Von Ohlen T, Noll M, Hooper JE: The Drosophila smoothened gene encodes 
a seven-pass membrane protein, a putative receptor for the hedgehog signal. Cell 1996, 86(2):221-
232. 
54. Egger-Adam D, Katanaev VL: Trimeric G protein-dependent signaling by Frizzled receptors in 
animal development. Front Biosci 2008, 13:4740-4755. 
55. Wang HY, Liu T, Malbon CC: Structure-function analysis of Frizzleds. Cell Signal 2006, 18(7):934-
941. 
56. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K: The 7 TM G-protein-coupled receptor target 
family. ChemMedChem 2006, 1(8):761-782. 
57. Liu T, Liu X, Wang H, Moon RT, Malbon CC: Activation of rat frizzled-1 promotes Wnt signaling 
and differentiation of mouse F9 teratocarcinoma cells via pathways that require Galpha(q) and 
Galpha(o) function. The Journal of biological chemistry 1999, 274(47):33539-33544. 
58. Katanaev VL, Ponzielli R, Semeriva M, Tomlinson A: Trimeric G protein-dependent frizzled 
signaling in Drosophila. Cell 2005, 120(1):111-122. 
59. Liu T, DeCostanzo AJ, Liu X, Wang H, Hallagan S, Moon RT, Malbon CC: G protein signaling from 
activated rat frizzled-1 to the beta-catenin-Lef-Tcf pathway. Science (New York, NY 2001, 
292(5522):1718-1722. 
60. Dirnberger D, Seuwen K: Signaling of human frizzled receptors to the mating pathway in yeast. 
PLoS ONE 2007, 2(9):e954. 
 99
61. Malbon CC, Wang H, Moon RT: Wnt signaling and heterotrimeric G-proteins: strange bedfellows 
or a classic romance? Biochemical and biophysical research communications 2001, 287(3):589-593. 
62. Angers S, Thorpe CJ, Biechele TL, Goldenberg SJ, Zheng N, MacCoss MJ, Moon RT: The KLHL12-
Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting 
Dishevelled for degradation. Nature cell biology 2006, 8(4):348-357. 
63. Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C, Kelley MW, Jiang L, Tasman W, 
Zhang K et al: Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, 
a high-affinity ligand-receptor pair. Cell 2004, 116(6):883-895. 
64. Kikuchi A, Yamamoto H, Kishida S: Multiplicity of the interactions of Wnt proteins and their 
receptors. Cell Signal 2007, 19(4):659-671. 
65. Kazanskaya O, Ohkawara B, Heroult M, Wu W, Maltry N, Augustin HG, Niehrs C: The Wnt signaling 
regulator R-spondin 3 promotes angioblast and vascular development. Development (Cambridge, 
England) 2008, 135(22):3655-3664. 
66. Herz J, Bock HH: Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002, 71:405-434. 
67. Semenov MV, Habas R, Macdonald BT, He X: SnapShot: Noncanonical Wnt Signaling Pathways. 
Cell 2007, 131(7):1378. 
68. Wallingford JB, Habas R: The developmental biology of Dishevelled: an enigmatic protein 
governing cell fate and cell polarity. Development (Cambridge, England) 2005, 132(20):4421-4436. 
69. Wong HC, Bourdelas A, Krauss A, Lee HJ, Shao Y, Wu D, Mlodzik M, Shi DL, Zheng J: Direct 
binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal 
region of Frizzled. Mol Cell 2003, 12(5):1251-1260. 
70. Cong F, Schweizer L, Varmus H: Casein kinase Iepsilon modulates the signaling specificities of 
dishevelled. Molecular and cellular biology 2004, 24(5):2000-2011. 
71. Willert K, Brink M, Wodarz A, Varmus H, Nusse R: Casein kinase 2 associates with and 
phosphorylates dishevelled. The EMBO journal 1997, 16(11):3089-3096. 
72. Sun TQ, Lu B, Feng JJ, Reinhard C, Jan YN, Fantl WJ, Williams LT: PAR-1 is a Dishevelled-
associated kinase and a positive regulator of Wnt signalling. Nature cell biology 2001, 3(7):628-636. 
73. Kinoshita N, Iioka H, Miyakoshi A, Ueno N: PKC delta is essential for Dishevelled function in a 
noncanonical Wnt pathway that regulates Xenopus convergent extension movements. Genes Dev 
2003, 17(13):1663-1676. 
74. Miller JR, Hocking AM, Brown JD, Moon RT: Mechanism and function of signal transduction by 
the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 1999, 18(55):7860-7872. 
75. Sheldahl LC, Slusarski DC, Pandur P, Miller JR, Kuhl M, Moon RT: Dishevelled activates Ca2+ flux, 
PKC, and CamKII in vertebrate embryos. J Cell Biol 2003, 161(4):769-777. 
76. Peterson-Nedry W, Erdeniz N, Kremer S, Yu J, Baig-Lewis S, Wehrli M: Unexpectedly robust 
assembly of the Axin destruction complex regulates Wnt/Wg signaling in Drosophila as revealed 
by analysis in vivo. Developmental biology 2008, 320(1):226-241. 
77. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X: Control of beta-catenin 
phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108(6):837-847. 
78. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K, Nakamichi I, Kikuchi A, 
Nakayama K, Nakayama K: An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of 
beta-catenin. The EMBO journal 1999, 18(9):2401-2410. 
79. Su Y, Fu C, Ishikawa S, Stella A, Kojima M, Shitoh K, Schreiber EM, Day BW, Liu B: APC Is 
Essential for Targeting Phosphorylated beta-Catenin to the SCF(beta-TrCP) Ubiquitin Ligase. 
Mol Cell 2008, 32(5):652-661. 
80. Gordon MD, Nusse R: Wnt signaling: multiple pathways, multiple receptors, and multiple 
transcription factors. The Journal of biological chemistry 2006, 281(32):22429-22433. 
81. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X: A dual-kinase 
mechanism for Wnt co-receptor phosphorylation and activation. Nature 2005, 438(7069):873-877. 
82. Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P, Glinka A, Niehrs C: Casein kinase 1 gamma 
couples Wnt receptor activation to cytoplasmic signal transduction. Nature 2005, 438(7069):867-
872. 
83. Nusse R: Cell biology: relays at the membrane. Nature 2005, 438(7069):747-749. 
84. Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M, Niehrs C: Wnt induces LRP6 
signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science (New York, NY 
2007, 316(5831):1619-1622. 
85. Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, Almeida K, Wang J, Doble B, Woodgett J 
et al: Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via 
frizzled, dishevelled and axin functions. Development (Cambridge, England) 2008, 135(2):367-375. 
86. Pan W, Choi SC, Wang H, Qin Y, Volpicelli-Daley L, Swan L, Lucast L, Khoo C, Zhang X, Li L et al: 
Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 
phosphorylation. Science (New York, NY 2008, 321(5894):1350-1353. 
87. Tolwinski NS, Wieschaus E: Rethinking WNT signaling. Trends Genet 2004, 20(4):177-181. 
88. Baig-Lewis S, Peterson-Nedry W, Wehrli M: Wingless/Wnt signal transduction requires distinct 
initiation and amplification steps that both depend on Arrow/LRP. Developmental biology 2007, 
306(1):94-111. 
 100
89. Fuerer C, Nusse R, Ten Berge D: Wnt signalling in development and disease. Max Delbruck Center 
for Molecular Medicine meeting on Wnt signaling in Development and Disease. EMBO Rep 2008, 
9(2):134-138. 
90. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F: Rac1 activation controls nuclear 
localization of beta-catenin during canonical Wnt signaling. Cell 2008, 133(2):340-353. 
91. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, Murone M, Zullig S, Basler K: 
Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear 
beta-catenin-TCF complex. Cell 2002, 109(1):47-60. 
92. Parker DS, Jemison J, Cadigan KM: Pygopus, a nuclear PHD-finger protein required for Wingless 
signaling in Drosophila. Development (Cambridge, England) 2002, 129(11):2565-2576. 
93. Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H, Bienz M: A new nuclear component of the 
Wnt signalling pathway. Nature cell biology 2002, 4(5):367-373. 
94. Townsley FM, Thompson B, Bienz M: Pygopus residues required for its binding to Legless are 
critical for transcription and development. The Journal of biological chemistry 2004, 279(7):5177-
5183. 
95. Arias AM, Hayward P: Filtering transcriptional noise during development: concepts and 
mechanisms. Nat Rev Genet 2006, 7(1):34-44. 
96. Hayward P, Kalmar T, Arias AM: Wnt/Notch signalling and information processing during 
development. Development (Cambridge, England) 2008, 135(3):411-424. 
97. Adler PN, Krasnow RE, Liu J: Tissue polarity points from cells that have higher Frizzled levels 
towards cells that have lower Frizzled levels. Curr Biol 1997, 7(12):940-949. 
98. Fahmy O.G. FM: New mutant report. Drosophila Information Service 1959, 33(85). 
99. Theisen H, Purcell J, Bennett M, Kansagara D, Syed A, Marsh JL: dishevelled is required during 
wingless signaling to establish both cell polarity and cell identity. Development (Cambridge, 
England) 1994, 120(2):347-360. 
100. Guo N, Hawkins C, Nathans J: Frizzled6 controls hair patterning in mice. Proc Natl Acad Sci U S A 
2004, 101(25):9277-9281. 
101. Wang Y, Nathans J: Tissue/planar cell polarity in vertebrates: new insights and new questions. 
Development 2007, 134(4):647-658. 
102. Seifert JR, Mlodzik M: Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and 
directed motility. Nat Rev Genet 2007, 8(2):126-138. 
103. Simons M, Mlodzik M: Planar cell polarity signaling: from fly development to human disease. Annu 
Rev Genet 2008, 42:517-540. 
104. Devenport D, Fuchs E: Planar polarization in embryonic epidermis orchestrates global asymmetric 
morphogenesis of hair follicles. Nature cell biology 2008, 10(11):1257-1268. 
105. Axelrod JD: Bad hair days for mouse PCP mutants. Nature cell biology 2008, 10(11):1251-1253. 
106. Lawrence PA, Struhl G, Casal J: Planar cell polarity: A bridge too far? Curr Biol 2008, 18(20):R959-
961. 
107. Kuhl M: The WNT/calcium pathway: biochemical mediators, tools and future requirements. Front 
Biosci 2004, 9:967-974. 
108. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P: 
Association of the APC gene product with beta-catenin. Science (New York, NY 1993, 
262(5140):1731-1734. 
109. Su LK, Vogelstein B, Kinzler KW: Association of the APC tumor suppressor protein with catenins. 
Science (New York, NY 1993, 262(5140):1734-1737. 
110. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480. 
111. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P: Binding of GSK3beta to the APC-
beta-catenin complex and regulation of complex assembly. Science (New York, NY 1996, 
272(5264):1023-1026. 
112. Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006, 
5(12):997-1014. 
113. Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature 2005, 434(7035):843-850. 
114. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of beta-
catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (New York, NY 
1997, 275(5307):1787-1790. 
115. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H: 
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. 
Science (New York, NY 1997, 275(5307):1784-1787. 
116. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, 
Coudreuse D, Haramis AP et al: The beta-catenin/TCF-4 complex imposes a crypt progenitor 
phenotype on colorectal cancer cells. Cell 2002, 111(2):241-250. 
117. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van 
de Wetering M, Pawson T et al: Beta-catenin and TCF mediate cell positioning in the intestinal 
epithelium by controlling the expression of EphB/ephrinB. Cell 2002, 111(2):251-263. 
118. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ, Clevers H: Depletion of epithelial 
stem-cell compartments in the small intestine of mice lacking Tcf-4. Nature genetics 1998, 
19(4):379-383. 
 101
119. Pinto D, Gregorieff A, Begthel H, Clevers H: Canonical Wnt signals are essential for homeostasis of 
the intestinal epithelium. Genes Dev 2003, 17(14):1709-1713. 
120. Kuhnert F, Davis CR, Wang HT, Chu P, Lee M, Yuan J, Nusse R, Kuo CJ: Essential requirement for 
Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression 
of Dickkopf-1. Proceedings of the National Academy of Sciences of the United States of America 2004, 
101(1):266-271. 
121. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, 
Clarke AR: Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446(7136):676-
679. 
122. Bommer GT, Fearon ER: Role of c-Myc in Apc mutant intestinal phenotype: case closed or time for 
a new beginning? Cancer cell 2007, 11(5):391-394. 
123. Major MB, Roberts BS, Berndt JD, Marine S, Anastas J, Chung N, Ferrer M, Yi X, Stoick-Cooper CL, 
von Haller PD et al: New regulators of Wnt/beta-catenin signaling revealed by integrative 
molecular screening. Sci Signal 2008, 1(45):ra12. 
124. Morris EJ, Ji JY, Yang F, Di Stefano L, Herr A, Moon NS, Kwon EJ, Haigis KM, Naar AM, Dyson NJ: 
E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 
2008, 455(7212):552-556. 
125. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S et al: 
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008, 
455(7212):547-551. 
126. Bernards R: Cancer: Entangled pathways. Nature 2008, 455(7212):479-480. 
127. Rivera MN, Haber DA: Wilms' tumour: connecting tumorigenesis and organ development in the 
kidney. Nature reviews 2005, 5(9):699-712. 
128. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, 
Vargas SO et al: An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 
(New York, NY 2007, 315(5812):642-645. 
129. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, 
Maccoss MJ et al: Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. 
Science (New York, NY 2007, 316(5827):1043-1046. 
130. Nusse R: Cancer. Converging on beta-catenin in Wilms tumor. Science (New York, NY 2007, 
316(5827):988-989. 
131. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, 
Nojima M, Sonoda T et al: Frequent epigenetic inactivation of Wnt antagonist genes in breast 
cancer. British journal of cancer 2008, 98(6):1147-1156. 
132. Matsuda Y, Schlange T, Oakeley E, Hynes N: Manuscript submitted 2008. 
133. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani 
RA: Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer cell 
2004, 5(1):91-102. 
134. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-
Dor A et al: Molecular classification of cutaneous malignant melanoma by gene expression 
profiling. Nature 2000, 406(6795):536-540. 
135. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM: Wnt5a signaling 
directly affects cell motility and invasion of metastatic melanoma. Cancer cell 2002, 1(3):279-288. 
136. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 
6(4):273-286. 
137. Ferrara N: Angiogenesis From basic science to clinical applications. Taylor & Francis group 2007. 
138. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 2005, 438(7070):932-936. 
139. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nature reviews 2002, 2(10):795-
803. 
140. Zetter BR: The scientific contributions of M. Judah Folkman to cancer research. Nature reviews 
2008, 8(8):647-654. 
141. Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nature 
reviews 2003, 3(6):422-433. 
142. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nature reviews 2003, 3(6):401-
410. 
143. Bertout JA, Patel SA, Simon MC: The impact of O2 availability on human cancer. Nature reviews 
2008, 8(12):967-975. 
144. Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, Jungles S, Carter R, Krieger JE, Manseau 
EJ, Harvey VS et al: Heterogeneity of the angiogenic response induced in different normal adult 
tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000, 
80(1):99-115. 
145. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, 
Thurston G: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. 
Nature 2006, 444(7122):1032-1037. 
146. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, 
Kasman I et al: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. 
Nature 2006, 444(7122):1083-1087. 
 102
147. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson 
L, Gaiano N et al: Dll4 signalling through Notch1 regulates formation of tip cells during 
angiogenesis. Nature 2007, 445(7129):776-780. 
148. Siekmann AF, Lawson ND: Notch signalling limits angiogenic cell behaviour in developing 
zebrafish arteries. Nature 2007, 445(7129):781-784. 
149. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL, Lewis J: Endothelial 
signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development (Cambridge, 
England) 2007, 134(5):839-844. 
150. Dufraine J, Funahashi Y, Kitajewski J: Notch signaling regulates tumor angiogenesis by diverse 
mechanisms. Oncogene 2008, 27(38):5132-5137. 
151. Shawber CJ, Funahashi Y, Francisco E, Vorontchikhina M, Kitamura Y, Stowell SA, Borisenko V, Feirt 
N, Podgrabinska S, Shiraishi K et al: Notch alters VEGF responsiveness in human and murine 
endothelial cells by direct regulation of VEGFR-3 expression. The Journal of clinical investigation 
2007, 117(11):3369-3382. 
152. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, 
Schomber T, Peltonen R et al: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular 
network formation. Nature 2008, 454(7204):656-660. 
153. Padera TP, Jain RK: VEGFR3: a new target for antiangiogenesis therapy? Developmental cell 2008, 
15(2):178-179. 
154. Hlushchuk R, Riesterer O, Baum O, Wood J, Gruber G, Pruschy M, Djonov V: Tumor recovery by 
angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with 
PTK787/ZK222584 or ionizing radiation. The American journal of pathology 2008, 173(4):1173-
1185. 
155. Hillen F, Griffioen AW: Tumour vascularization: sprouting angiogenesis and beyond. Cancer 
metastasis reviews 2007, 26(3-4):489-502. 
156. Monkley SJ, Delaney SJ, Pennisi DJ, Christiansen JH, Wainwright BJ: Targeted disruption of the 
Wnt2 gene results in placentation defects. Development (Cambridge, England) 1996, 122(11):3343-
3353. 
157. Jeays-Ward K, Hoyle C, Brennan J, Dandonneau M, Alldus G, Capel B, Swain A: Endothelial and 
steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. 
Development (Cambridge, England) 2003, 130(16):3663-3670. 
158. Shu W, Jiang YQ, Lu MM, Morrisey EE: Wnt7b regulates mesenchymal proliferation and vascular 
development in the lung. Development (Cambridge, England) 2002, 129(20):4831-4842. 
159. Parmalee NL, Kitajewski J: Wnt signaling in angiogenesis. Current drug targets 2008, 9(7):558-564. 
160. Ishikawa T, Tamai Y, Zorn AM, Yoshida H, Seldin MF, Nishikawa S, Taketo MM: Mouse Wnt 
receptor gene Fzd5 is essential for yolk sac and placental angiogenesis. Development (Cambridge, 
England) 2001, 128(1):25-33. 
161. Robitaille J, MacDonald ML, Kaykas A, Sheldahl LC, Zeisler J, Dube MP, Zhang LH, Singaraja RR, 
Guernsey DL, Zheng B et al: Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative 
vitreoretinopathy. Nat Genet 2002, 32(2):326-330. 
162. Kaykas A, Yang-Snyder J, Heroux M, Shah KV, Bouvier M, Moon RT: Mutant Frizzled 4 associated 
with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization. 
Nature cell biology 2004, 6(1):52-58. 
163. Zerlin M, Julius MA, Kitajewski J: Wnt/Frizzled signaling in angiogenesis. Angiogenesis 2008, 
11(1):63-69. 
164. Stenman JM, Rajagopal J, Carroll TJ, Ishibashi M, McMahon J, McMahon AP: Canonical Wnt 
signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science (New 
York, NY 2008, 322(5905):1247-1250. 
165. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, Wolburg H, 
Fruttiger M et al: Wnt/beta-catenin signaling controls development of the blood-brain barrier. The 
Journal of cell biology 2008, 183(3):409-417. 
166. Daneman R, Agalliu D, Zhou L, Kuhnert F, Kuo CJ, Barres BA: Wnt/{beta}-catenin signaling is 
required for CNS, but not non-CNS, angiogenesis. Proceedings of the National Academy of Sciences 
of the United States of America 2009. 
167. Cheng CW, Smith SK, Charnock-Jones DS: Wnt-1 signaling inhibits human umbilical vein 
endothelial cell proliferation and alters cell morphology. Experimental cell research 2003, 
291(2):415-425. 
168. Goodwin AM, Sullivan KM, D'Amore PA: Cultured endothelial cells display endogenous activation 
of the canonical Wnt signaling pathway and express multiple ligands, receptors, and secreted 
modulators of Wnt signaling. Dev Dyn 2006, 235(11):3110-3120. 
169. Masckauchan TN, Shawber CJ, Funahashi Y, Li CM, Kitajewski J: Wnt/beta-catenin signaling 
induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis 2005, 
8(1):43-51. 
170. Goodwin AM, Kitajewski J, D'Amore PA: Wnt1 and Wnt5a affect endothelial proliferation and 
capillary length; Wnt2 does not. Growth factors (Chur, Switzerland) 2007, 25(1):25-32. 
 103
171. Masckauchan TN, Agalliu D, Vorontchikhina M, Ahn A, Parmalee NL, Li CM, Khoo A, Tycko B, 
Brown AM, Kitajewski J: Wnt5a signaling induces proliferation and survival of endothelial cells in 
vitro and expression of MMP-1 and Tie-2. Molecular biology of the cell 2006, 17(12):5163-5172. 
172. Cirone P, Lin S, Griesbach HL, Zhang Y, Slusarski DC, Crews CM: A role for planar cell polarity 
signaling in angiogenesis. Angiogenesis 2008, 11(4):347-360. 
173. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a 
vascular permeability factor that promotes accumulation of ascites fluid. Science (New York, NY 
1983, 219(4587):983-985. 
174. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor 
specific for vascular endothelial cells. Biochemical and biophysical research communications 1989, 
161(2):851-858. 
175. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R, 
Feder J: Human vascular permeability factor. Isolation from U937 cells. The Journal of biological 
chemistry 1989, 264(33):20017-20024. 
176. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a 
secreted angiogenic mitogen. Science (New York, NY 1989, 246(4935):1306-1309. 
177. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability 
factor, an endothelial cell mitogen related to PDGF. Science (New York, NY 1989, 246(4935):1309-
1312. 
178. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocrine 
reviews 2004, 25(4):581-611. 
179. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, 
Harpal K, Eberhardt C et al: Abnormal blood vessel development and lethality in embryos lacking a 
single VEGF allele. Nature 1996, 380(6573):435-439. 
180. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore 
MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 
1996, 380(6573):439-442. 
181. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-
Arispe ML: Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130(4):691-
703. 
182. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular 
endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 
362(6423):841-844. 
183. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck 
H et al: Synergism between vascular endothelial growth factor and placental growth factor 
contributes to angiogenesis and plasma extravasation in pathological conditions. Nature medicine 
2001, 7(5):575-583. 
184. Fischer C, Mazzone M, Jonckx B, Carmeliet P: FLT1 and its ligands VEGFB and PlGF: drug targets 
for anti-angiogenic therapy? Nature reviews 2008, 8(12):942-956. 
185. Achen MG, Mann GB, Stacker SA: Targeting lymphangiogenesis to prevent tumour metastasis. 
British journal of cancer 2006, 94(10):1355-1360. 
186. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: 
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR 
(VEGFR-2) receptor tyrosine kinases. The EMBO journal 1996, 15(7):1751. 
187. Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI: Vascular endothelial growth factor-related 
protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proceedings of the 
National Academy of Sciences of the United States of America 1996, 93(5):1988-1992. 
188. Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K: VEGF-C receptor 
binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular 
development. Development (Cambridge, England) 1996, 122(12):3829-3837. 
189. Tammela T, Enholm B, Alitalo K, Paavonen K: The biology of vascular endothelial growth factors. 
Cardiovascular research 2005, 65(3):550-563. 
190. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, 
Alitalo K: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (New York, NY 
1997, 276(5317):1423-1425. 
191. Oh SJ, Jeltsch MM, Birkenhager R, McCarthy JE, Weich HA, Christ B, Alitalo K, Wilting J: VEGF and 
VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian 
chorioallantoic membrane. Developmental biology 1997, 188(1):96-109. 
192. Haiko P, Karkkainen, M., Achen, M., Stacker, S., Alitalo, K.: Growth factors and lymphangiogenesis. 
Angiogenesis: From basic science to clinical applications, Edited by Napoleone Ferrara 2007:53-74. 
193. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald 
DM, Achen MG et al: Signalling via vascular endothelial growth factor receptor-3 is sufficient for 
lymphangiogenesis in transgenic mice. The EMBO journal 2001, 20(6):1223-1231. 
194. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka 
M, Rauvala H et al: Vascular endothelial growth factor C is required for sprouting of the first 
lymphatic vessels from embryonic veins. Nature immunology 2004, 5(1):74-80. 
 104
195. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA: Vascular 
endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) 
and VEGF receptor 3 (Flt4). Proceedings of the National Academy of Sciences of the United States of 
America 1998, 95(2):548-553. 
196. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholova I, Kauppinen 
RA, Achen MG, Stacker SA et al: VEGF-D is the strongest angiogenic and lymphangiogenic effector 
among VEGFs delivered into skeletal muscle via adenoviruses. Circulation research 2003, 
92(10):1098-1106. 
197. Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, 
Siemionow M, Deitcher SR et al: Adenovirus encoding vascular endothelial growth factor-D induces 
tissue-specific vascular patterns in vivo. Blood 2002, 99(12):4434-4442. 
198. Baldwin ME, Halford MM, Roufail S, Williams RA, Hibbs ML, Grail D, Kubo H, Stacker SA, Achen 
MG: Vascular endothelial growth factor D is dispensable for development of the lymphatic system. 
Molecular and cellular biology 2005, 25(6):2441-2449. 
199. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, 
Detmar M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. 
Nature medicine 2001, 7(2):192-198. 
200. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, 
Jackson DG et al: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes 
tumour metastasis. The EMBO journal 2001, 20(4):672-682. 
201. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, 
Kubo H, Achen MG: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. 
Nature medicine 2001, 7(2):186-191. 
202. Eichmann A, Le Noble F, Autiero M, Carmeliet P: Guidance of vascular and neural network 
formation. Current opinion in neurobiology 2005, 15(1):108-115. 
203. Kurschat P, Bielenberg, D., Klagsbrun, M.: Neuropilins, receptors for the VEGF and semaphorin 
families, link angiogenesis and axon guidance. Angiogenesis: From basic science to clinical 
applications, Edited by Napoleone Ferrara 2007:111-131. 
204. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a 
receptor for vascular endothelial growth factor. Science (New York, NY 1992, 255(5047):989-991. 
205. Park JE, Chen HH, Winer J, Houck KA, Ferrara N: Placenta growth factor. Potentiation of vascular 
endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not 
to Flk-1/KDR. The Journal of biological chemistry 1994, 269(41):25646-25654. 
206. Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in 
regulating the assembly of vascular endothelium. Nature 1995, 376(6535):66-70. 
207. Fong GH, Zhang L, Bryce DM, Peng J: Increased hemangioblast commitment, not vascular 
disorganization, is the primary defect in flt-1 knock-out mice. Development (Cambridge, England) 
1999, 126(13):3015-3025. 
208. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M: Flt-1 lacking the tyrosine kinase domain is 
sufficient for normal development and angiogenesis in mice. Proceedings of the National Academy of 
Sciences of the United States of America 1998, 95(16):9349-9354. 
209. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D: Migration of human monocytes in 
response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. 
Blood 1996, 87(8):3336-3343. 
210. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L et al: 
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from 
bone-marrow microenvironment. Nature medicine 2002, 8(8):841-849. 
211. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N: Angiogenesis-
independent endothelial protection of liver: role of VEGFR-1. Science (New York, NY 2003, 
299(5608):890-893. 
212. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M: Involvement of Flt-1 tyrosine kinase 
(vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer research 2001, 
61(3):1207-1213. 
213. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De 
Mol M, Bono F et al: Role of PlGF in the intra- and intermolecular cross talk between the VEGF 
receptors Flt1 and Flk1. Nature medicine 2003, 9(7):936-943. 
214. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K: The role of VEGF receptors in angiogenesis; 
complex partnerships. Cell Mol Life Sci 2006, 63(5):601-615. 
215. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen 
P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth 
factor. Biochemical and biophysical research communications 1992, 187(3):1579-1586. 
216. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of 
blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376(6535):62-66. 
217. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling - in control of 
vascular function. Nat Rev Mol Cell Biol 2006, 7(5):359-371. 
218. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nature medicine 2003, 
9(6):669-676. 
 105
219. Hamada K, Oike Y, Takakura N, Ito Y, Jussila L, Dumont DJ, Alitalo K, Suda T: VEGF-C signaling 
pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood 2000, 
96(12):3793-3800. 
220. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K: 
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (New York, NY 
1998, 282(5390):946-949. 
221. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, 
Kubo H, Nishikawa S et al: Inhibition of lymphangiogenesis with resulting lymphedema in 
transgenic mice expressing soluble VEGF receptor-3. Nature medicine 2001, 7(2):199-205. 
222. Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin ME, Stacker SA, Achen MG, 
Alitalo K: Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not 
equivalent to VEGF receptor 3 deletion in mouse embryos. Molecular and cellular biology 2008, 
28(15):4843-4850. 
223. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, 
Kerjaschki D et al: Isolated lymphatic endothelial cells transduce growth, survival and migratory 
signals via the VEGF-C/D receptor VEGFR-3. The EMBO journal 2001, 20(17):4762-4773. 
224. Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, Claesson-Welsh L: 
Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization 
with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. The 
Journal of biological chemistry 2003, 278(42):40973-40979. 
225. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M: Neuropilin-1 is expressed by endothelial 
and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 
92(6):735-745. 
226. Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, Fujisawa H: A requirement for 
neuropilin-1 in embryonic vessel formation. Development (Cambridge, England) 1999, 126(21):4895-
4902. 
227. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsch B, Richards LJ, Kolodkin AL, Ginty DD: 
Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular 
development. Developmental cell 2003, 5(1):45-57. 
228. Barr MP, Bouchier-Hayes DJ, Harmey JJ: Vascular endothelial growth factor is an autocrine 
survival factor for breast tumour cells under hypoxia. International journal of oncology 2008, 
32(1):41-48. 
229. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco 
G et al: Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor 
growth. Cancer cell 2007, 11(1):53-67. 
230. Ellis LM, Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature reviews 
2008, 8(8):579-591. 
231. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, 
Davis MI, Edeen PT et al: A quantitative analysis of kinase inhibitor selectivity. Nature 
biotechnology 2008, 26(1):127-132. 
232. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nature reviews 2008, 
8(8):592-603. 
233. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for 
combination therapy. Nature medicine 2001, 7(9):987-989. 
234. Shojaei F, Ferrara N: Refractoriness to antivascular endothelial growth factor treatment: role of 
myeloid cells. Cancer research 2008, 68(14):5501-5504. 
235. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both pericytes 
and endothelial cells in the tumor vasculature with kinase inhibitors. The Journal of clinical 
investigation 2003, 111(9):1287-1295. 
236. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z et 
al: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to 
regulate tumor angiogenesis and invasion. Cancer cell 2008, 13(3):206-220. 
237. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, 
Koch M, De Mol M et al: Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors 
without affecting healthy vessels. Cell 2007, 131(3):463-475. 
238. Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, Detmar M: Concurrent 
induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular 
endothelial growth factor-C in melanoma. The American journal of pathology 2001, 159(3):893-903. 
239. Das S, Skobe M: Lymphatic vessel activation in cancer. Annals of the New York Academy of Sciences 
2008, 1131:235-241. 
240. Yan M, Plowman GD: Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res 
2007, 13(24):7243-7246. 
241. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K: Suppression of 
tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth 
factor receptor 3 signaling. Journal of the National Cancer Institute 2002, 94(11):819-825. 
242. Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, Tomarev S, Wilting J, Sleeman JP: Differential in 
vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in 
 106
tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer research 
2003, 63(3):713-722. 
243. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He 
Y et al: Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene 
transfer of a soluble VEGFR-3 decoy receptor. Cancer research 2005, 65(15):6901-6909. 
244. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE, Singh RK: Down-regulation 
of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in 
mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances 
survival. Cancer research 2005, 65(19):9004-9011. 
245. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M: Inhibition 
of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and 
distant metastases than inactivation of VEGFR-2. Cancer research 2006, 66(5):2650-2657. 
246. Wong SY, Haack H, Crowley D, Barry M, Bronson RT, Hynes RO: Tumor-secreted vascular 
endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but 
lymphangiogenesis is unnecessary for lymph node metastasis. Cancer research 2005, 65(21):9789-
9798. 
247. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS: Vascular endothelial growth factor 
(VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001, 
98(6):1904-1913. 
248. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M et al: 
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. The 
Journal of clinical investigation 2000, 106(4):511-521. 
249. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, Zambruno G, D'Atri S: Human 
melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth 
factor. The Journal of investigative dermatology 2000, 115(6):1000-1007. 
250. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ 
et al: Expression and function of vascular endothelial growth factor receptor-1 on human 
colorectal cancer cells. Oncogene 2005, 24(16):2647-2653. 
251. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ et 
al: The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer cell 2006, 
9(3):209-223. 
252. Lesslie DP, Summy JM, Parikh NU, Fan F, Trevino JG, Sawyer TK, Metcalf CA, Shakespeare WC, 
Hicklin DJ, Ellis LM et al: Vascular endothelial growth factor receptor-1 mediates migration of 
human colorectal carcinoma cells by activation of Src family kinases. British journal of cancer 2006, 
94(11):1710-1717. 
253. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ et al: 
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal 
transition in human pancreatic carcinoma cells. Cancer research 2006, 66(1):46-51. 
254. Sini P, Samarzija I, Baffert F, Littlewood-Evans A, Schnell C, Theuer A, Christian S, Boos A, Hess-
Stumpp H, Foekens JA et al: Inhibition of multiple vascular endothelial growth factor receptors 
(VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor 
cells to platinum-based chemotherapeutics. Cancer research 2008, 68(5):1581-1592. 
255. Hess-Stumpp H, Haberey M, Thierauch KH: PTK 787/ZK 222584, a tyrosine kinase inhibitor of all 
known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 2005, 6(3):550-
557. 
256. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P: Monoclonal antibodies 
targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer 
metastasis reviews 1998, 17(2):155-161. 
257. Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF 
therapy for cancer. Nature clinical practice 2006, 3(1):24-40. 
258. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J, Martiny-Baron G, Unger 
C, Marme D: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth 
factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a 
murine renal cell carcinoma model. Cancer research 2000, 60(17):4819-4824. 
259. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T 
et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor 
receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and 
tumor growth after oral administration. Cancer research 2000, 60(8):2178-2189. 
260. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee 
L et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the 
pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth 
factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: 
results from two phase I studies. J Clin Oncol 2003, 21(21):3955-3964. 
261. Klem J: Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in 
colorectal cancer. Clinical colorectal cancer 2003, 3(3):147-149. 
 107
262. Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S, Jalava T, Laurent 
D et al: Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic 
gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 2008, 19(1):173-177. 
263. Fan D, Liaw A, Denkins YM, Collins JH, Van Arsdall M, Chang JL, Chakrabarty S, Nguyen D, Kruzel 
E, Fidler IJ: Type-1 transforming growth factor-beta differentially modulates tumoricidal activity 
of murine peritoneal macrophages against metastatic variants of the B16 murine melanoma. 
Journal of experimental therapeutics & oncology 2002, 2(5):286-297. 
264. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, 
Schlessinger J, Francke U et al: Tyrosine kinase receptor with extensive homology to EGF receptor 
shares chromosomal location with neu oncogene. Science (New York, NY 1985, 230(4730):1132-1139. 
265. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human 
mammary carcinoma. Science (New York, NY 1985, 229(4717):974-976. 
266. Marmor MD, Skaria KB, Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. 
International journal of radiation oncology, biology, physics 2004, 58(3):903-913. 
267. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of 
all ErbB receptors, is a mediator of lateral signaling. The EMBO journal 1997, 16(7):1647-1655. 
268. Citri A, Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 
7(7):505-516. 
269. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: 
correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New 
York, NY 1987, 235(4785):177-182. 
270. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE: Correlation of c-
erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status 
and nuclear grading. Cancer research 1988, 48(5):1238-1243. 
271. Hynes NE, MacDonald G.: ErbB receptors and signaling pathways in cancer. Curr Opin in Cell Biol 
2009, in press. 
272. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, 
Jeffrey SS et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with 
clinical implications. Proceedings of the National Academy of Sciences of the United States of America 
2001, 98(19):10869-10874. 
273. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice 
EC, Burgess AW et al: The crystal structure of a truncated ErbB2 ectodomain reveals an active 
conformation, poised to interact with other ErbB receptors. Molecular cell 2003, 11(2):495-505. 
274. Dankort D, Maslikowski B, Warner N, Kanno N, Kim H, Wang Z, Moran MF, Oshima RG, Cardiff RD, 
Muller WJ: Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary 
tumorigenesis: implications for human breast cancer. Molecular and cellular biology 2001, 
21(5):1540-1551. 
275. Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ: Distinct tyrosine autophosphorylation 
sites negatively and positively modulate neu-mediated transformation. Molecular and cellular 
biology 1997, 17(9):5410-5425. 
276. Schade B, Lam SH, Cernea D, Sanguin-Gendreau V, Cardiff RD, Jung BL, Hallett M, Muller WJ: 
Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic 
and transcriptional profiles. Cancer research 2007, 67(16):7579-7588. 
277. Ursini-Siegel J, Muller WJ: The ShcA adaptor protein is a critical regulator of breast cancer 
progression. Cell cycle (Georgetown, Tex 2008, 7(13):1936-1943. 
278. Marone R, Hess D, Dankort D, Muller WJ, Hynes NE, Badache A: Memo mediates ErbB2-driven cell 
motility. Nature cell biology 2004, 6(6):515-522. 
279. Saucier C, Khoury H, Lai KM, Peschard P, Dankort D, Naujokas MA, Holash J, Yancopoulos GD, 
Muller WJ, Pawson T et al: The Shc adaptor protein is critical for VEGF induction by Met/HGF 
and ErbB2 receptors and for early onset of tumor angiogenesis. Proceedings of the National 
Academy of Sciences of the United States of America 2004, 101(8):2345-2350. 
280. Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD, Pawson T, Muller WJ: 
ShcA signalling is essential for tumour progression in mouse models of human breast cancer. The 
EMBO journal 2008, 27(6):910-920. 
281. Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM: Signaling through 
ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell 
motility and invasion. Molecular and cellular biology 2008, 28(10):3162-3176. 
282. Qiu C, Lienhard S, Hynes NE, Badache A, Leahy DJ: Memo is homologous to nonheme iron 
dioxygenases and binds an ErbB2-derived phosphopeptide in its vestigial active site. The Journal of 
biological chemistry 2008, 283(5):2734-2740. 
283. Meira M, Masson, R., Stagljar, I., Lienhard, S., Maurer, F., Boulay, A., Hynes, N.E.: Memo is a novel 
cofilin interacting protein that influences PLC&[gamma]1 and cofilin activities, and is essential for 
maintaining directionality during ErbB2-induced tumor cell migration. J Cell Sci in press. 
284. Zaoui K, Honore S, Isnardon D, Braguer D, Badache A: Memo-RhoA-mDia1 signaling controls 
microtubules, the actin network, and adhesion site formation in migrating cells. The Journal of cell 
biology 2008, 183(3):401-408. 
 108
285. Logan CY, Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev 
Biol 2004, 20:781-810. 
286. Veeman MT, Axelrod JD, Moon RT: A second canon. Functions and mechanisms of beta-catenin-
independent Wnt signaling. Dev Cell 2003, 5(3):367-377. 
287. Kestler HA, Kuhl M: From individual Wnt pathways towards a Wnt signalling network. Philos 
Trans R Soc Lond B Biol Sci 2008, 363(1495):1333-1347. 
288. Hsieh M, Boerboom D, Shimada M, Lo Y, Parlow AF, Luhmann UF, Berger W, Richards JS: Mice null 
for Frizzled4 (Fzd4-/-) are infertile and exhibit impaired corpora lutea formation and function. 
Biol Reprod 2005, 73(6):1135-1146. 
289. Sheldahl LC, Park M, Malbon CC, Moon RT: Protein kinase C is differentially stimulated by Wnt 
and Frizzled homologs in a G-protein-dependent manner. Curr Biol 1999, 9(13):695-698. 
290. Umbhauer M, Djiane A, Goisset C, Penzo-Mendez A, Riou JF, Boucaut JC, Shi DL: The C-terminal 
cytoplasmic Lys-thr-X-X-X-Trp motif in frizzled receptors mediates Wnt/beta-catenin signalling. 
Embo J 2000, 19(18):4944-4954. 
291. Mikels AJ, Nusse R: Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling 
depending on receptor context. PLoS Biol 2006, 4(4):e115. 
292. Golan T, Yaniv A, Bafico A, Liu G, Gazit A: The human Frizzled 6 (HFz6) acts as a negative 
regulator of the canonical Wnt. beta-catenin signaling cascade. J Biol Chem 2004, 279(15):14879-
14888. 
293. Gonzalez-Sancho JM, Brennan KR, Castelo-Soccio LA, Brown AM: Wnt proteins induce dishevelled 
phosphorylation via an LRP5/6- independent mechanism, irrespective of their ability to stabilize 
beta-catenin. Molecular and cellular biology 2004, 24(11):4757-4768. 
294. Torres MA, Yang-Snyder JA, Purcell SM, DeMarais AA, McGrew LL, Moon RT: Activities of the 
Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant 
negative cadherin in early Xenopus development. J Cell Biol 1996, 133(5):1123-1137. 
295. Tu X, Joeng KS, Nakayama KI, Nakayama K, Rajagopal J, Carroll TJ, McMahon AP, Long F: 
Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone 
formation. Dev Cell 2007, 12(1):113-127. 
296. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 
18(1):4-25. 
297. Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, Wiesmann M, Garcia PD, Fuller JH, Chan 
V et al: beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. 
Cancer Res 2003, 63(12):3145-3153. 
298. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW: 
Identification of c-MYC as a target of the APC pathway. Science 1998, 281(5382):1509-1512. 
299. Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE: Novel c-MYC target genes mediate 
differential effects on cell proliferation and migration. EMBO Rep 2007, 8(1):70-76. 
300. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A: The cyclin D1 
gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999, 96(10):5522-
5527. 
301. Aslakson CJ, Miller FR: Selective events in the metastatic process defined by analysis of the 
sequential dissemination of subpopulations of a mouse mammary tumor. Cancer research 1992, 
52(6):1399-1405. 
302. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 2001, 411(6835):355-365. 
303. van Amerongen R, Mikels A, Nusse R: Alternative wnt signaling is initiated by distinct receptors. 
Science signaling 2008, 1(35):re9. 
304. Weinberg RA: The biology of cancer. Garland Science, Taylor & Francis Group 2007. 
305. Dey J, et al: Manuscript in preparation 2009. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 109
IX. ACKNOWLEDGMENTS  
 
First and foremost, I would like to thank Professor Nancy Hynes for giving me the 
opportunity to work on three different, equally exciting projects within her group. Many 
thanks to Dr Klaus Seuwen and Professor Susan Gasser, the members of my Thesis 
Committee, for helping to shape my PhD path. Thanks to Professor Jan Hofsteenge for kindly 
agreeing to chair my Thesis Defense.   
 
It is my pleasure to acknowledge Drs Patrizia Sini, Thomas Schlange and Gwen MacDonald 
for helping me at different stages of my work. I would like to thank Patrizia for introducing 
me to the research field of signaling pathways; Thomas, for kindly sharing his broad 
knowledge on Wnt pathway; and Gwen, for critically reviewing this manuscript and being 
supportive during the final part of my studies. 
 
My sincere thanks to great people, current and former members of the Hynes group, Francie, 
Susanne, Anne, Regis, Berengere, Susan, Shunya, Ivan, Tina, Julien, Patrick, Maria, Barbara, 
Constanze, Colin and Jakub, for stimulating discussions and the nice atmosphere. 
 
Finally, I would like to thank my dear friends Yutaka, Janice, Teppei and Elena for sharing 
great times together and being there for me when I needed their support.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 110
X. CURRICULUM VITAE 
 
 
Personal details 
 
Family name  Samarzija 
First name  Ivana 
Gender   Female 
Nationality  Croat 
Date and place of birth September 10th 1979, Sibenik, Croatia 
 
Address  Bleichestrasse 13, 4058 Basel, Switzerland 
Work address  Friedrich Miescher Institute for Biomedical Research 
   Maulbeerstrasse 66, 4058 Basel, Switzerland 
 
Tel.   +41 (0)61 697-8089 
Fax.   +41 (0)61 697-3976 
E-mail   ivana.samarzija@fmi.ch 
 
 
University and scientific education 
 
2004 - present 
PhD student at University of Basel,  
group of Prof. Nancy E. Hynes, Friedrich Miescher Institute for Biomedical Research  
PhD projects: 
The role of Wnt signaling in angiogenesis  
Studies on Memo, a novel ERBB2 effector protein 
VEGF receptors and lymph node metastasis 
 
 
Diploma studies                                                                                                
 
1998 - 2003   
University of Zagreb, Faculty of Science, Department of Molecular Biology 
Diploma Thesis: Analysis of Staphylococcus epidermidis clinical isolates constitutively 
resistant to macrolide antibiotics (performed at PLIVA Research Institute, Department of 
Microbiology)  
 
 
Manuscripts 
 
Samarzija I, Sini P, Schlange T, Hynes NE Wnt3a promotes proliferation and migration of 
HUVEC Manuscript in preparation  
 
Sini P, Samarzija I, Baffert F, Littlewood-Evans A, Schnell C, Theuer A, Christian S, Boos A, 
Hess-Stumpp H, Foekens JA, Setyono-Han B, Wood J, Hynes NE Inhibition of multiple 
vascular endothelial growth factor receptors blocks lymph node metastases, but inhibition of 
VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics Cancer 
Res 2008 
 
 
Conference abstracts 
 
 111
Samarzija I, Jacob S, Maurer F, Haenzi B, Masson R, Hynes N Studies on Memo, a novel 
ERBB2 effector protein National Cancer Research Institute Cancer Conference 2007 
 
Samarzija I, Sini P, Schlange T, Hynes N The role of Frizzled-4 and -6 in angiogenesis 
Targeting the Kinome 2006 
 
 
Presentations 
Memo, a protein involved in tumor cell migration. NCRI Cancer Conference, Birmingham 
2007 (proffered paper presentation) 
 
 
Conferences 
 
NCRI Cancer Conference, Birmingham 2007 
USGEB and [BC] 2 joined Conference, From Euler to Computational Biology: Integrating 
mathematics into biological research, Basel 2007 (participation) 
Targeting the Kinome, Basel 2006 (poster) 
FMI Annual Meeting 2005, 2006, 2007, 2008 (poster) 
 
 
Courses 
 
EMBO Practical Course, Anatomy and Embryology of the Mouse, Zagreb 2006 
 
 
 
 
 
